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Abstract 
Background:  Asthma is the commonest chronic disease of childhood. The earliest 
manifestation is often preschool wheezing, which affects up to 50% of young children, but is 
difficult to evaluate practically.  Observational studies suggest that low prenatal vitamin D 
status may be a risk factor for childhood wheezing. 
Aims: To evaluate the measurement of preschool lung function using impulse oscillometry, 
and to test the hypotheses that prenatal vitamin D supplementation may promote lung 
development or prevent preschool wheezing.  
Methods:  We recruited 3 to 5 year olds from outpatient clinics to evaluate the quality of 
impulse oscillometry readings and the relationship between lung function and wheezing.  We 
then evaluated impulse oscillometry in a group of 3-year-old children whose mothers had 
participated in a prenatal vitamin D supplementation trial.  Next we evaluated the effect of 
prenatal vitamin D supplementation on lung function parameters and on the prevalence of 
wheeze and atopy in the first 3 years of life in this population (ISRCTN 68645785).  
Findings:  In 3 to 5 year old children, we successfully acquired high quality impulse 
oscillometry readings in 37/66 (56%). We found increased bronchodilator responses in those 
who had previously wheezed, with adjusted mean difference in respiratory resistance at 
25Hz (95% confidence intervals) of -8.65 Kpa/Ls-1 (-16.63, -0.67), p=0.04. In 3-year-old 
children whose mothers participated in a prenatal vitamin D trial, we acquired high quality 
readings in 51/105 (49%), but found no relationship between wheezing history and 
bronchodilator response.  In the randomised controlled trial of prenatal vitamin D 
supplementation, we evaluated 158/180 (88%) offspring at age 3 years and found no 
difference in wheeze, atopy, lung function or healthcare utilisation between vitamin D 
supplemented groups and controls. 
Conclusions:  It is possible to acquire high quality lung function data using impulse 
oscillometry for half of preschool children, however we found no consistent relationship 
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between lung function and wheezing history.  There may be age related differences in the 
pathophysiology of wheezing and its relationship to lung function, which should be explored 
in future studies.  Prenatal vitamin D supplementation in late pregnancy was not associated 
with differences in lung function or wheezing.  Future research should explore the effect of 
higher doses and earlier administration of vitamin D in pregnancy. 
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1 Literature review 
1.1 Abstract 
Asthma is the commonest chronic disease of childhood.  Its prevalence has increased 
rapidly over the last 50 years. The earliest manifestation is often preschool wheezing which 
affects up to 50% of children before the age of three years. Asthma is a heterogeneous 
disorder with considerable variation in causation between individuals.  Two key pathways 
lead to asthma – an abnormal airway and an abnormal immune response to environmental 
antigens. Early atopic sensitization and respiratory tract infections make persistent asthma 
more likely.  
 
There is a large body of evidence suggesting antenatal and early life influences are 
important in the development of asthma. Changing environmental factors acting on 
genetically susceptible individuals are likely to explain the increase in asthma prevalence in 
the last century.  However, the precise environmental factors remain unidentified. 
Micronutrient status may be particularly important. 
 
Early life vitamin D status is one proposed environmental factor. Opposing hypotheses 
argue that either high or low vitamin D status, at critical times in development have 
contributed to the asthma epidemic.  Epidemiological data support both hypotheses.  The 
nature of vitamin D’s influence on immune and lung development, through its active 
metabolite calcitriol, illustrates how these hypotheses may not be mutually exclusive, and 
how such biological effects may be possible.   
 
Modifying the vitamin D status of women of childbearing age is an attractive public health 
intervention for the primary prevention of asthma.  The purpose of this thesis is to explore 
the potential role of vitamin D in early lung development. 
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1.2 Asthma and preschool wheezing 
1.2.1 Introduction 
The prevalence of asthma has increased dramatically over the second half of the 20th 
century (1, 2).  It is estimated that 300 million people worldwide are affected by asthma and 
this figure is expected to rise to 400 million by 2025 (3, 4). In longitudinal birth cohort 
studies, up to half of all children experience at least one episode of wheezing before 6 years 
of age (5, 6).  Of these nearly 40% experience persistent wheezing as adolescents (7). 
Asthma is estimated to affect 20% of children aged 6-7 in the United Kingdom, and 24% of 
13-14 year olds (8), and is the commonest chronic disease of childhood (9). Many of these 
children have life long asthma (10). In the United Kingdom, the direct NHS costs attributable 
to asthma were over 700 million pounds in 2000 (11). Preschool wheezing itself was 
estimated to cost 0.15% of the total UK NHS budget in 2003 (12).  
1.2.2 Defining asthma and preschool wheeze 
Asthma is defined as a chronic inflammatory disorder of the airways associated with airway 
hyper-responsiveness that leads to recurrent episodes of wheezing, breathlessness, chest 
tightness and coughing (9). Since airflow limitation and airway inflammation cannot be 
routinely assessed in preschool children, this definition is of limited use in young children, 
and applying the label asthma in children under 6 years is not recommended (13). In 
Europe, for clinical purposes, children under six years with wheezing may be categorised 
using a symptoms based approach (13). Children with ‘episodic (viral) wheeze’ have 
symptoms with viral colds only, and no symptoms between episodes; Children with ‘multiple 
trigger wheeze’ have symptoms in response to a number of triggers including tobacco 
smoke, allergen exposure, mist, crying, laughter or exercise. Pharmacological therapy is 
recommended based on this classification, although the evidence base in this age group is 
acknowledged to be weak (13).  Furthermore, this classification is not robust over time, with 
more than half of children classified into either group switching to the other over the course 
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of a year (14). In the United States, an approach based on whether symptoms are 
intermittent or persistent is recommended (15). 
 
1.2.3 Preschool wheezing phenotypes 
Insight into the natural history of preschool wheezing comes from prospective cohort studies 
that have tracked the respiratory health of individuals from birth or early childhood. Such 
studies have been conducted worldwide and with varying degrees of biological and 
epidemiological data collected. The earliest prospective birth cohort study was the Tuscon 
Children’s Respiratory Study (5).   
 
In this study, 1246 newborn babies, not selected for asthma risk, were recruited between 
1980 and 1984.  At age six years, 51% had never wheezed, 20% had wheezing that began 
in the first three years and resolved by six years (early transient wheezing), 14% had 
wheezing that was present at three and six years (persistent wheezing) and 15% had 
wheezing that started after age three years (late onset wheezing) (5). Thus three different 
wheezing phenotypes were identified based on the presence of wheezing at three and six 
years. Risk factors associated with persistent wheeze included maternal asthma, male sex, 
atopic dermatitis, rhinitis apart from colds and elevated serum IgE levels in the first year of 
life (5).  
 
Other birth cohorts have confirmed the presence of these wheezing phenotypes (6, 16, 17). 
By using latent class analysis, where children are categorised into patterns of wheezing over 
a fixed number of observation points, combined with detailed epidemiological data of 
individuals under study, further detail is emerging (6, 18, 19).  The Avon Longitudinal Study 
of Parents and Children study (ALSPAC) identified two additional phenotypes in 6265 
children followed from birth to 7 years (6).  Prolonged early wheeze (around 9% of children), 
characterised by wheezing from 6 to 54 months and low prevalence from 69 months 
 
 
17 
onwards, and intermediate onset wheeze (around 2.5% of children) with onset between 18 
and 42 months.  In this study, phenotypes most strongly associated with atopy and airway 
responsiveness were characterised by onset after 18 months (6). The associations between 
preschool wheezing and asthma, atopy and lung function found in the ALSPAC study are 
summarised in Table 1.1. 
 
Table 1.1 Associations between phenotypes and clinical outcomes in the ALSPAC study.   
Phenotype Asthma Atopy FEV1 FEF25-75 AHR 
Transient early  X    
Prolonged early  X    
Intermediate onset      
Late onset      
Persistent      
Asthma and atopy (skin prick test reactivity) assessed at age 7 years. Lung function and 
airway hyper-responsiveness assessed at age 8 years. The strength of association of each 
wheezing phenotype with each outcome is represented by the number of symbols (, or ) 
with a cross representing absence of an association with that outcome.  AHR, airway hyper-
responsiveness; FEF25-75, mid expiratory flow; FEV1 forced expiratory volume in 1 second. 
Reproduced from Henderson et al (6). 
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1.2.4 Role of atopic sensitization  
Asthma in children often occurs with other allergic diseases such as eczema, allergic rhinitis 
and food allergy.  The pattern of progression from eczema and food allergy in infancy to 
asthma and allergic rhinitis in older children is called ‘the allergic march’.  Atopic 
sensitisation is one of the most important risk factors for the development of asthma (20).  
Early sensitisation to allergens is associated with loss of lung function at school age (21, 22) 
and is a risk factor for persistence of asthma (21-23). Although both allergy and respiratory 
infections during early life are independently associated with developing asthma, the highest 
odds ratio is seen in children who have both (20, 24, 25).  Early life sensitization to multiple 
aeroallergens carries the greatest risk for developing asthma (26).   
 
However, wheezing occurs in both atopic and non-atopic children (27), and many atopic 
individuals do not develop asthma.  In studies of school aged children in the United 
Kingdom, the percentage of atopic sensitization in asthmatic children ranged from 40-54%, 
and in non-asthmatics from 11 to 26% (28-30).  In the European Community Respiratory 
Health Survey, the attributable fraction of asthma symptoms caused by atopy was 30%, but 
varied widely between centres from 4 to 61% (31). This highlights the heterogeneity of 
asthma, with approximately half of all asthma cases not attributable to atopic sensitisation, a 
key pathway in our understanding of asthma. 
 
1.2.5 Role of early viral infection 
In offspring of mothers with asthma, rhinovirus induced wheezing in the first three years of 
life was the greatest risk factor for developing asthma at age 6 years in one study (32).  
Rhinovirus infection, but not other viruses that induce wheezing, was also related to the 
number of sensitisations, total IgE level and nasal eosinophil count in the same cohort (33), 
with the evidence suggesting sensitization precedes rhinovirus infection, not vice versa (34).   
 
 
19 
1.2.6 Long term outcome of preschool wheezing 
Longitudinal cohort studies demonstrate that early life wheezing that continues into school 
years generally persists into adulthood . For example, since 1964, the Melbourne Asthma 
Study (35) has followed up 401 randomly selected children from age 7 years who were 
classified as either controls (never wheezed), wheezy bronchitis (<5 episodes of wheezing 
associated with respiratory tract infection) or asthmatic (wheezing not associated with 
respiratory tract infection).  In 1967, they were joined by 83 children with severe asthma 
defined as follows: onset of asthma before three years of age; persistent symptoms at age 
10; barrel chest deformity or ratio of forced expiratory volume in one second to forced vital 
capacity < 50%.  At 42 years of age, persistent asthma (defined as wheezing more than 
once per week) was present in 5% of the control group, 24% of the remaining cohort 
originally classified as asthmatic and 47% of severe asthmatics (35). Lung function showed 
a similar pattern with FEV1 values at age 42 years of 104%, 102%, 95% and 85% for adults 
originally classified as controls, wheezy bronchitis, asthma and severe asthma respectively.  
Other cohorts have found similar long-term rates of asthma and impaired lung function (10).  
More than one in four children who wheeze in early childhood have wheezing that persists 
into adulthood (10, 36). 
 
1.2.7 Limitations of wheeze as the hallmark of asthma 
Wheezing is defined as a continuous high-pitched sound with musical quality emitting from 
the chest during expiration (13).  It represents narrowing of the intra-thoracic airways and 
expiratory flow limitation and has many causes other than ‘asthma’. From a parental 
perspective, wheezing is just one form of noisy breathing in their children (37). It is known 
that both parents (38, 39) and health professionals (40) differ in their interpretation of 
wheeze. Furthermore, researchers have questioned the role of wheeze as the hallmark of 
asthma in young children (41, 42). Parents reported wheeze in relation to only half the 
asthma exacerbations in young children during a RCT of asthma therapy, with cough the 
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individual symptom most strongly associated with an imminent asthma exacerbation (41).  
This suggests caregivers perceive a specific pattern of lung symptoms in relation to asthma, 
rather than an individual symptom such as wheeze (41). Furthermore, in the Copenhagen 
Prospective Study of Asthma in Childhood, total number of clinic visits for troublesome lung 
symptoms during the first three years of life was more predictive for asthma at age seven 
years, than whether wheeze was present on auscultation at these visits or not (42).  
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1.3 Pathophysiology of asthma 
1.3.1 Introduction 
Asthma is a disease of the airway characterized by inflammation, increased mucous 
production and airway remodelling leading to bronchial hyperactivity and airway obstruction 
(43). Airway inflammation is central to disease pathophysiology (44).  As the disease 
progresses, the airway becomes susceptible to a wide range of environmental insults 
(allergens, viruses, air pollutants, drugs, chemical) leading to mucous cell metaplasia, 
smooth muscle proliferation, angiogenesis, fibrosis and nerve proliferation (44). 
 
1.3.2 Allergic inflammation 
Atopy is defined as the predisposition of individuals to produce IgE in response to 
environmental allergens, such as house dust mites.  The healthy adaptive immune response 
is characterised by an appropriate balance between T helper 1 (Th-1) cells and T helper 2 
(Th-2) cells.  The former produce the cytokines interferon-gamma (IFN-γ) and interleukin 2 
(IL-2), and the latter cytokines IL-4, IL-5 and IL-13 (45).  T regulatory cells (Tregs) are crucial 
for maintaining balance, by cell-to-cell contact and the generation of IL-10 and transforming 
growth factor beta (TGF-β) (45). Over expression of Th-2 activity or a failure of control by 
Tregs will result in a higher probability of the development of allergic inflammation and 
sensitisation (45).  
 
The nature of initial antigen exposure, and the subsequent co-stimulatory signalling during 
antigen-presentation by, for example, dendritic cells (DCs) to a naïve T cell determines the T 
cell response (45).  In asthma, this is skewed towards Th-2 cells, resulting in increased 
production of cytokines that promote Th-2 cell survival (IL-4), IgE production (IL-4 and IL-13), 
mast cell differentiation and maturation (IL-3, IL-9 and IL-13), eosinophil maturation and 
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survival (IL-3, IL-5 and Granulocyte macrophage colony stimulating factor (GM-CSF)) and 
basophil recruitment (IL-3 and GM-CSF) (44).   
 
Tregs are responsible for dampening immune responses and induction of allergen tolerance 
(44). Tregs are identified by co-expression of the transcription factor forkhead box protein 3 
(FoxP3), CD4 and CD25. They exist as either naturally occurring or inducible forms (44). 
Naturally occurring Tregs influence allergic responses by secreting IL-10 and TGF-β which 
mediate suppression of DCs, direct inhibition of Th-1, Th-2 and Th-17 cells, suppression of 
allergen-specific IgE and induction of IgG4, inhibition of mast cells, basophils and 
eosinophils and prevention of effector T cell migration into the target tissue (44). 
 
1.3.3 Breakdown of barrier function 
The asthmatic epithelium is intrinsically defective with incomplete formation of tight junctions 
that facilitate penetration of inhaled allergens into the airway (46).  Additional environmental 
stimuli such as respiratory viruses and air pollutants such as environmental tobacco smoke 
(ETS) can also disrupt tight junctions and impair barrier function (47). 
 
1.3.4 Role of viral infection 
The mechanism may relate to impaired Toll Like Receptor mediated responses by asthmatic 
epithelial cells that predispose to viral lung infection and allergic sensitization (44). These 
defects enable rhinovirus and other viruses to replicate, leading to cytotoxic cell death 
(rather than apoptosis), release of inflammatory products and enhanced viral shedding, 
events which act as a strong stimulus for recruitment of immature DCs and priming for 
allergen sensitization (44).   
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1.3.5 Airway remodelling  
Accompanying these immunological changes are structural changes called airway 
remodelling.  These consist of increased smooth muscle mass in the surrounding airway 
wall, deposition of extracellular matrix in the epithelial basement membrane, a loss of 
integrity of the airway epithelium, and goblet cell metaplasia leading to increased mucous 
production (43).  Studies have confirmed that increased reticular basement membrane 
thickness and eosinophillic inflammation, the characteristic pathological features of adult 
asthma, are present in preschool children with confirmed wheeze between one and three 
years of age (48). 
 
1.3.6 Role of the epithelium 
The airway epithelium controls many aspects of allergic sensitization and is important in 
allergic inflammation, remodelling and bronchial hyper-reactivity (44).  Airway epithelial cells 
(AECs) are equipped with pattern recognition receptors to enable defence against 
microorganisms, gases and allergens (43).  Activation leads to the release of inflammatory 
mediators that initiate innate and adaptive immunological responses (43).  For example, 
expression of Toll Like Receptor 4 (TLR-4) on the epithelium is crucial for promotion and 
activation of DCs and development of allergy to house dust mites (HDM), a response that is 
up regulated by viral infection of the airway epithelium with RSV or exposure to cigarette 
smoke (43).  When AECs are chronically triggered by allergens, pollutants or Th-2 cytokines, 
they produce an array of cytokines and growth factors that may induce pathological changes 
(43).  For example, TGF-β production activates underlying fibroblasts to differentiate into 
myofibroblasts that synthesize more collagen and extracellular matrix components (43). 
There is also evidence for epithelial mesenchymal transition, a process whereby AECs 
acquire characteristics of fibroblasts.  The interaction between AECs and fibroblasts is 
known as the epithelial-mesenchymal trophic unit (43). 
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1.4 Lung function assessment in preschool children 
1.4.1 Introduction 
Objective measures of lung function in preschool children are important for evaluating the 
evolution of disease processes and response to interventions during this crucial 
developmental stage (49). However, practical evaluation of lung function in young children 
represents a major challenge (49). Preschool children are generally not able to perform the 
physiological manoeuvres required for techniques used in older children and adults.  They 
are too old to sedate for lung function testing as is done in infants.  They are easily 
distracted.  The ideal pulmonary function test in preschool children should be applicable at 
any age (to allow for longitudinal studies), simple to perform, safe, reproducible, sensitive 
and specific enough to detect changes with growth, distinguish clearly between health and 
disease, and be acceptable to both the subject and parents (49). Impulse oscillometry (IOS) 
is one such technique that has been used in the clinical trial setting (50).  IOS simply 
requires a child to breathe tidally through a mouthpiece for up to 30 seconds whilst 
measurements are taken.  This section will outline the principles of impulse oscillometry and 
summarise previous work in preschool children. 
1.4.2 Impulse oscillometry  
The principle originated as the forced oscillation technique (FOT) described by Dubois et al 
in 1956 (51).  As opposed to a traditional flow-volume loop, where the subject performs a 
maximal forced expiration to give physiological measurements such as the forced expiratory 
volume in one second (FEV1), the oscillation technique superimposes a small external 
pressure sine wave of a known frequency to the respiratory system, and the resulting 
pressure-flow relationship is measured (52).  The ratio of the amplitude of the pressure 
wave, to the amplitude of the resulting flow wave, gives the respiratory impedance (Zrs), 
which represents the overall impediment to flow within the lung (49).   Impedance is the 
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complex sum of lung resistance (Rrs) and reactance (Xrs), where Rrs represents frictional 
losses in the proximal and distal airways and lung parenchyma, of which airway resistance 
(Raw) is the most significant (49), and Xrs represents elastic and inertial properties within 
the lung.  
 
These physical properties can be defined further as follows.  Rrs equals pressure/flow 
(KPa.L-1.s), lung elastance equals pressure/volume (KPa.L-1) (the reciprocal of compliance) 
and lung inertance represents the relationship between pressure and volume acceleration.  
By applying different frequencies, the respiratory system can thus be evaluated for its 
oscillation properties. 
 
Frey elegantly described these principles (52).  Consider the lung as a single unit containing 
one resistive element, one elastic element and one inertial element.  If an external pressure 
sine wave is applied, the resulting flow will be in phase providing inertia and elastance are 
zero.  In this state the impedance is simply a function of the ratio of pressure and flow, or 
resistance.  However, any increase in elastic forces causes a negative phase lag between 
pressure and flow, and any increase in inertial forces causes a positive phase lag between 
pressure and flow.   
 
Mathematically, impedance can thus be represented as a vector with a given length 
(equivalent to the resistance) and phase angle (representing the phase lag between 
pressure and flow) which in turn can be represented as a complex mathematical number 
containing a real part (equivalent to the resistance) and an imaginary part (equivalent to the 
reactance).  Thus, for a given frequency, Impedance (Zrs), [kPa.L-1.s] = resistance (Rrs) 
[kPa.L-1.s] + reactance (Xrs) [kPa.L-1].  Figure 1-1, from Frey (52), summarises this 
representation of the human respiratory impedance spectrum. 
 26 
 
 
Figure 1-1  Schematic representation of the human respiratory input impedance spectrum.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced from Frey (52). 
 
 
27 
1.4.3 Equipment 
Initial techniques used monofrequencies that were time-consuming (51). With the 
development of Fast Fourier transformations, multiple frequencies could be analysed 
simultaneously (53). The impulse oscillation technique (IOS) generates multiple frequencies 
from a loudspeaker that are superimposed to generate a rectangular pulse applied to the 
airways every 200 milliseconds via a mouthpiece. Analysis of the superimposed pressure 
oscillations during normal spontaneous breathing allows calculation of Rrs and Xrs at 
multiple frequencies simultaneously.  This has the advantages of reducing measurement 
time and generating continuous rather than discrete data.  
 
1.4.4 Parameters 
Respiratory resistance at different oscillating frequencies, for example at 5Hz, 10Hz and 
15Hz, is represented by R5, R10 and R15.  Likewise, for reactance the notation is X5, X10 
and X15.   Clinical applications generally use oscillating frequencies in the range 5 to 30 Hz.  
In this range, the impedance of the healthy respiratory system is dominated by airway 
resistance, and Rrs is considered a reasonable surrogate of airway resistance, Raw (49). 
Frequencies below 15Hz reflect the peripheral airways and frequencies above 20Hz, the 
central airways (54). There is a frequency dependence of resistance such that between four 
and 35 Hz, Rrs generally decreases with increasing frequency (49).  
 
In the range from 5 to 30 Hz, the imaginary part of impedance, reactance Xrs, transitions 
from negative values where elastic properties dominate to positive values where inertial 
properties dominate (52).  The resonant frequency, Fres, is defined as the point at which the 
magnitudes of elastic and inertial forces are equal and theoretically, Zrs equals Rrs (55).   
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1.4.5 Comparison of IOS with other lung function techniques 
Several studies have compared IOS with other lung function techniques in young children, 
and found good correlation. In an observational study of 121 children aged 2 to 7 years, 
mean values of resistance measured by whole body plethysmography, the interrupter 
technique, and Rrs and Zrs measured by IOS were highly correlated (56).  In children with 
acute asthma in the emergency department there was good correlation between percentage 
change in R8 after administration of bronchodilators and reversibility measured by 
spirometry, although the number of children under 7 years of age able to perform spirometry 
was limited (57). IOS using a facemask technique was more sensitive than the interrupter 
technique or whole body plethysmography in measuring metacholine induced lung function 
changes in children aged 2 to 7 years (58). Specific airway resistance (sRaw) measured by 
whole body plethysmography, respiratory resistance measured by the interrupter technique 
(Rint) and IOS were all able to discriminate bronchodilator responses in children aged 2 to 5 
years with and without asthma, although sRaw provided the best discriminative power, with 
a sensitivity of 66% and specificity of 81% at the cut off level of a 25% decrease in sRaw 
after bronchodilator administration (59). In this study asthma was defined empirically based 
on typical asthma symptoms such as recurrent wheeze, cough and breathlessness; 
symptom relief with inhaled B2 agonist; relief with inhaled corticosteroids (ICS) and relapse 
during interruption of ICS therapy (59). 
 
1.4.6 Determinants of lung function measured by IOS in healthy children 
Several reference ranges for oscillatory mechanics in young children have been published 
and reviewed (49, 52, 60). Respiratory impedance is determined by height, with resistance 
decreasing and reactance increasing, as children get taller (61).  The majority of studies do 
not show an effect of gender (52).  It should be noted that most reference ranges have been 
performed on Caucasian children which may not be appropriate for African or Asian 
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subjects, where ethnic differences in lung function have been described (62). 
1.4.7 Success rate of IOS in preschool children 
Few studies have reported the success rate of impulse oscillometry in preschool children.  
Klug et al performed a community based study of 93 children aged 4 years or less, with a 
success rate of 57%, 65% and 82% for children aged 2,3 or 4 years respectively (56). In this 
study, IOS was performed along with the interrupter technique and whole body 
plethysmography at the same assessment.  A facemask was used to increase compliance.  
Reasons for IOS failure were unacceptability of the facemask (90% of cases) and poor 
quality of measurements (10% of cases).  In a study of 131 children aged 2 to 7 years, 
including 54 children aged 4 years or under, 13 children (9.9% of those eligible to perform 
IOS) refused to cooperate. Success rates were not reported by age (63). In a large 
community based study, 11 out of 233 (4.3%) children aged 3 to 10 years were unable to 
participate with IOS (64).  This included 45 children aged 4 years or under, but again 
success rates were not given by age.  Guilbert et al performed IOS yearly from 4 to 8 years 
as part of the annual assessment of a birth cohort of children at high risk for asthma (65).  
Success rates for IOS significantly increased with age.  At 4 years only 21% of children 
could provide acceptable IOS tests.  This increased to 58%, 74%, 79% and 86% at 5,6,7 
and 8 years respectively.  In the acute setting, the acceptability of IOS for assessing lung 
function in wheezy children presenting to the emergency room ranged from 20% in three 
year olds to more than 80% in 5 year olds (57).   
 
1.4.8 Repeatability of IOS in preschool children 
The coefficient of variation (CV) (within-occasion, within-test repeatability) is calculated as 
the standard deviation (SD) as a percentage of the mean (49), and the coefficient of 
repeatability (CR) (within-occasion, between-test) is defined as twice the SD of the mean 
difference between two series of measurements performed a few minutes apart, without any 
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intervention. The reported CV for IOS in young children ranges from 6.0% to 11% for 
resistance measurements (61) and up to 16% for reactance (66).  Reported CR ranges from 
6.1 to 10.2% (49) for resistance. The majority of children included in these studies were 
aged over 4 years. 
 
1.4.9 Ability of IOS to discriminate between preschool children with and 
without wheezing  
Studies that have looked for differences in lung function between preschool children with 
and without a history of wheezing or asthma using the Jaeger IOS system (Jaeger, 
Wurzburg, Germany) are show in Table 1.2.  
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Table 1.2 Studies investigating the ability of IOS to discriminate between preschool children with and without wheeze or asthma. 
Ref Design Population Age range Parameters Children with wheeze compared to controls 
     Baseline IOS BDR 
Hellinck 
18 (67) 
Case-control 247 healthy children vs 
34 children with asthma 
recruited from 
Kindergarten 
Age 3 to 6 
years 
(Mean 4.5) 
Rrs and Xrs at 
5,10, 15, 20, 
25 and 35 Hz, 
and Fres. 
No difference No difference 
Nielsen 
2001 (59) 
Case-control 
 
37 healthy controls from 
the community vs 55 
children attending a 
hospital asthma clinic 
Age 2 to 5 
years 
(Mean 4.6) 
R5 and X5 
 
Significantly higher 
R5 and reduced X5 
Significantly greater 
for R5 and X5 
 
 
Marotta 
2003 (68) 
RCT of an 
environmental 
intervention for 
prevention of 
asthma 
All children selected for 
higher risk of asthma at 
9m to 2 years.  At age 4, 
42 children without, and 
27 with asthma* 
Age 4yrs 
(Median 4.1) 
R5, R10, X5, 
X10, Fres 
No difference Significantly greater 
for R5 and R10 
 
 
Song Case-control 55 healthy children vs 77 Age 3 to 6 R5, R10, R20, Significantly higher Significantly greater 
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2008 (69) study 
 
children attending a 
hospital *asthma clinic 
years 
(Mean 5.0) 
R35, X5, Fres R10 for R5, R10, R20 
and R35 
Komarow 
2012 (70) 
Case control 
study 
29 non-asthmatic vs 88 
children with asthma 
attending a hospital 
allergy clinic. 
Age 3 to 18 
years 
(Mean 7.7) 
R5, R10, R20, 
X5, AX 
No differences Significant greater 
for R5, R10, X5 and 
AX 
 
Malmberg 
2008 (71) 
Case control 
study 
 
79 healthy controls vs 
130 children with 
suspected asthma 
referred to a hospital 
allergy clinic. 
Age 3 to 7 
years 
(Mean 5.6) 
R5, X5 and 
Fres 
- Significantly greater 
R5, X5 and Fres 
following a free 
running test 
 
Shin 2012 
(72) 
Case control 
study 
29 healthy controls vs 30 
children with asthma 
Age 2 to 6 
years 
R5, X5 and AX - Significantly greater 
for 
R5, X5 and AX 
IOS = impulse oscillometry readings, BDR = IOS reading changes after administration of bronchodilator 
*Asthma diagnosed if at least 4 out of 5 positive responses to the Modified ATS-B questions for asthma in childhood for the preceding 
12 months, (wheeze with colds, wheeze apart from colds, dyspnoea associated with wheeze, wheeze after exercise, persistent cough). 
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Three studies in preschool children have found no differences in baseline IOS parameters 
between children with and without asthma (65, 67, 68, 70).  However, two studies did find 
significant differences, with higher baseline R10 in asthmatics vs. controls in a Korean study 
(69), and higher R5 and lower X5 in asthmatics vs. controls in a Danish study (59). 
 
The Bronchodilator response (BDR) measured by IOS is generally greater in children with 
asthma compared to controls (59, 68-70, 72). One, well conducted study that examined BDR 
in preschool children did not find a significant difference (67).  The key difference with this 
study is that it was entirely community based, being set in a Kindergarten as opposed to 
recruiting children with asthma from hospital based clinics which may skew the severity of 
underlying illness.  IOS is also able to discriminate a difference in response to exercise 
challenge, with greater changes in R5, X5 and Fres in asthmatics vs. controls after a free 
running test (71). 
 
Differences in IOS parameters have been found in preschool children with a history of 
wheezing undergoing pharmacotherapy (50, 73).  For example, in a randomised controlled 
trial of fluticasone vs. placebo in children with a positive asthma predictive index, children in 
the fluticasone group had significantly more symptom free days and significantly higher X5 
than controls at the end of the study (50, 73).   
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1.5 Early life origins of asthma 
1.5.1 Introduction 
Asthma is a complex polygenic disease with a high degree of heritability.  However, the rapid 
rise in asthma prevalence in the latter part of the 20th century in many industrialised 
countries cannot be explained by a population level genetic change (1).  Asthma hypotheses 
propose that changing environmental exposures acting on genetically susceptible hosts - 
gene-environment interactions – have led to the asthma epidemic (1). The Developmental 
Origins of Health and Disease hypothesis states that intrauterine events can have lifelong 
health consequences (74).  For asthma, four lines of evidence support this.  
 
First, cohort studies from birth and early childhood show that physiological changes in early 
life track through to adulthood (7, 10, 36, 75). Reduced lung flow at one month of age 
predates the onset of early childhood wheezing and correlates with the persistence of 
asthma in adults (28). Airway hyper-responsiveness at age 11 years shows a significant 
association with measurements in late infancy (76).  Thus impaired respiratory development 
is established at or shortly after birth, and tracks into adulthood.   
 
Second, migration studies show that environmental influences that determine asthma risk 
act in early life. The prevalence of asthma in South Indian women in Leicestershire was 
significantly higher in those individuals who were born, or moved to the United Kingdom 
before the age of five years.  After this period, individuals retain the asthma prevalence of 
their county of origin (77).  This suggests that early life environmental factors are key to the 
initiation of asthma. 
 
Third, associations between early life anthropometry data and the development of asthma 
suggest there are fetal origins to respiratory disease.  Turner recently reviewed the literature 
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and performed a semi-structured review of 22 studies relating birth weight and asthma (78). 
There is consistent evidence of increased asthma among those of low birth weight (less than 
2.5 kg), although the role of prematurity is not clear. There is also evidence of increased 
asthma among very heavy infants (>4.5 kg) (78).  However, an infant’s postnatal growth 
trajectory may be a better indicator of antenatal growth, with rapid infant growth suggesting 
growth suppression in utero (78). As the airways are established by mid pregnancy they may 
not be able to catch up to the same extent as somatic growth, resulting in a dissociation that 
is termed dysanapsis (78).  Evidence for this comes from a Chilean cohort study that found 
that increased gain in weight and length during infancy is associated with increased asthma 
symptoms in young adults (79), a finding that has been replicated by a cohort from 
Southampton, who reported that increased weight and adiposity during infancy is associated 
with increased risk for wheeze at the age of three years (80). Similarly, reduced early fetal 
growth, based on ultrasound assessment of head circumference and abdominal girth, has 
been related to childhood asthma outcomes in two cohorts (80) (81, 82).  This data suggests 
that factors which influence an individuals early life growth are also important in determining 
asthma risk. 
 
Finally, studies of cord blood mononuclear cell proliferative responses in infants at high risk 
of atopy and asthma suggest that the immunological bias towards atopy is established in-
utero (83) (84) and is predictive of asthma in later childhood (85). 
 
Exactly how genetic and environmental factors interact to influence the development and 
expression of asthma is complex. Genes interact with other genes, and with environmental 
factors to determine asthma susceptibility (4).  In addition, developmental aspects such as 
maturation of the immune response and the timing of infectious exposures during the first 
years of life are important risk modifying factors (4).  Furthermore, asthma does not have a 
unifying pathological explanation (86).  It is a heterogeneous disease with sub-phenotypes, 
each with specific determinants (45). This makes the challenge of identifying early life risk 
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factors, and potential interventions an even greater challenge than if there was single 
common pathway for the inception and expression of asthma. 
 
1.5.2 Genetic factors 
It has long been recognized that asthma runs in families and has a clear hereditary 
component (87). Twin studies show heritability rates of between 35% and 95% for asthma, 
with similar ranges for Total IgE, bronchial hyper-responsiveness and blood eosinophil 
counts (88).  
Wheezing is more common amongst boys than girls in early years.  Data from the National 
Child Development study followed a British national cohort of 17,414 children born during 
one week in March in 1958, with data available at ages 7, 11, 16 and 23 years. The male to 
female ratio for asthma or wheezy bronchitis rose from 1.23 in the 0 to 7 year period, to 1.48 
at 12 to 16 years, and then reversed to 0.59 at 17 to 23 years (11).  This is explained in part 
by differences in airway physiology. Male infants have smaller airways in relation to lung size 
than females, and females have a lower specific airway resistance and consistently higher 
threshold response to methacholine and decreased prevalence of airway hyper-
responsiveness (AHR) than boys, relationships that reverse after adolescence (89). 
  
1.5.3  Asthma genes 
In 2007, Vercelli identified 33 genes associated with asthma and/or asthma related 
phenotypes that had been replicated in at least five independent candidate genome wide 
association studies (GWAS) or positional cloning studies (87).  These genes were grouped 
into four main areas according to function as follows; Innate immunity and immune 
regulation; Th-2 cell differentiation and effector functions; Epithelial biology and mucosal 
immunity; Lung function, airway remodelling and disease severity.  More recently, two meta-
analysis of asthma GWAS have been published (90, 91). The following genes or regions had 
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p values at or near genome-wide levels of significance in both studies: the 17q21 locus, the 
IL1RL1/IL18R1 locus, TSLP, and IL33. These therefore represent four highly replicated, 
robust asthma susceptibility genes. 
 
1.5.4  Limitations of genetic studies 
Genotyping is not yet able to classify an individual’s risk of asthma (90).  In the GABRIEL 
GWAS  study, the sensitivity and specificity of genotyping for predicting individual asthma 
risk was 35% and 75% respectively (90).   This was based on a classification analysis, with 
subjects classified as having asthma if the predicted probability of disease was ≥0.5 using 
seven single nucleotide polymorphisms (SNPs) associated with childhood asthma. Thus 
these common genetic variants only account for a small proportion of asthma risk. Asthma’s 
heterogeneous nature is likely to mean there are many genetically mediated pathways in 
asthma’s development and manifestation (87).   Furthermore, such studies do not take into 
account the complexities of gene-environment interactions.  It is known that gene-
environment interactions can critically modify the impact of a given gene on complex 
phenotypes.  For example, the influence of the CD14-159CT polymorphism on IgE levels 
and asthma seems to depend on the relevant environmental exposures: cat and dog versus 
stable animals in a European population (92), and low versus high endotoxin in subjects of 
African descent (93).  The same gene polymorphism can be associated with either disease 
or protection depending on the environment a subject is exposed to (45).   
 
An additional factor explaining the limitation of genetic studies in accounting for asthma risk 
is that heritability estimates based on twin studies may be inflated. Twins, especially 
monozygotic twins, not only share all of their genes, but also a common uterine and early life 
environment. Thus heritability studies of twins may be telling us more about shared gene-
environment interactions, than simply asthma ‘genes’ (88). An important question is to 
determine the nature of the biological switches that turn environmental exposures into 
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distinct immune response patterns (94). 
 
1.5.5 Environmental determinants 
Epidemiologic studies have highlighted many associations between environmental 
exposures and subsequent risk for asthma and allergy. Environmental modifiers include 
prenatal and postnatal environmental tobacco smoke exposure (95-98), growing up on a 
farm (99), exposure to cats, dogs and furry pets (100-103), family size and birth order (104, 
105), day care attendance in early childhood (106), respiratory viral infections (32, 107), 
microbial exposures (108), pre and postnatal paracetamol exposure (109, 110), antibiotics 
(111, 112), mode of delivery (113, 114), breastfeeding (115, 116), diet and nutrition (117), air 
pollution (118), obesity (119), stress in family or other primary caregivers (120) and allergen 
exposure (121, 122).  The following section will review prenatal determinants of asthma. 
 
1.5.5.1 Maternal asthma 
A meta-analysis of 33 childhood asthma studies has shown that maternal asthma increases 
the risk of disease in offspring to a greater extent than paternal asthma (123). This suggests 
either a specific role for maternal genetic components such as mitochondrial genes or those 
on the X chromosome, or that non-genetic in-utero and/or postnatal environmental factors 
mediated through the mother play a significant role in asthma susceptibility (123).   
 
1.5.5.2 Maternal stress 
Maternal stress in the pre and postnatal period is associated with increased wheezing in 
offspring (120).   Mothers with higher stress in both periods appear to confer greatest risk 
(124). Higher prenatal maternal stress is associated with increased cord blood IgE (125) and 
altered innate and adaptive immune responses in cord blood mononuclear cells (126), an 
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association that may be modified by maternal atopic status (125). It is known that increased 
maternal stress in the third trimester is associated with altered methylation status of the 
human glucocorticoid receptor gene (NR3C1) in newborns, and increased salivary cortisol 
responses at 3 months (127), establishing the principle that maternal stress may alter 
biological responses in the newborn (128).   
 
1.5.5.3 Maternal smoking 
There is evidence to suggest that intrauterine exposure to environmental tobacco smoke is 
more strongly associated with asthma and poor lung function than passive exposure to 
second hand smoke after birth (129-131). In a systematic review of prospective cohort 
studies (98), overall, there was a 21% to 85% increase in asthma attributable to pre or 
postnatal passive smoke exposure, with the strongest effect from prenatal maternal smoking 
on asthma in children aged ≤2 years.  A second review performed a pooled analysis of eight 
European birth cohorts (132). Cohort-specific effects of maternal smoking during pregnancy, 
but not during the first year, on wheeze and asthma at age four to six years were estimated. 
Among the 21,600 children included in the analysis, 735 children (3.4%) were exposed to 
maternal smoking exclusively during pregnancy.  This was significantly associated with 
wheeze and asthma at age four to six years compared to no exposure. The likelihood 
increased in a dose-dependent linear manner with daily maternal cigarette consumption 
during the first trimester of pregnancy (132). Studies of asymptomatic infants have reported 
decrements in lung function shortly after birth in infants exposed to maternal smoking during 
pregnancy (96, 133, 134).  In utero exposure to maternal smoking is independently 
associated with decreased lung function in children of school age, especially for small airway 
flows (130). It is possible that such deficits persist into later childhood (135, 136) and adult 
life (137). 
 
One proposed hypothesis for the effect of maternal smoking on asthma risk in childhood was 
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the effect of polymorphisms in maternal antioxidant genes (Glutathione S-transferase (GST) 
M1) (138).  However this was not supported in a recent study (139). Nicotine is the key 
chemical component of cigarette smoke, and recent studies have shown that nicotine can 
permanently affect the developing lung such that its final structure and function are 
adversely affected (140). Of note, the increased risk of asthma conferred by 17q21 genetic 
variants is restricted to early-onset asthma and the risk is further increased by early-life 
exposure to environmental tobacco smoke (141).   
 
Grandmaternal smoking is also associated with increased asthma risk in childhood (142), 
suggesting a trans generational effect may operate. In a recently published rat model of in 
utero nicotine exposure, potential mechanisms were described (143). F1 offspring of 
nicotine-treated pregnant rats exhibited asthma-like changes to lung function, and 
associated epigenetic changes to DNA and histones. These alterations were blocked by co-
administration of the peroxisome proliferator-activated receptor-γ  agonist, rosiglitazone, 
implicating downregulation of this receptor in the nicotine effects. F2 offspring of F1 mated 
animals exhibited similar changes in lung function to that of their parents, even though they 
had never been exposed to nicotine (143).  
 
1.5.5.4 Maternal paracetamol use 
The use of paracetamol during pregnancy is associated with an increased risk of childhood 
asthma (109, 110, 144, 145).  Features of studies are an association with paracetamol use 
during all trimesters of pregnancy and an association with persistent asthma, severe asthma, 
and with atopy. 
 
Several mechanisms have been proposed to explain why early life paracetamol exposure 
may increase susceptibility to asthma and other allergic disorders. Paracetamol may 
decrease the amount of reduced glutathione present, resulting in impaired respiratory 
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antioxidant defences and airway inflammation (146-148), or may modulate the effect of 
glutathione levels on Th-1 and Th-2 cytokine response patterns (147, 149). Depleting 
glutathione in APCs in animal models causes a shift from Th-1 to Th-2 cytokine production 
that could pre-dispose to atopic diseases such as asthma. Other possible mechanisms are 
that by reducing fever, paracetamol use may reduce the cytokine storm that occurs as part 
of the febrile response, and that paracetamol may influence the production of prostaglandin 
E2 (150).   
 
1.5.5.5 Fetal growth 
Tedner reviewed 29 studies reporting on foetal growth, birth characteristics and allergy/ 
respiratory outcomes in offspring, excluding studies reporting only on gestational age or 
children born prematurely (151). Most studies show a correlation between low birth weight 
and increased risk of asthma or decreased lung function (151). For example, in one 
longitudinal study, reduced foetal size from the first trimester was associated with increased 
risk for asthma and obstructed lung function at age 10 years (81). In this study, for each 
millimetre increase in first trimester size, asthma risk reduced by 6% and FEV1 was higher 
by an average of 6 ml (81).  
 
1.5.5.6 Obstetric factors 
A meta-analysis (152) of 19 articles found that preterm babies (GA< 37 weeks) have an 
increased risk of asthma compared with term babies (152).  Maternal complications during 
pregnancy and at delivery may also increase the risk of wheezing in childhood. In a large 
study of 15,609 children, maternal hypertension or preeclampsia, use of antibiotics for 
urinary tract infections, maternal antibiotic administration at delivery and offspring of a 
mother with diabetes were all risk factors for preschool wheezing (153). Neither 
amniocentesis/chorionic villus sampling, weight gain in pregnancy, or caesarean section was 
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associated with subsequent development of wheezing (153). However, in another meta-
analysis, caesarean section has been linked to risk of asthma in offspring (113).  
 
1.5.5.7 Maternal microbial exposure 
There is a marked gradient in asthma prevalence between urban and rural areas (154).  This 
has been demonstrated most strongly in children who grow up on traditional livestock farms 
or in families with an anthropomorphic lifestyle (154), and is attributed to the wide range of 
microbial exposures.  Such children are protected from childhood asthma and atopy in 
proportion to their level of microbial exposure (155).  This protective effect against the onset 
of asthma is stronger if the microbial exposure occurred during the mother’s pregnancy 
(156). 
 
1.5.5.8 Maternal allergen exposure 
Allergen exposure can lead to the development of tolerance or sensitization, depending on a 
complex set of factors (157). This is also likely to be true during the antenatal period. Trials 
of early allergen avoidance for primary disease prevention have conflicting results (158). 
Food allergen (egg) avoidance in pregnancy has been shown to reduce levels of maternal 
ovalbumin specific IgG as well as the levels of specific antibody reaching the foetus (159). In 
this study, women were randomized to an egg-free or egg containing diet. The effects on this 
risk for allergic disease in the infants were complex. Children with “mid-range” exposure to 
egg were at highest risk for atopy at 6 months, whereas low-level or high-level exposure 
appeared protective. In a Manchester based study of early inhalant allergen (HDM) 
avoidance (160), this was associated with significantly better lung function in preschool 
children, but rates of sensitization were significantly higher. In another study, HDM 
avoidance beginning in the prenatal period was associated with reduced sensitization at 3 
years of age (161).  
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Although these strategies were initiated in pregnancy, it is not possible to separate antenatal 
and postnatal effects.  Currently, there is insufficient evidence to support specific allergen 
avoidance in pregnancy.  Given that asthma is a complex multifactorial disease, it may be 
impossible to prevent by eliminating only one risk factor.  A meta-analysis of 
multifaceted and monofaceted intervention studies suggested the former will have a 
much greater chance of being successful, with the latter being unlikely to yield a 
clinically relevant reduction of asthma(162). 
 
1.5.5.9 Maternal cats and dog exposure 
The literature relating pet exposure and risk of development of asthma and allergic diseases 
is contradictory.  A systematic review in 2009 reviewed a total of 17 and 13 birth cohort 
studies on cat and dog exposure, respectively (102).  The authors concluded that cat or dog 
exposure in early life had no effect on the development of asthma or wheezing symptoms 
and that dog exposure during infancy was found to protect children from developing 
sensitization against aeroallergens. A more recent systematic review identified 9 articles 
relating perinatal pet exposure (from 20 weeks gestation to 4 weeks postnatal life) and 
subsequent asthma and allergic disease (101).  Three articles measured asthma or wheeze 
as an outcome (163-165). All of these studies reported reduced odds or a reduced hazard 
ratio associated with a dog (163, 165) or with pets at birth (164). No studies showed an 
association with cats alone.  A major limitation of these reviews is the inability to completely 
account for the confounding effects of pet-keeping choices made by allergic families.  
 
1.5.5.10  Maternal nutrition  
Subjects exposed to the Dutch famine (1944-45) during early and mid gestation had an 
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increased risk of obstructive airways disease in adult life, not associated with allergy, 
suggesting an effect on lung and airway development (166). Studies have shown an 
association between large head circumference at birth and levels of total IgE in childhood 
(167, 168) and adulthood (169). It is postulated that good nutrient delivery to the foetus in 
early pregnancy programmes for growth in later gestation. If nutrient demand is not met, 
there will be continued head growth at the expense of relatively poorer nutrition to the body 
with consequent effects on rapidly dividing tissues such as those in the immune system (45).  
 
Many dietary components have been proposed as causal in this process, include vitamins 
(A, C, E and D) trace elements (selenium, zinc), food groups (fruit and vegetables) and 
adherence to dietary patterns (Mediterranean diet). A recent systematic review and meta-
analysis investigated the role of nutrients and foods during pregnancy for the primary 
prevention of asthma and atopic disorders in children and is summarised in Table 1.3 (170). 
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Table 1.3 Nutrients and foods for the primary prevention of asthma   
Nutrient/ pattern References Method of assessment Outcome and follow up Effect 
Vitamin A (171, 172) Dietary intake Wheeze age 2 years No association  
Vitamin C (171, 172) Dietary intake Wheeze age 2 years No association  
Vitamin E (171-173) Dietary intake Wheeze age 2 years Higher intake protective 
Vitamin D (174-177) Dietary intake Wheeze age 2 to 5 years Higher intake protective 
 (175, 176) Dietary intake Asthma age 5 years No association  
Selenium (178, 179) Maternal and cord blood levels Wheeze age 5 years No association 
Zinc (171, 179, 180) Cord blood levels Wheeze age 5 years No association  
Fruit and vegetables (181) Fruit and vegetable intake  Asthma age 3 years Higher intake protective 
 (182) Fruit and vegetable intake  Asthma age 8 years No effect 
 (181) Apple intake  Wheeze age 5 years  Higher intake protective 
 (181) Apple intake  Asthma age 5 years Higher intake protective 
Mediterranean diet (183) Adherence to Mediterranean diet  Atopic wheeze age 6 years Higher adherence protective 
 (183) Adherence to Mediterranean diet  Persistent wheeze age 6 years Higher adherence protective 
Reproduced from Nurmatov et al 2011 (170). 
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Overall, the authors found a substantial risk of bias in the studies.  However, the results were 
nonetheless suggestive of potentially beneficial associations of maternal intake of vitamins 
E, D, fruits and vegetables and adherence to Mediterranean diet during pregnancy for 
prevention of wheezing or asthma in offspring (170).  In the ALSPAC study, no association 
was found between dietary patterns in pregnancy and respiratory and atopic outcomes in 
childhood (184). No intervention studies have yet established whether nutrient or dietary 
supplementation during pregnancy will change the risk of asthma in offspring.  
 
Results of a recent randomized controlled trial of vitamin A supplementation in a population 
of married women of childbearing age with chronic vitamin A deficiency in rural Nepal are of 
great relevance to this thesis. At age 9 to 13 years, offspring of mothers who received 
vitamin A before, during and for 6 months after pregnancy had significantly improved lung 
function compared with a placebo group (mean increase in FEV1 46mls, 95% CI 6-86mls) 
(185). All children in the trial received supplemental vitamin A from 6 months of age, 
suggesting that vitamin A status from preconception through to age 6 months influences 
long-term lung development.  It should be noted that data regarding potential confounders 
such as later nutritional status were not reported in this trial. The data regarding vitamin A 
are particularly relevant, due to the common signalling pathway shared by the activated 
forms of vitamins A and D. The active metabolite of vitamin A, retinoic acid (RA), is a critical 
signalling molecule in early lung development with maternal deficiency causing profound 
abnormalities of the infant respiratory system, including tracheoesophageal fistula, lung 
hypoplasia and lung agenesis (186).  Mechanisms include RA effects on TGF-β and 
Fibroblast growth factor 10 (FGF-10) pathways at prospective sites of lung formation 
(187).   RA also influences alveolarisation (188) so that postnatal treatment with RA 
increases the number of pulmonary alveoli in rats (189).  The study provides evidence that 
maternal micronutrient status can influence foetal/infant lung development with significant 
consequences for longer-term respiratory health in humans.  
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1.5.5.11  Maternal fatty acid intake 
There is evidence from epidemiological studies, mechanistic data and results of randomised 
intervention trials to suggest a protective role for maternal supplementation with omega-3 
polyunsaturated fatty acids (n-3 PUFA) during pregnancy on asthma risk in offspring (190, 
191).  The underlying hypothesis states that Western diets have shifted from a state of 
balance between anti-inflammatory omega-3 fatty acids (n-3 PUFA) and pro-inflammatory 
omega-6 fatty acids (n-6 PUFA), to a state where dietary n-6 PUFA are predominant (190). 
High concentrations of dietary n-6 PUFA favour Th-2 differentiation, and thus atopic 
sensitization, during immune system development (192). Also, n-3 PUFA supplementation 
may alter T helper cell balance through suppression of IL-13 production, which has a role in 
induction of IgE synthesis in B cells and Th-2 type differentiation in T cells (193). 
 
Several intervention trials have been conducted (194-198) and systematically reviewed (190, 
191). In the review by Klemens (190), n-3 PUFA supplementation during pregnancy reduced 
12-month prevalence of positive egg SPT (two trials) and childhood asthma (two trials) and 
significantly reduced cord blood IL-13 levels. Supplementation during lactation did not 
prevent asthma, food allergy or atopy. The authors concluded that large randomized 
controlled studies are needed before clinical recommendations can be made regarding the 
benefit of n-3 PUFA supplementation in pregnancy.  However other systematic reviews did 
not confirm this relationship and do not advocate fish oil supplementation for primary 
prevention of asthma (199). 
 
More recently, a postnatal fish oil supplementation trial has reported and found no effect on 
childhood allergic disease at 12 months of age (200).  A prenatal intervention study of n-3 
PUFA’s during pregnancy in mothers with a foetus at high hereditary risk of allergic disease 
found no effect on IgE associated allergies in the first year of life, although atopic eczema 
and egg sensitisation was lower (201).   A prenatal intervention study of n-3 PUFAs in 
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pregnancy and lactation in women at high risk of having an allergic infant found no difference 
in prevalence of allergic symptoms between intervention groups.  However the cumulative 
incidence of IgE associated disease was reduced in the intervention group (202).  
 
 
1.6 Nutritional interventions for Primary Prevention of asthma 
1.6.1 Introduction 
Asthma has its origins in early life and it is hypothesised that environmental or nutritional 
manipulation during this period may prevent asthma, known as primary prevention.  A 
number of strategies have been investigated with mixed results.  Manipulating early life 
environmental house dust mite exposure has been unsuccessful, and is associated with 
increased allergen sensitisation and eczema in offspring in the intervention groups in some 
trials. Multifaceted environmental interventions combining reduced exposure to 
environmental and food allergens, along with promotion of breast-feeding and reduced 
environmental tobacco smoke exposure have shown some clinical benefit in high-risk 
children.  Supplementation with n-3 PUFA’s has been effective in reducing asthma in some 
trials. Results of trials of early life vitamin or food group supplementation are awaited. 
 
1.6.2 n-3 PUFA’s 
See section 1.5.5.11. 
1.6.3  Vitamins and foods 
As discussed in section 2.4.4.9, a recent systematic review of nutrition and food for the 
primary prevention of asthma and allergy found epidemiological and biological evidence 
suggestive of potentially beneficial associations of maternal intake of vitamins E, D, fruits 
and vegetables and adherence to a Mediterranean diet during pregnancy on risk of offspring 
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developing asthma (170).  No intervention studies have yet established whether nutrient or 
dietary supplementation during pregnancy will change the risk of asthma in offspring. One 
study found that high-dose antenatal vitamin C and E supplementation does not improve 
infant respiratory outcome and is associated with increased healthcare utilisation and cost of 
care (203).  However, a number of randomised intervention trials are currently in progress.  
These include a double blind randomised placebo controlled pilot study of a dietary soup 
intervention during pregnancy to optimise dietary vitamin E (NCT01661530), trials of vitamin 
D supplementation in pregnancy that will be described later in this thesis, and a randomized 
trial of the effectiveness of the Mediterranean diet in pregnant women at high risk of having a 
child with allergy (NCT01634516). 
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1.7 Vitamin D physiology 
1.7.1 Sources 
Vitamin D is a pro-hormone made by most living plants and animals. Vitamin D comes in two 
main forms – vitamin D2 (ergocalciferol - the major form made by plants), and vitamin D3 
(cholecalciferol - from animals, including humans). With adequate sunlight exposure, the 
main source for humans is synthesis of vitamin D3 in the skin by the action of ultraviolet B in 
the range of 280-320nm on 7-dihydrocholesterol (204). Although humans can only 
synthesise vitamin D3 de novo, they can also metabolise vitamin D2.  For the purpose of this 
thesis, vitamin D (without subscript) refers to ergocalciferol and cholecalciferol.  Vitamin D is 
measured in international units (IU) or micrograms. 40 IU equals 1 microgram. 
 
1.7.1.1 Sunlight 
Human cutaneous vitamin D3 synthesis is sunlight dependent and therefore determined by 
latitude, time of day and season of the year (205).  For example, comparing production 
between different latitudes, in Boston (latitude 42o N) synthesis is possible between March 
and November, whereas in Bergen (latitude 60o N) synthesis is only possible between April 
and October, with a difference in peak production between Boston and Bergen of 200% 
(206).  Additional environmental determinants include atmospheric pollutants such as ozone, 
a major absorber of UVB radiation that is found in the stratosphere, aerosol content, cloud 
cover, albedo (which describes the amount of radiation reflected by the earth’s surface, with 
snow having 90% albedo) and diffusion, which refers to the scattering of UVB radiation as it 
passes through the atmosphere (205).  How much UVB penetrates through the skin to 
initiate vitamin D synthesis depends on the concentration of melanin (207).  This is 
genetically determined, and those with darker skin types require longer sun exposure to 
produce the same amount of vitamin D (208, 209).  Clothing is an obvious barrier to vitamin 
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D production by UV radiation, and women who wear veils are at especially high risk of 
vitamin D deficiency (207). Proper application of sunscreen will reduce vitamin D synthesis 
by 99.9% (210). Other factors that determine vitamin D status include adiposity, ethnic and 
genetic variation, poor renal function, malabsorption, and use of medication such as 
anticonvulsants and glucocorticoids (211) 
 
1.7.1.2 Diet 
Natural dietary sources include oily fish (rich in vitamin D3), and plant derived sources such 
as sun dried shitake mushrooms (rich in vitamin D2) (210).   The method of cooking food can 
have significant effects on the vitamin D content, with frying fish reducing the active vitamin 
D content by approximately 50% (207).  Fortification of foods with vitamin D was introduced 
as part of a range of public health measures for the prevention of rickets in the 1930’s (212).  
Policies vary considerably between countries, but in the UK, the only statutory requirements 
are to fortify margarine and infant milk formula (213).  In addition, many manufacturers 
voluntarily fortify breakfast cereals, soya and some dairy products, although this is often a 
minimal amount (213).   
 
1.7.1.3 Nutritional supplements 
A range of vitamin supplements containing vitamin D3, vitamin D2, or a combination of the 
two are available.  Although traditionally vitamin D2 and D3 have been considered to be 
equipotent, studies have suggested that supplementation with vitamin D3 is superior (207). 
 
1.7.1.4 Vitamin D from breast milk and infant formulae  
Breast milk is a poor source of vitamin D (207).  The average content is 22IU/L (range 15-
50IU/L) in a vitamin D-sufficient mother (214), which equates to an intake of approximately 
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11 to 38IU/day for an infant consuming 750mls of breast milk per day. This compares with 
infant formulas which in the United Kingdom, as for many countries, are legally obliged to be 
fortified with 40 to 100IU of vitamin D per 100 kcal per day which provides 300 to 750IU /day 
for the same estimated intake (215). 
 
1.7.2 Metabolism in the liver and kidneys 
Following synthesis in the skin or absorption from the gut, vitamin D can be stored in and 
then released from fat cells (210).  Vitamin D in the circulation travels in the circulation 
bound to vitamin D binding protein (VDBP).  To become metabolically active, vitamin D must 
undergo two hydroxylations.  The first occurs primarily in the liver to form 25-hydroxyvitamin 
D (25(OH)D), which is biologically inactive but the best marker of an individual’s vitamin D 
status. 25(OH)D is expressed as ng/ml or nmol/L, with 1.0 ng/ml equivalent to 2.5 nmol/L 
(216).   The second hydroxylation occurs in the epithelial cells of the proximal tubules of the 
kidney and converts 25(OH)D to the biologically active hormone 1,25-dihydroxyvitamin D 
(1,25(OH)2D).  This is driven by the action of CYP27B1, a mitochondrial P450 hydroxylase 
and is regulated by parathyroid hormone, calcium and phosphorous levels to maintain 
calcium homeostasis (216).  Finally, 1,25(OH)2D induces the expression of the enzyme 
CYP24, which catabolises 25(OH)D and 1,25(OH)2D to biologically inactive calcitroic acid, 
which is excreted in bile (216). 
 
1.7.3 Placental metabolism 
The vitamin D status of a pregnant woman directly influences that of her foetus/infant 
(217).   During the course of pregnancy, maternal levels of 25(OH)D modestly decline and at 
delivery, cord 25(OH)D levels are typically ≤ 20% lower than maternal levels (218, 219).  The 
decidua and placenta have large amounts of CYP27B1 enzyme activity resulting in 
generation of 1,25(OH)2D (220). Methylation of the gene that codes for placental CYP24A1 
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(the enzyme responsible for catabolism of 1,25(OH)2D to inactive metabolites) results in 
maternal 1,25(OH)2D levels increasing to as high as two fold in late pregnancy compared to 
postpartum or non pregnant controls (221).  However, 1,25(OH)2D does not readily cross the 
placenta and combined with foetal suppression of renal CYP27B1 by low parathyroid 
hormone and phosphorous levels, circulating foetal 1,25(OH)2D3 concentrations are 
significantly lower than maternal values in humans (218). Postnatally, foetal dependency on 
maternal vitamin D may manifest in infants of deficient mothers with hypocalcaemia and 
rickets.  Breast milk has a low vitamin D and 25(OH)D content unless the mother takes 
supplements (218) and so exclusively breastfed infants are largely dependent on their 
prenatally acquired vitamin D stores or supplementation. For this reason infant formula is 
supplemented with vitamin D, and many countries have a policy of routine vitamin D 
supplementation for breastfed infants (213).   
1.7.4 Extra-skeletal metabolism 
In addition to this classic pathway, the enzyme CYP27B1 is widely expressed in cells 
throughout the body (210).  The extra-skeletal effects of vitamin D were first recognized in 
1979 with the observation that patients with sarcoidosis may present with hypercalcemia 
secondary to elevated circulating levels of 1,25(OH)2D (222).  In these patients, the high 
serum 1,25(OH)2D arises from increased activity of CYP27B1 in disease-associated 
macrophages (223).  Following this discovery, synthesis of 1,25(OH)2D and the ability to 
elicit intracrine or paracrine responses from immune cells has been described for 
macrophages, dendritic cells, T-lymphocytes, B-lymphocytes and other cell types from the 
immune system (224-226). 1,25(OH)2D is now widely recognized as having well defined 
actions in innate and adaptive immunity including induction of antimicrobial peptide secretion 
in response to innate immune stimuli (227) and as a potent promoter of tolerogenic dendritic 
cells and regulatory T cells (228).   Importantly for this thesis, extra-renal 1,25(OH)2D is not 
under feedback control from parathyroid hormone, and it has been argued that global 
deficiency or excess of 25(OH)D may lead to adverse consequences on immune 
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development (229). However, it is very important to note that the majority of observations on 
the extra-skeletal effects of 1,25(OH)2D have been in-vitro, and the extent to which extra-
renal metabolism occurs in normal health is disputed (230).  
 
1.7.5 Mechanism of action 
The actions of 1,25(OH)2D are mediated via two pathways; a slow genomic response and a 
rapid,  non-genomic response (231, 232).  Both involve binding to its nuclear receptor, the 
vitamin D receptor (VDR).  In the genomic pathway, VDR functions as a heterodimer with the 
retinoid X receptor (RXR) (233).  After binding, VDR undergoes a conformation change that 
promotes RXR-VDR heterodimerization. The bound heterodimer translocates to the nucleus 
where VDR binds to vitamin D responsive elements (VDRE) and ultimately modifies gene 
transcription (233). The expression of over 200 genes are controlled via 1,25(OH)2D/ VDR 
dependant pathways acting on VDREs (210).  In the non-genomic pathway, 1,25(OH)2D 
binds to VDR present in the caveolae of the plasma membrane, forming  ligand bound VDR 
which activates signalling cascades including protein kinase C and phospholipase C (234).  
Rapid responses triggered by this pathway include intestinal absorption of calcium and the 
secretion of insulin by pancreatic β-cells (232).   
 
1.7.6 Optimum levels of vitamin D for health 
In the United Kingdom levels of 25(OH)D ≤ 25nmol/L and levels between 25 and 50nmol/L 
are considered to represent vitamin D deficiency and insufficiency respectively (213).  This is 
based on corresponding markers of bone health such as parathyroid hormone levels, and 
clear cause and effect clinical outcomes such as rickets in children and osteomalacia in 
adults (215, 235, 236).  Beyond skeletal health, there is a growing body of observational 
data relating hypovitaminosis D with a range of adverse health outcomes including 
cardiovascular disease, cancer, autoimmune disease, infection, and all cause mortality (213, 
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237, 238). For example, studies suggest that levels of 25(OH)D below 50nmol/L are 
associated with a 30-50% increased risk of incident colon, prostate and breast cancer, along 
with higher mortality from these cancers (210). Many prospective randomized controlled 
trials are in progress to answer this question.  Many researchers argue that the optimum 
level of 25(OH)D for health is ≥ 75nmol/L (239).  However, the fundamental question is 
whether vitamin D deficiency is causal in these adverse outcomes, or simply an effect of 
residual or unrecognized confounding.  For example, lower levels of 25(OH)D may simply be 
a reflection of an unhealthy, sedentary lifestyle, or a type of unhealthy dietary pattern.  Also, 
and of particular relevance to the proposed role for vitamin D in the development of asthma, 
there is evidence to suggest that plasma concentrations of 25(OH)D decrease after an 
inflammatory insult(240).  This may be a cause of reverse causality, with more severely 
affected individuals with asthma (inflammation) having lower levels of vitamin D because of 
their disease.  It should be noted that the United States Institute of Medicine committee 
report on dietary reference intakes for calcium and vitamin D concluded that for extra-
skeletal outcomes, including cancer, cardiovascular disease, diabetes and autoimmune 
disorders, evidence is inconsistent, inconclusive as to causality and insufficient to inform 
nutritional requirements (241).  Randomised trials are sparse. The committee concluded that 
the prevalence of vitamin D inadequacy in North America has been overestimated, and 
reiterated that 25(OH)D levels above 50nmol/L are clinically sufficient (241). 
 
1.7.7 Prevalence of perinatal vitamin D deficiency 
Early life hypovitaminosis D is common and increasingly recognized as a global public health 
issue (238).  Table 1.4 lists recent studies describing the prevalence of hypovitaminosis D 
amongst pregnant women and their newborn infants in different populations.   
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 Table 1.4  Vitamin D status of pregnant women and their offspring in cross sectional studies worldwide 
Setting Population Cut off for 
‘deficiency' 
% cord 25(OH)D 
deficient 
% maternal 25(OH)D 
deficient 
US national survey (242) 928 unselected pregnant women <50 nmol/L - 33% 
US antenatal clinic (236) 433 unselected pregnant women 
376 newborns 
<37.5 
nmol/L 
38% 23% 
US antenatal clinic (237) 80 pregnant Black adolescents <37.5 
nmol/L 
- 21% 
US antenatal clinic (238) 400 pregnant women: 
200 black, 200 white 
<37.5 
nmol/L 
46% Black 
10% white 
45% Black 
2% white 
UK antenatal clinic (240) 466 pregnant Caucasian women <50 nmol/L - 50% 
UK antenatal clinic (241) 263 pregnant adolescents <25 nmol/L - 30% 
UK antenatal clinic (243) 180 pregnant women 
45 Asian, 45 Middle Eastern, 
45 Black, 45 Caucasian 
<25 nmol/L - 47% Asian 
64% Middle Eastern 
58% Black 
13% Caucasian 
Dutch antenatal clinic (244) 86 pregnant women: 
48 ‘high risk’ (dark skin or veiled) 
<25 nmol/L - 
63% high risk 
- 
- 
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38 ‘controls’ (light skin, not veiled) 16% controls - 
Australian antenatal clinic (243) 971 pregnant women and 901 offspring <25 nmol/L 11% 15% 
(Veiled women 71%) 
(Non-veiled women 11%) 
NZ primary care clinic (246) 90 unselected pregnant women <25nmol/L - 61% 
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At risk groups include ethnicities with pigmented skin, women who wear concealing clothing 
(244-248), poor uptake of vitamin D supplementation (243, 249-251) and prolonged breast 
feeding (213).  Hypovitaminosis D is also common in pregnant white women with no 
additional ‘risk factors’ (252).   
 
1.7.8 Genetic determination of vitamin D status 
Family and twin studies suggest that a substantial portion of the variability in vitamin D can 
be attributed to genetics, with heritability estimates of 43% to 65% for 25(OH)D, 1,25(OH)2D 
and VDBP (253, 254).   In large, healthy populations, GWAS have shown that genes 
involved in cholesterol synthesis (DHCR7), vitamin D hydroxylation (CYP2R1), and vitamin 
D transport (VDBP, or GC) affect vitamin D status, with variation at these loci identifying 
individuals at substantial increased risk of vitamin D insufficiency (255-257). 
 
1.7.9  Health implications of vitamin D deficiency in pregnant women 
The clearest health implications of vitamin D deficiency in pregnant women are on bone 
health and calcium homeostasis in offspring. There is a strong causal relationship between 
maternal and foetal cord circulating 25(OH)D levels (204).  Severe maternal vitamin D 
deficiency may manifest as rickets in utero (258).  Neonatal hypocalcaemia secondary to 
vitamin D deficiency is a well-recognized clinical entity. Reduced maternal vitamin D intake is 
also associated with reduced foetal growth (259) and smaller head circumference (260). 
Reduced concentration of 25(OH)D in mothers during late pregnancy are associated with 
reduced whole body and lumbar spine bone mineral content in children aged 9 years (261).  
 
However, observational evidence now links low maternal vitamin D levels during pregnancy 
with a range of short and long term adverse health outcomes.  For the mother, increased risk 
of pre-eclampsia, gestational diabetes, preterm labour, obstructed labour, caesarean section 
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and bacterial vaginosis have all been described (262).  For offspring, and of most relevance 
to this thesis, there is accumulating evidence of a role for vitamin D in developmental 
programming of chronic diseases including type 1 diabetes, multiple sclerosis and 
schizophrenia (262).  The data for schizophrenia are intriguing.  It is known that individuals 
born in winter and spring have increased risk of later developing schizophrenia, and the 
effect size of this observation is magnified by latitude (263). Individuals with darker skins are 
at greater risk of developing schizophrenia (263). The VDR is widely expressed in the 
human brain (264), and in experimental models of developmental vitamin D deficiency in 
rats, offspring born of deficient mothers have anatomical brain changes and alterations in 
biological pathways including dopamine metabolism (264).  Finally, in a case-control linkage 
study of the Danish Psychiatric Central register and neonatal dried blood spot analysis, the 
risk of schizophrenia was significantly associated with neonatal 25(OH)D concentrations 
(265).  In this study, infants with lower and also the highest vitamin D levels had higher risk 
of schizophrenia - suggesting a U-shaped risk relationship.  As will be shown, this has 
parallels with the data relating prenatal vitamin D status and atopic sensitisation in later life. 
 
1.7.10 Recommendations on Vitamin D intake during pregnancy 
In the UK, the National Institute for Clinical Excellence recommends pregnant women and at 
risk groups take 400IU daily (266).  In the United States, the advice is to take 600IU through 
pregnancy (241).  It is acknowledged that current guidance from health care providers to 
pregnant women is inconsistent and a barrier to effective primary prevention of 
hypovitaminosis D (252). A recent editorial has called for urgent intervention to address early 
life hypovitaminosis D (267). 
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1.8 Evidence of an association between prenatal vitamin D status and 
child health 
1.8.1 Vitamin D hypotheses 
Changing early life vitamin D status is one proposed environmental factor for the asthma 
epidemic. Opposing hypotheses argue that either high or low vitamin D status, at critical 
times in development have contributed to the asthma epidemic. In the former, Wjst and Dold 
argue that it was the introduction of vitamin D supplementation in the 1950’s to prevent 
rickets that led to the asthma epidemic (268).  Contrary to this, Litonjua argue that as 
populations have grown more prosperous since the 1960s, more time is spent indoors and 
there is less exposure to sunlight.  This, coupled with inadequate intake from food and 
supplements, increasing obesity and migration patterns to Western countries have led to an 
epidemic of vitamin D deficiency, particularly in pregnant women (269).  Epidemiological 
data support both hypotheses.   
1.8.2 Ecological epidemiology 
Ecological studies provide weak evidence of a relationship between developmental vitamin 
D deficiency and allergic health outcomes.  Limitations include the risk of confounding, and 
of studying large aggregates of individuals.  However, using latitude as a proxy for vitamin D 
status,  rates of prescription of hypoallergenic formulae (270) and epinephrine auto-injectors 
(271) are significantly higher in those living further south in Australia.  In the case of 
hypoallergenic formulae, there was also a significant East-West effect with more 
prescriptions in Eastern Australia (270), suggesting a metropolitan effect may be an 
additional factor.  In the United States, the North-East New England region has a higher 
epinephrine prescription rate compared to Southern regions (272), and rates of emergency 
department visits for acute allergic reactions are statistically higher in North Eastern vs 
Southern regions, an association that was stronger when restricted to food related allergic 
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reactions (273).  For epinephrine prescriptions, although a North-South gradient was 
observed, neither latitude nor longitude were independently analysed for the entire data set.  
There were clear inconsistencies, with Alaska not having the highest rate (in fact the same 
as Wisconsin and Tennessee), and South Eastern states (Florida) having higher levels than 
more Northerly states (272). 
 
Studies using birth month as a surrogate for vitamin D status have shown mixed results with 
positive, negative and unclear outcomes (274).  In one of the largest analyses, which used a 
validated questionnaire distributed in 54 centres to a representative sample of 20 to 44 year 
old men and women mainly in Europe, but including North Africa, India, North America, 
Australia and New Zealand (200,682 participants), allergic rhinitis decreased with 
geographical latitude, (with many exceptions), and no significant effect of birth month was 
observed (274).  Effect estimates by multivariate analysis of total and specific IgE values in 
18,085 individuals excluded major birth month effects and confirmed the independent effect 
of language grouping (274).   
 
However, fall birth was statistically more common among food allergic subjects in the United 
States National Health and Nutrition Examination Survey (NHANES) and amongst patients 
attending a North American allergy clinic patients (n=1514) (275). Also, children less than 5 
years of age born in fall/ winter had a 53% higher odds of presenting to a Boston emergency 
department with food related acute allergic reactions compared to controls in a retrospective 
review, a relationship independent of suspected trigger and allergic comorbidities (276).  
 
1.8.3 Genetic studies 
A number of genes involved in vitamin D metabolism (DHCR7, CYP2R1 and GC) have been 
identified as conferring substantial risk of vitamin D insufficiency (255-257).  These 
associations were explored in a GWAS of asthmatic patients in three separate cohorts –
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Boston, USA, Costa Rica and Puerto Rico (277).  The most significant gene, GC, had a 
strong association in all three cohorts (277) a finding that has been replicated in a cohort of 
Chinese Han asthmatics (278). 
 
Other genetic studies in asthma populations have shown conflicting results. Variants in the 
VDR gene have been associated with increased asthma risk (279, 280) but this has not 
been replicated in all studies (278, 281, 282).  Variants in vitamin D pathway genes (283) 
have also been associated with asthma susceptibility.  There is evidence that 
polymorphisms in the class I MHC-restricted T cell associated molecule gene (CRTAM) are 
associated with increased rate of asthma exacerbations in the presence of low circulating 
vitamin D levels, a finding that was replicated in a second independent population (284).  
CRTAM is highly expressed in activated human CD8+ and natural killer T cells, both of which 
have been implicated in asthmatic patients (284). 
 
In a study of 649 children (285), vitamin D deficiency increased the risk of food sensitization, 
but only among individuals with certain polymorphisms [IL-4 (rs2243250), MS4A2 
(rs512555), FCER1G (rs2070901) and CYP24A1 (rs2762934)].  This suggests there may be 
gene–vitamin D interactions determining allergic sensitization(285), a finding that has been 
replicated in a study on white European adults (286), with the polymorphism MS4A2 
(rs512555) and IL-4 (rs2243250) modifying the association between vitamin D deficiency 
and total IgE concentrations. 
 
1.8.4 Birth cohort studies 
15 cohort studies have examined the relationship between early life vitamin D exposure and 
respiratory or allergic related outcomes (145, 174-176, 285, 287-296).  A detailed description 
of these studies is presented in Table 1.5, followed by a summary of the available evidence 
for each outcome. 
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Table 1.5 Epidemiological associations between early life vitamin D status and allergic or respiratory health  
Country 
(Ref) 
Follow up Methodolog
y 
Comparison 
groups 
Maternal 
25(OH)D 
(nmol/L) 
Median 
(IQR) 
Outcome in 
offspring 
Result Effect of 
exposure 
USA 
(174) 
1194 of 2198 
pregnancies to 
3 years 
Maternal 
diet FFQ 
Highest vs. lowest 
quartile of intake in 
mother 
- Recurrent wheeze 
Respiratory 
infection 
Eczema 
aOR 0.38 (0.22, 0.65) 
aOR 0.75 (0.52, 1.09) 
aOR 0.92 (0.63, 1.35) 
Protective 
No association 
No association 
UK (175) 1212 of 2000 
pregnancies to 
5 years 
Maternal 
diet FFQ 
Highest vs. lowest 
quintile of intake 
in mother 
 
 
- Ever wheezed 
Wheeze in last 
12m 
Persistent wheeze 
Spirometry 
BDR 
 
aOR 0.48 (0.25, 0.91) 
aOR 0.35 (0.15, 0.83) 
aOR 0.33 (0.11, 0.98) 
No association 
Lower intake associated 
with decreased BDR 
No association 
Protective 
Protective 
Protective 
No association 
Harmful 
 
No association 
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Skin prick atopy 
eNO 
No association No association 
Finland 
(176) 
1669 of 4193 
pregnancies to 
5 years 
Maternal 
diet FFQ 
Highest vs. lowest 
quartile of intake in 
mother 
- Asthma 
Allergic rhinitis 
Atopic eczema 
aHR 0.80 (0.64, 0.99) 
aHR 0.85 (0.75, 0.97) 
aHR 0.94 (0.84, 1.04) 
Protective 
Protective 
No association 
 
UK (287) 178 of 596 
pregnancies to 
9 years 
Maternal 
25(OH)D 
 
Mothers with levels 
>75nmol/L vs. 
<30nmol/L 
50 (30-75) 
 
Eczema 
Eczema 
Asthma 
aOR 1.62 (0.67, 3.89) 
aOR 1.89 (0.51, 6.99) 
aOR 5.40 (1.09, 26.65) 
No association 
No association 
Increased risk 
Finland 
(288) 
7648 of 12,058 
infants born in 
1966 to 
31 years 
Vitamin D 
supplement
s during first 
year 
Supplementation 
>2000 IU/day vs. 
no 
supplementation 
- Atopy 
Allergic rhinitis 
Asthma 
aOR 1.33 (1.07, 1.64) 
aOR 1.33 (1.12, 1.58) 
aOR 1.33 (0.97, 1.82) 
Harmful 
Harmful 
No association 
Japan 
(289) 
763 of 1002 
pregnancies to 
24 months 
Maternal 
diet FFQ 
Maternal intake 
172IU/day vs. 
<172IU/day 
- Wheeze 
Eczema 
 
aOR 0.64 (0.43, 0.97) 
aOR 0.63 (0.41, 0.98) 
 
Protective 
Protective 
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New 
Zealand 
(290) 
823 of 922 
newborns 
to 5yrs 
Cord 
25(OH)D 
 
Mothers with levels 
<25nmol/L vs. 
75nmol/L 
 
44 (29-78) RTI at 3 months 
Any infection 
Cumulative 
wheeze 
Incident asthma 
aOR 2.04 (1.13, 3.67) 
aOR 2.36 (1.17, 4.73) 
aOR 2.15 (1.39, 3.33) 
aOR 1.03 (0.97, 1.10) 
Protective 
Protective 
Protective 
No association 
USA (291) 
 
 
219 children 
enrolled at 
birth 
to 5 years 
Cord 
25(OH)D 
 
Comparing 
mothers with low 
(<50) and high 
(100) levels to the 
reference group 
(50-74.9 nmol/L) 
64 (49-81) Total IgE 
 
Specific IgE 
 
Skin prick atopy 
 
Allergic rhinitis 
 
Asthma 
 
Low: aC 0.27 (0.08, 
0.47) 
High: aC 0.27 (-0.00, 
0.54) 
Low: aC 2.8 (1.2, 6.6) 
High: aC 3.6 (1.2,10.5) 
Low: aOR 1.2 (0.5, 2.7) 
High: aOR 3.4 (1.0, 11.4) 
Low: aOR 1.1 (0.4, 2.8) 
High: aOR 2.4 (0.8, 7.3) 
Low: aOR 0.5 (0.2, 1.6) 
High aOR 1.4 (0.4, 5.4) 
Harmful 
No association 
Harmful 
Harmful 
No association 
Harmful 
No association 
No association 
No association 
No association 
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Spain (292) 
 
1724 
pregnancies to 
6 years 
Maternal 
25(OH)D 
 
Highest vs. lowest 
quartile of intake in 
mother 
73.8 (56-93) LRTI at 1 year 
Wheezing at 1 year 
Wheezing at 4 
years 
Asthma 
aOR 0.67 (0.50, 0.90) 
aOR 0.91 (0.67, 1.23) 
aOR 0.94 (0.62, 1.43) 
aOR 0.89 (0.59, 1.32) 
Protective 
No association 
No association 
No association 
UK (293) 860 mother-
child pairs to 6 
years 
Maternal 
25(OH)D 
 
Change in relative 
risk per 
10nmol/litre 
change in maternal 
25(OH)D 
59 (41-85) Any wheeze 
Current wheeze 
Current asthma 
Skin prick atopy 
eNO at 6 years 
Spirometry 
BHR 
aRR 1.00 (0.92, 1.02) 
aRR 0.99 (0.94, 1.05) 
aRR 0.98 (0.92, 1.04) 
Not associated 
Not associated 
Not associated 
Not associated 
No association 
No association 
No association 
No association 
No association 
No association 
No association 
Netherland
s (294) 
156 neonates 
followed to 1 
year 
 
Cord 
25(OH)D 
 
Mothers with levels 
<50nmol/L vs. 
75nmol/L 
82 (SE 3.5) RSV 
 
 
aRR 6.2 (1.6, 24.9) Protective 
Netherland 436 of 2343 Maternal Mother or child’s Mean ± SD Spirometry No association No association 
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s 
(295) 
pregnancies to 
7 years* 
 
 
25(OH)D 
 
vitamin D level, or 
vitamin D 
supplementation in 
childhood 
46 ±18 
 
 Lower intake associated 
with reduced FEV1 z 
scores 
 
Inconsistent 
 
USA (285) 649 children 
enrolled at 
birth 
Cord 
25(OH)D 
Effect of vitamin D 
deficiency 
explored 
individually and 
with 
polymorphisms 
known regulate 
IgE and VD 
- Specific IgE to 
foods 
 
No association when 
examined alone 
Strong gene-vitamin D 
deficiency interaction 
evident 
 
Deficiency 
may increase 
risk of food 
sensitivity 
among 
individuals with 
certain 
genotypes 
Germany 
(296) 
378 mother-
child pairs 
Maternal 
and cord 
25(OH)D 
 Maternal = 
55 (36, 78) 
Cord = 27 
(18, 44) 
Risk of food allergy 
Sensitisation 
against food 
antigens at age two 
Both positively 
associated 
Higher maternal levels 
associated with 
increased risk of 
Harmful 
Harmful 
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sensitisation 
 
UK 
(145) 
5513 mother-
child pairs 
Maternal 
25(OH)D 
level 
Analysed across 
quintiles of 
maternal 25(OH)D 
level 
Maternal = 
62 
(46, 81) 
Wheeze at 7.5 yrs 
Asthma at 7.5 yrs 
Atopy at 7.5 yrs 
Eczema at 7.5 yrs 
Hayfever at 7.5 yrs 
IgE at 7 yrs 
Lung function 8.7 
yrs 
BDR at age 8.7 yrs 
No association for any 
outcomes. 
No association 
FFQ (Food frequency questionnaire), aOR (adjusted odds ratio), BDR (Bronchodilator response), eNO (exhaled nitric oxide), aHR (adjusted 
Hazard ratio), RTI (Respiratory tract infection), aC (adjusted coefficient), aRR (adjusted relative risk), SE (standard error), RSV (respiratory 
syncytial virus) and FEV1 (forced expired volume in 1 second) 
*2052 mothers with ‘conventional lifestyle’ and 291 with ‘alternative lifestyle’  
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1.8.4.1 Wheezing 
Three studies based on vitamin D status estimated by maternal dietary intake in pregnancy 
have suggested a protective effect of a higher intake on wheezing in childhood (175, 289, 
297). In studies that measured early life 25(OH)D levels, one study supports this observation 
with reduced cumulative wheeze by 5 years (290) and three studies found no relationship 
with wheezing at 1 year, 4 years (292), 6 years (293) and 7.5 years (145). 
 
1.8.4.2 Asthma 
One study based on vitamin D status estimated by maternal dietary intake in pregnancy 
suggested a protective effect of higher intake on asthma diagnosis at 5 years of age (298).  
In contrast, one study of infant supplementation with 2000 IU of vitamin D in infancy 
suggested no effect on asthma at 31 years of age (288).  Of the five studies that measured 
early life 25(OH)D levels, none have found an effect on asthma (145, 290-293), and one 
study found an increased risk of asthma at age 9 years (287). 
 
1.8.4.3 Allergic rhinitis 
One study based on vitamin D status estimated by maternal dietary intake in pregnancy 
suggested a protective effect of higher intake on allergic rhinitis at 5 years (298).  In contrast, 
one study of infant supplementation with 2000 IU in infancy has suggested an increased risk 
of allergic rhinitis at 31 years of age (288). In the two studies that measured cord 25(OH)D 
levels, no effect was found (145, 291). 
 
1.8.4.4 Eczema 
One study based on vitamin D status estimated by maternal dietary intake in pregnancy 
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suggested a protective effect of a higher intake on eczema at 24 months (177) and two 
studies no effect (297, 298).  In the two studies that measured maternal 25(OH)D levels in 
pregnancy, no effect was seen on eczema (145, 287). 
 
1.8.4.5 Respiratory tract infection 
In one study based on vitamin D status estimated by maternal dietary intake in pregnancy 
that reported respiratory tract infection as an outcome, no effect was found (297).  However, 
three studies that measured early life 25(OH)D levels have found a protective effect of 
higher early life 25(OH)D levels on respiratory tract infections in the first three months (290), 
or at 1 year of age (292, 294). 
 
1.8.4.6 Skin prick test positivity 
One study based on vitamin D status estimated by maternal dietary intake in pregnancy 
found no association with skin prick test positivity (175), and one study of infant 
supplementation with 2000 IU in infancy suggested no association at 31 years of age (288).  
In studies that measured early life 25(OH)D levels, two studies found no association with 
atopy (145, 293), one study found both low (<50nmol/L) and high (100nmol/L) levels of 
25(OH)D in cord blood are associated with increased atopy at 5 years compared to a 
reference group with 25(OH)D levels in the range 50 to 75nmol/L (291), and one study found 
increased risk of food sensitisation in those with higher early life 25(OH)D levels (296).   
 
1.8.4.7 IgE 
In one study that measured 25(OH)D levels in cord blood, both high (>100nmol/L) and low 
(<50nmol/L) levels were associated with increased specific IgE to 6 aeroallergens at 1,2,3 
and 5 years compared to the reference group with levels 50 to 75nmol/L (291).  In a second 
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study that measured cord 25(OH)D levels, vitamin D deficiency was found to increase the 
risk of raised IgE, but only amongst individuals with polymorphisms known to be involved in 
regulating IgE and vitamin D (285).   In a third study that measured maternal 25(OH)D 
levels, no association was seen(145). 
 
1.8.4.8 Spirometry 
Four studies, one with vitamin D status estimated by maternal dietary intake in pregnancy 
(175) and three with maternal 25(OH)D levels in pregnancy (145, 293, 299) found no 
association with lung function measured by spirometry in preschool years. 
 
1.8.4.9 Bronchodilator response 
One study with vitamin D status estimated by maternal dietary intake in pregnancy found 
that lower maternal intake of vitamin D was associated with decreased BDR (175).  One 
study with maternal 25(OH)D levels in pregnancy known found no association (145). 
 
1.8.4.10 Exhaled nitric oxide 
Two studies, one with vitamin D status estimated by maternal dietary intake in pregnancy 
(175) and one with maternal 25(OH)D levels in pregnancy (293) reported on eNO levels in 
offspring at 5 and 6 years respectively, and found no association.   
 
1.8.4.11 Summary of evidence from birth cohort studies 
Early life Vitamin D exposure was assessed in a number of different ways amongst these 
studies and is an important source of heterogeneity. The gold standard measure of vitamin D 
status is the blood concentration of 25(OH)D, as it captures vitamin D exposure from diet 
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and sunlight combined (300). In contrast, dietary intake of vitamin D makes a relatively small 
contribution to overall vitamin D status, and apparent effects of vitamin D intake may be 
confounded by other correlated nutrients and socioeconomic factors. 
 
Although early studies suggested higher maternal intake of vitamin D was protective against 
a range of wheezing and atopic outcomes in offspring (175, 177, 297, 298), well conducted 
studies with baseline measurements of 25(OH)D levels in pregnancy or cord blood have not 
replicated these observations (145, 290-293) (287, 291, 297, 298).  There is no evidence for 
an effect on exhaled nitric oxide (175, 293).  There is no evidence of an association between 
early life vitamin D status and lung function measured by spirometry (145, 175, 293, 299), 
although one study found evidence of an increasing bronchodilator response with higher 
dietary vitamin D intake in mothers (175).   
 
There is evidence for a protective effect on LRTI in the first year of life (290, 292, 294, 297).  
There is evidence for a U shaped relationship between 25(OH)D levels and atopic 
sensitization, with both high and low vitamin D levels associated with increased risk (288, 
291), a relationship that has also been found in a recent large British adult cohort (301).  
However, this relationship was not replicated in two well-conducted birth cohort studies (145, 
293).   
 
In summary, it is likely that many of the positive observations found in cohort studies based 
on estimation of maternal dietary intake of vitamin D are the result of unrecognized 
confounding from the influence of correlated nutrients or socioeconomic factors. Only 
through prospective randomised controlled trials of vitamin D supplementation in pregnancy 
can these observations be clearly determined. 
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1.8.5 Vitamin D intervention trials 
No trials are currently reported in the literature.  Five prospective randomized controlled trials 
of vitamin D supplementation during pregnancy are in progress, and will shed light on the 
relevance of the mechanisms described above to human health.  
 
In the United States, the ‘Maternal Vitamin D Supplementation to Prevent Childhood asthma’ 
(VDAART) study (NCT00920621), will randomise 870 women carrying a foetus at high risk 
of asthma, to receive 4000IU of cholecalciferol vitamin D daily, or placebo from 10-18 weeks 
gestation to delivery. The primary outcome measure is asthma or recurrent wheeze at 1 year 
and 3 years.  Also in the united States, Hollis et al are conducting a three arm randomised 
trial of ether 400, 2000 or 4000IU of vitamin D per day from 12 weeks gestation in healthy 
women (NCT00292591). Primary outcomes are 25(OH)D3 levels throughout pregnancy and 
bone mineral density in mother and infant.  To our knowledge this trial is not evaluating 
respiratory or atopic outcomes in the offspring.   
 
In the Copenhagen Vitamin D Supplementation During Pregnancy for Prevention of Asthma 
in Childhood (ABCvitaminD; ISRCTN NCT00856947), 600 women will be randomised to 
receive either 2400IU daily of cholecalciferol vitamin D or placebo in addition to 400IU of 
vitamin D daily from 24 weeks gestation to 1 week after delivery. The primary outcome is 
recurrent wheeze in the first 3 years. This is a factorial randomised controlled trial with a 
second intervention of prenatal fish oil or no fish oil.  In Southampton the Maternal Vitamin D 
Osteoporosis Study (MAVIDOS; ISRCTN 82927713) is randomising 1074 pregnant women 
with a 25(OH)D3 concentration of 25-100nmol/l during pregnancy who receive vitamin D 
supplementation at a dose determined in pilot work, or placebo from 14 weeks gestation to 
delivery. Primary outcome measures relate to bone health, but the trial may also yield 
information on pulmonary and atopic outcomes at follow up.  
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In our own study (ISRCTN 68645785) 180 women in London with a high prevalence of 
vitamin D deficiency, were randomised to no additional vitamin D in pregnancy, 200,000IU of 
calciferol once at 27 weeks gestation or 800IU daily of ergocalciferol from 27 weeks to 
delivery. The primary outcome measure is history of wheezing during the first 3 years of life, 
and the results form the main body of work of this thesis. 
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1.9 Potential mechanisms:  Vitamin D and early lung development 
1.9.1 Early life nutritional influences on lung development 
The respiratory system originates as an outgrowth of the primitive foregut between the 4th 
and 7th week of human gestation (302).  Through timely orchestration of a complex array of 
transcription factors, growth factors and physical forces (303), epithelial tubules invaginate 
the surrounding splanchnic mesenchyme to form the bronchial tree.  Key processes are 
branching morphogenesis, angiogenesis, epithelial cell differentiation, sacculation, surfactant 
production and alveolarisation, the latter being predominantly a postnatal event in humans 
(188).  Epithelial-mesenchyme interactions play a crucial role (304).  
 
Early life influences on this process include both genetic and environmental factors, and 
minor alterations during foetal and perinatal life may have significant postnatal 
consequences. For example they may alter responses to early life infections and other 
airway insults that are implicated in the aetiology of asthma (305, 306). Several long-term 
cohort studies have established that infant lung function tracks into later life, suggesting that 
successful modification of early lung development may influence lung function in the long 
term (75, 307). 
 
Known environmental, and nutritional factors which may influence lung development (117, 
308) include cigarette smoking (96), polyunsaturated fatty acids (194, 309) milk fat (310), 
vitamin E (171), and vitamin A (185).   
 
1.9.2 Animal data 
A number of separate observations from animal work suggest that alveolarisation may be 
influenced in part by a complex growth axis which involves 1,25(OH)2D. First, an early study 
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of the offspring of vitamin D deprived rats showed a significant decrease in lung compliance  
and compliance to dry lung weight ratio compared with the offspring of vitamin D sufficient 
rats, suggesting vitamin D deficiency may decrease lung distensibility through an effect on 
interstitial tissue modelling (311). Second, the VDR is expressed during late intrauterine life 
in rat pulmonary tissues (312, 313).  This is during the period of maturation of alveolar type 
two (ATII) cells which synthesise and release surfactant (314, 315).  1,25(OH)2D stimulates 
DNA synthesis in ATII cells (316).  The discovery that lung fibroblasts are capable of 
metabolising 25(OH)D to 1,25(OH)2D identified a paracrine system for vitamin D in the 
developing rat lung (317).  
 
Other data suggest a role for 1,25(OH)2D  in lung fibroblast development, which may in turn 
influence alveolarisation.  1,25(OH)2D significantly increases proliferation of rat perinatal 
lung fibroblasts, an effect which is greatest in combination with retinoic acid (RA) on 
postnatal day 4 (PN4) (318). This effect is dependent on platelet derived growth factor-AB 
(PDGF-AB). The PDGF null mouse has a bronchopulmonary dysplasia (BPD) like picture 
with an absence of fibroblasts and abnormal septation, and PDGF appears to be essential 
for normal alveolarisation of the developing lung (319). PDGF contains a transcriptional 
control region containing response elements to 1,25(OH)2D  (320) and vitamin A (321).  
Thus a proposed mechanism of action for 1,25(OH)2D in promoting lung development is via 
a  synergistic effect with RA in stimulating growth of immature fibroblasts in the postnatal 
lung, with PDGF as the critical effector (318). Further experiments have demonstrated a role 
for the vitamin D analogue EB1089 on fibroblast proliferation but suggested, contrary to 
other work, that relatively high doses of this vitamin D analogue may disrupt alveolarisation 
(322). Histological findings in EB1089-treated rats include increased alveolar chord length 
and prominent regions of fibroblast hypercellularity.  These stained strongly for 
alveolarisation growth factors PDGF-AA and vascular endothelial growth factor (VEGF) and 
the overall effect was to promote fibroblast proliferation but disrupt alveolarisation (322). 
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Whether this disruptive effect is dose dependant or related to other effects of the vitamin D 
analogue in question is not known. 
 
A third mechanism through which 1,25(OH)2D  may influence alveolarisation is via the 
inhibition of apoptosis in lipid laden interstitial lung fibroblasts (323).  Lung fibroblasts 
become highly apoptotic during the first 1-2 weeks of postnatal life in rats, a developmental 
process that contributes to alveolar wall thinning and alveolarisation (324).   Both in vitro 
treatment (at embryological day 19) and in vivo treatment (at postnatal days 0 to 14) with 
1,25(OH)2D resulted in dose-dependent increases in lung fibroblasts and ATII cell 
proliferation and decreased apoptosis, accompanied by increases in the expression of 
epithelial mesenchyme differentiation markers (323).  These data suggest a role of 
1,25(OH)2D  in alveolar thinning. 1,25(OH)2D  may have a specific role in transcriptional 
regulation of Lgl1 (late gestation lung 1) during alveolarisation (325).  Lgl1 is a mesenchymal 
protein found in foetal lung that regulates epithelial airway branching and is maximally 
expressed in late gestation and early postnatal life (326).   In LgL1 null mice, absence of 
Lgl1 is lethal prior to lung formation (14).  Heterozygotes also display an abnormal 
respiratory phenotype. In vitro experiments in rat lung fibroblasts from E18 to PN14 suggest 
1,25(OH)2D has a complex interplay with glucocorticoid (GC) and RA in the control of 
Lgl1.  1,25(OH)2D directly inhibits Lgl1 mRNA production, and inhibits GC induction of 
Lgl1.  When combined with RA there was no effect on GC induction of Lgl1 gene 
transcription.  Lgl1 may be a mesenchymal mediator of 1,25(OH)2D  effects on epithelial 
maturation, with regulation of the target gene promoter by GC and RA as well as 1,25(OH)2D 
(325).  
 
Further, less direct, evidence of a role for vitamin D status in foetal lung development come 
from studies of VDUP1 (vitamin D up regulated protein 1) expression in the ovine foetal 
lung.  The basal level of lung expansion is an important determinant of airway epithelial cell 
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phenotype (327).  VDUP1 is an intracellular protein whose expression is up regulated by 
vitamin D3 administration (328).  In sheep lung, VDUP1 is localized to airway epithelium in 
small bronchioles, AEC’s and mesenchymal cells.  Expression of VDUP1 mRNA increase 
significantly during the alveolar stage of lung development (329).   Furthermore, VDUP1 
mRNA correlate with different levels of lung expansion, with increased levels in under 
expanded lungs and decreased levels in over expanded lungs compared to normal controls 
(329).  Pressure effects in the airways induced by respiratory movements, contraction and 
relaxation of smooth muscle in the airway wall and the pressure of amniotic fluid have a 
potent influence on airway and alveolar development. Reduced amniotic fluid is associated 
with lung hypoplasia, and reduced foetal respiratory effort (eg opiate-dependent mothers) 
has a profound effect on post-natal lung function. Thus it is possible that VDUP1 is a vitamin 
D status dependent moderator of foetal lung growth and development in response to 
changes in foetal lung expansion(329).   
 
Finally, in mature rats, VDR expression is present in lung fibroblasts and 1,25(OH)2D 
appears to have a role. Recent work shows that 1,25(OH)2D inhibited TGFβ1-induced 
fibroblast proliferation, and blunted TGFβ1-induced up regulation of mesenchymal cell 
markers and abnormal expression of epithelial cell markers.   TGFβ is expressed during 
branching morphogenesis and has an important role in modelling of the airway wall by 
stimulating fibroblast collagen production (330). Thus vitamin D status may have a 
homeostatic role in the developing lung, preventing some of the effects of excess TGFβ on 
the developing epithelial-mesenchymal trophic unit, which are thought to lead to changes 
such as the airway remodelling commonly seen in asthma. 
 
1.9.3 Human data 
Rachitic respiratory distress has been described very early in infancy, for example in small 
preterm infants (331). This suggests that vitamin D deficiency of prenatal origin can have a 
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profound acute effect on early lung function. As with the animal studies, there is also 
evidence in human studies that 1,25(OH)2D3  influences different components of lung 
development including fibroblast proliferation and alveolarisation. The VDR has been 
detected in human foetal lung fibroblasts from 16 weeks gestation, (332, 333) and in ATII 
cells from the second trimester (334). In ATII cells, VDR expression is largely dependent on 
induction by 1,25(OH)2D (334). After incubation of a human ATII cell line with 1,25(OH)2D, a 
number of metabolites are also formed including 1,25-(OH)2-3-epi-VD3, which can increase 
surfactant phospholipid synthesis, surfactant SP-B mRNA gene expression and surfactant 
SP-B protein synthesis in pulmonary ATII cells (335).  However the effects of vitamin D 
metabolites on human lung development are likely to be complex since decreased, 
increased and no effect on surfactant protein synthesis have been observed on treating 
human fetal lung explants and ATII cells with calcitriol (334). 
 
In the mature human lung, data are now emerging as to the cellular targets that may be 
influenced by vitamin D status. The VDR is expressed in the epithelia of normal and 
malignant bronchial tissue (336), in lung epithelial cells treated with vitamin D metabolites 
(337), and in airway smooth muscle (ASM) cells which demonstrate a large array of changes 
in gene expression in response to stimulation by 1,25(OH)2D (338). In ASM cells that were 
passively sensitized with serum from an asthmatic, 1,25(OH)2D suppressed proliferation and 
significantly down regulated expression of matrix metalloproteinases-9 (MMP-9) and a 
disintegrin and metalloprotease 33 (ADAM33); both of these being significant promoters of 
airway remodelling (339-341).  Polymorphisms of ADAM 33 are associated with a higher risk 
of asthma particularly in relation to bronchial hyper-responsiveness.  In British Bangladeshi 
adults, 25(OH)D status has been found to be inversely associated with plasma MMP-9 
levels, with supplementation in vitamin D deficient individuals leading to reduced MMP-9 
levels in vivo (342).  In vitro 1,25(OH)2D inhibits MMP-9 expression by M. Tuberculosis in 
cell culture (343).  Therefore any effects of vitamin D status on lung development may be 
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mediated through effects on MMP-9 levels in plasma or lung tissue.  Finally, in bronchial 
ASM samples taken during surgery, 1,25(OH)2D decreased PDGF induced cell proliferation 
(344).   
 
Whilst speculative, if such relationships are present in the developing lung this could explain 
potential benefits of vitamin D metabolites on future lung health.  In light of current concepts 
that molecular regulators originally associated with developmental processes may be 
implicated in adult diseases such as chronic obstructive airway disease (188) this is of great 
interest, and suggests a potential role for maintaining adequate vitamin D repletion to ensure 
25(OH)D and 1,25(OH)D are available to the tissues for treatment, or prevention, of airway 
remodelling in asthma (345). 
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1.10  Potential mechanisms:  Vitamin D and immune development 
1.10.1 Introduction 
Animal data on the role of 1,25(OH)2D in allergic asthma is contradictory.  In human, in-vitro 
studies, 1,25(OH)2D influences several immune-cell types, including macrophages, dendritic 
cells and lymphocytes, with an overall immunosuppressive effect.  In the innate immune 
system, 1,25(OH)2D is able to induce cathelicidin production, an antimicrobial peptide, by 
macrophages and airway epithelial cells, which contributes to defence against bacteria. In 
dendritic cells, 1,25(OH)2D inhibits up regulation of co-stimulatory molecules necessary for 
antigen presentation to T cells, thus promoting immune tolerance. In T cells, 1,25(OH)2D 
decreases the production of IL-2, IL-17 and interferon-γ (IFN-γ) and attenuates the cytotoxic 
activity and proliferation of CD4+ and CD8+ T cells. 1,25(OH)2D also promotes the 
development of regulatory T cells that promote a balanced immune response, and blocks B-
cell proliferation, plasma-cell differentiation and immunoglobulin production.   
 
1.10.2 Animal knockout models 
Despite the large body of evidence suggesting an important role for 1,25(OH)D in immune 
homeostasis, VDR knockout mice have a normal composition of immune cell populations 
and reject allogenic and xenogenic transplants at the same rate as wild type mice (233).  
VDR knockout mice do not develop experimental allergic airway disease suggesting that 
VDR expression may be necessary for lung inflammation to occur (346, 347).  
 
1.10.3 Animal models of airway inflammation 
In mouse models of asthma, 1,25(OH)2D inhibits airway inflammation and decreases IL-4 
levels in bronchoalveolar lavage (BAL) fluid and impairs T cell migration to lymph nodes 
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(348).  Irradiation of mice with UVB light prior to sensitization with antigen blunts airway 
hyper-responsiveness and inflammation, suggesting 1,25(OH)2D may ameliorate airway 
inflammation (349).  In one mouse asthma model, duel effects of 1,25(OH)2D were seen, 
with promotion of Th-2 cytokines (IL-4 and IL-13) and increased IgE production, but impaired 
recruitment of eosinophil’s and inferior levels of IL-5 seen in BAL fluid (350).   
 
These data illustrate the complexity of the role for vitamin D in inflammatory responses 
involved in the pathogenesis of asthma. Their contradictory nature may relate to the 
differences between mouse models of allergic asthma and the human disease, or to the 
critical importance of dose, nature of vitamin D supplement and timing of administration for 
its immune effects. 
 
1.10.4 Other animal models of disease 
Beneficial immunomodulatory effects of 1,25(OH)2D have been seen in several experimental 
animal models of Th-1 mediated disease including uveitis and colitis, inflammatory bowel 
disease, multiple sclerosis, systemic lupus erythematous, allergic encephalitis and diabetes 
(reviewed in (351)).  1,25(OH)2D prolongs survival in mouse cardiac allografts (233).   
 
Promotion of IL-10+ Treg cell function is thought to be a major mechanism for allergen 
specific immunotherapy (352).  In mouse models of sublingual immunotherapy, calcitriol and 
dexamethasone both increased the efficacy of immunotherapy through the promotion of 
Treg function via increased foxp3+ T cell numbers (353, 354). 
 
1.10.5 Enhanced production of antimicrobial peptides 
The innate immune system plays a key role in early defence against pathogens and antigen 
presentation.  Cells of the innate immune system include macrophages, neutrophils and 
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dendritic cells which are important for phagocytosis and antigen presentation, and airway 
epithelial cells that are the first line of defence against respiratory infection.    
 
The most widely studied effect of 1,25(OH)2D on the innate immune system is the ability to 
enhance the production of naturally occurring antimicrobial peptides, such as cathelicidin.  
Cathelicidin has antibiotic properties and is naturally expressed in human cells including 
neutrophils, alveolar macrophages, epithelial cells and keratinocytes (355). In-vitro 
stimulation of TLR2 in macrophages results in increased expression of CYP27B1, local 
1,25(OH)2D production and increased expression of cathelicidin that enhances killing of 
intracellular Mycobacterium tuberculosis (227).  This effect is blunted by lack of 25(OH)D 
(356). AEC’s also express CYP27B1, and produce cathelicidin in response to 1,25(OH)2D, 
but using a mechanism independent of TLR2 activation (357).  Other peptides regulated by 
vitamin D include Defensin-B 2 and 4 (358).  
 
1,25(OH)2D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines 
and cytokines in airway epithelium while maintaining the antiviral state, suggesting that 
adequate vitamin D levels could contribute to reduced inflammation and less severe disease 
in RSV-infected individuals (337), 
 
These effects have been proposed to explain the increased susceptibility to tuberculosis in 
patients with vitamin D deficiency (359) and to confer protection against viral infection (337). 
 
1.10.6 Inhibition of lymphocyte proliferation 
1.10.6.1 Animal data 
In-vitro studies demonstrate a duel effect on Th-1/Th-2 cytokine expression (350). In one 
study, 1,25(OH)2D inhibited IL-4 synthesis during polarisation of naïve T cells suggestive of 
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Th-2 suppression (360) whereas in another 1,25(OH)2D appeared to promote IL-4, IL-5 and 
IL-10 secreting cells suggestive of Th-2 phenotype development (361). 
 
1.10.6.2 Human data 
The VDR is expressed on activated T lymphocytes (224, 225) with greater expression in 
effector and memory T cells than naïve T cells (233, 362).  There are conflicting reports of 
the expression of VDR on B lymphocytes, and it is unclear whether 1,25(OH)2D can act 
directly on B cells (233).  
 
The overall effect of 1,25(OH)2D is a marked inhibitory effect on adaptive immune cells (363-
367).  For example, inhibiting T cell proliferation and the expression of IL-2 and INF-γ by T 
cells (363, 368-370), and decreasing CD8 T cell mediated cytotoxicity (233), and inhibiting 
production of IL-17 (371, 372).  Inhibition of T cell proliferation is partly mediated through IL-
2 inhibition, and may be partially rescued by exogenous IL-2 (362, 363, 368).  Inhibition of 
IL-2 and IFN-γ is mediated by a genomic mechanism of action, with the VDR-RXR complex 
binding to VDRE in the promoters of genes encoding IL-2 and INF-γ (373, 374).  Overall the 
effect is to block the induction of Th-1 cytokines, particularly IFN-γ, while promoting Th-2 cell 
responses (IL-4) (233).  The effects on T cell mediated cytotoxicity are similar to those 
observed with cyclosporine (375). 
 
For B cells, 1,25(OH)2D suppresses proliferation, plasma cell differentiation and IgG 
secretion (368, 376-378).  B cells can secrete significant amounts of 1,25(OH)2D that inhibits 
IgE production by a direct action on the immunoglobulin class switch (379). 
 
1,25(OH)2D is able to induce CD200 expression by peripheral and respiratory tract T cells, 
suggesting an additional pathway by which vitamin D can prevent inflammation in the 
airways to maintain respiratory health (380).  CD200 is a cell-surface immunoglobulin-like 
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molecule expressed by immune and stromal cells, which dampens the pro-inflammatory 
activity of tissue-resident innate cells via its receptor, CD200R.  This interaction is important 
for promoting peripheral immune tolerance. 
 
1.10.7 Duel effects on Th1/Th2 balance 
In terms of the balance between Th-1 and Th-2 cells, the picture is less clear-cut.  In adult 
human in-vitro studies, 1,25(OH)2D reduces IFN-γ (364, 365, 381, 382) and IL-2 production 
(363, 364, 370, 382-384) characteristic of Th-1 responses, suggesting a favouring of Th-2 
responses, which would promote allergic responses.  Other human studies have found 
1,25(OH)2D to reduce numbers of IL-4 secreting cells, and demonstrated no favouring of the 
Th-2 phenotype (385).  Concentration in vitro may account for this dual effect on Th-2 cell 
differentiation, with experiments using high concentrations (1x10-6M) of 1,25(OH)2D 
favouring enhanced IL-5 and IL-13 secretion, and lower concentrations (1x10-7 to 10-9) 
suppression (386). 
 
Recent in-vivo data from a cross-sectional survey of over seven thousand white British 45 
year olds reflect these observations, with a non-linear relationship between 25-
hydroxyvitamin D status and total IgE levels described.  Both low (<25nmol/L) and excess 
(>135nmol/L) levels were associated with elevated IgE. (301).  This suggests there may be a 
U shaped dose relationship (301). 
 
 
1.10.8 Influencing DC’s and Tregs to promote immune tolerance 
1.10.8.1 Human data 
Tregs are important for exerting a suppressive influence on effector T cell activity such as IL-
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4, IL-5 and IL-13 secretion characteristic of Th-2 responses (387). In asthma and allergy, the 
numbers or function of Tregs may be deficient (387). Key suppressive signalling molecules 
involved in this process include TGF-β and IL-10 (387).  Human in-vitro studies show the 
effect of 1,25(OH)2D on antigen presentation by dendritic cells, and on T cell regulatory 
function is to promote a more balanced, or tolerogenic phenotype (387).     
 
DC’s express the VDR and CYP27B1 once stimulated (388, 389).  1,25(OH)2D suppresses 
APC’s capacity to act as efficient antigen presenting cells which in turn leads to T cell hypo-
responsiveness (390, 391).  This involves reduced differentiation of dendritic cells, reduced 
up regulation of co-stimulatory molecules CD40/CD80/CD86, reduced expression of class II 
MHC molecules, (390) reduced secretion of the pro-inflammatory cytokine IL-12 and 
increased production of the anti-inflammatory cytokine IL-10 (392, 393). 1,25(OH)2D 
promotes the induction of CD4+FoxP3+ Treg cells by dendritic cells (392), and also the 
induction of naïve T cells into IL-10 secreting regulatory T cells when incubated with 
dexamethasone (394-396).   
 
Ingestion of 1,25(OH)2D by human volunteers led to an increase of both IL-10 and TLR9 
expression by CD3+CD4+ T cells (395).  In steroid resistant asthmatics, CD4+ T cells do not 
show steroid induction of IL-10 secretion in vitro.  In a landmark paper, this impaired 
induction of IL-10 by glucocorticoids from steroid resistant patients was reversed by addition 
of calcitriol in-vitro (396). 
 
1.10.8.2 Human in-vitro and in-vivo data 
In steroid resistant patients who received oral administration of vitamin D3, enhanced IL-10 
secretion in response to stimulation in vitro with glucocorticoids was seen (396).  There is 
evidence that vitamin D deficiency may modify the glucocorticoid response in children with 
asthma.  In one study, vitamin D enhanced the glucocorticoid action in peripheral blood 
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mononuclear cells from asthmatic patients and enhanced the immunosuppressive function of 
dexamethasone in vitro (397).   
 
In rheumatoid arthritis, 25(OH)D levels are inversely correlated with disease activity (233).  
In multiple sclerosis, vitamin D supplementation has been shown to increase the serum 
levels of immune modulating TGF-β and IL-10 (398).  In cystic fibrosis patients with allergic 
bronchopulmonary aspergillosis, heightened Th-2 reactivity correlated with lower mean 
serum vitamin D levels.  The co-stimulatory molecule OX40 ligand was critical in driving Th-2 
responses to A. fumigatus, and in-vitro addition of 1,25(OH)2D substantially reduced DC 
expression of OX40 Ligand and increased DC expression of TGF-β (399). 
 
1.10.9 Effect of developmental vitamin D deficiency and prenatal vitamin 
D supplementation 
1.10.9.1 Animal data 
In animal models the principle that vitamin D deficiency at a critical time in development may 
adversely affect immune development has been supported.  Developmental deficiency of 
vitamin D in rats induces alterations in immune organ morphology and function in adult 
offspring, with an increase in central organ size and a pro-inflammatory IL-2 response by 
lymphocytes, consistent with a role for vitamin D in promoting immune regulation (400).  
 
1.10.9.2 Human data 
1,25(OH)2D has been shown to inhibit both Th-1 and Th-2 differentiation in cord blood in 
vitro (385).  A recent in-vivo study lends support to the role of vitamin D in inducing 
tolerogenic dendritic cells, with offspring of mothers who took vitamin D supplements during 
pregnancy having increased expression of immunoglobulin like transcripts 3 and 4 in cord 
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blood, inhibitor receptors that are up regulated in tolerogenic dendritic cells (401). 
 
1.10.10 Conclusions 
Although 1,25(OH)2D clearly exerts immunomodulatory activity in-vitro and in-vivo, its 
relative physiological role in maintaining immune tolerance and in shaping immune 
responses is still unclear (233).   
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1.11  Public health importance 
The economic burden of allergic disease is an increasing problem, especially in developed 
countries within northern latitudes. In the United Kingdom, allergic conditions account for up 
to 6% of primary care utilization, 70,000 hospital admissions a year and 10% of the primary 
care prescribing costs, representing a direct burden of over a billion pounds per anum (402).  
Primary prevention of asthma and allergic disorders is a high priority.   
 
Since early life vitamin D deficiency is common (403), and supplementation during 
pregnancy is safe in higher doses in studies with short term follow up (404), and 
inexpensive, this represents an attractive public health intervention for asthma prevention.  
 
One important measure of any potential impact is healthcare utilization.  This has been 
defined as the outcome of the interaction between health professionals and patients, and in 
economic terms corresponds to the volume of health services used (405). In the United 
Kingdom, one such measure for all children registered with a general practice is the 
electronic health record (e-HR). This is a contemporaneous record of all health care 
utilisation from that practice. Use of primary out of hours services (OOH) or secondary 
healthcare is also recorded. In this way the e-HR forms a complete record of a child’s 
healthcare utilisation from birth. 
 
Determinants of a child’s overall healthcare utilisation are their underlying health status (406-
410), parent mental health and family functioning (411-413), and socioeconomic predictors 
(age and ethnicity of the child, family income, area of residence, parental educational 
attainment and social class) (406, 410, 414, 415), although some studies found no effect of 
social class (407, 408).  For hospital utilisation, predictors include socioeconomic position at 
the time of birth, mother’s age, mother’s age on leaving education, gestational age, ethnicity, 
parity, maternal BMI, maternal smoking during pregnancy and mode of delivery (415).  
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The high prevalence of vitamin D deficiency in pregnancy and infancy in the populations of 
many countries may be of critical public health importance if the associations between 
Vitamin D status and disease are confirmed in prospective randomized controlled trials. It is 
increasingly recognized that many chronic diseases of childhood and adulthood are 
influenced by early life developmental events, so the potential adverse effects of widespread 
deficiency of vitamin D at these time points on future population health may be serious. 
Measuring healthcare utilization in offspring is one important means of assessing the 
potential impact of vitamin D supplementation in pregnancy. 
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1.12  Conclusions 
The precise relationship between vitamin D status and asthma, and the impact of dietary 
vitamin D supplementation on this risk, are unclear.   Potential mechanisms through which 
perinatal vitamin D may influence asthma or lung development include direct effects on lung 
growth and development particularly on alveolarisation, fibroblast proliferation and airway 
smooth muscle.  Interactions with correlated nutrients such as vitamin A, which interacts with 
vitamin D metabolites in essential ways but can antagonise in excess, may complicate this 
relationship (416, 417).  Other potential mechanisms include increased microbial killing 
capacity limiting the host consequences of viral infections, and increased immune regulation 
preventing atopic immune responses. 
 
Current intervention trials evaluating the effects of early life vitamin D supplementation at a 
range of doses, in a range of populations and using a range of treatment schedules will play 
a critical role in establishing the possible role of vitamin D. 
 
1.13  Aims of the thesis 
The thesis consists of three main bodies of work.  First, a pilot study to evaluate the 
feasibility of performing IOS in preschool children, and its ability to detect differences 
between children with and without clinical disease.  Second, a follow up study of a 
randomised controlled trial of vitamin D supplementation during pregnancy to evaluate it’s 
effect on parentally reported respiratory and allergic health, objective measures of allergic 
inflammation and lung function in childhood.  Third, an evaluation of the effects of prenatal 
vitamin D supplementation on healthcare utilization in the first three years of life using the 
same established randomised trial. 
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2 General Methods 
2.1 Pilot study to evaluate the feasibility of impulse oscillometry in 
preschool children 
This was a cross-sectional survey of 3 to 5 year old children recruited from St. Mary’s 
Hospital Paediatric Outpatient department, to identify success rate, repeatability, and ability 
of IOS to discriminate between health and disease.   
 
2.1.1 Study subjects 
St. Mary’s Hospital Research Ethics Committee approved the study (REC reference 
10/H0712/13). Children aged 3 to 5 years of age attending St Mary’s hospital paediatric 
outpatient department were eligible to participate.  Exclusion criteria were acute illness at the 
time of the study, known chronic respiratory disease apart from recurrent wheezing, and 
gestational age <37 weeks. Informed, written, parental consent was obtained for all subjects 
(See appendix for information leaflet and consent form).   
 
2.1.2 Protocol and questionnaire 
Children had their standing height and weight measured. Parents completed a general 
health (Appendix 10.1) and validated allergy questionnaire (Appendix 10.2) to identify risk 
factors for abnormal lung function, including previous history of wheezing, wheeze in the 
year prior to assessment, eczema ever and eczema in the year prior to assessment as 
defined by the International Study of Asthma and Allergies in Childhood (ISAAC) (8).  Other 
variables recorded included recurrent wheezing (≥2 episodes of reported wheezing since 
birth), allergic rhinitis, history of doctor diagnosed food allergy and history of >4 episodes of 
upper respiratory tract infections (frequent URTI) per year (defined as a positive answer to 
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the question ‘how often does your child have an upper respiratory tract infection, with at 
least two of the following symptoms, cough, runny nose and fever?’)  
 
2.1.3 IOS measurements 
Impulse oscillometry (IOS) was performed in accordance with ERS/ATS task force 
guidelines (49) using the Jaeger IOS system (Jaeger, Wurzburg, Germany), before and 15 
minutes after inhalation of 400mcg salbutamol sulphate via a large volume spacer  
(Volumatic, Allen and Hanbury, Middlesex, UK).  Total impedance (Z), resonant frequency 
(Fres), area under the reactance curve (AX), reactance at 5Hz (Xrs5) and resistance (R) at 
5, 10, 15, 20 and 25 Hz were chosen for data analysis. The IOS system was calibrated twice 
daily using a 3L volume syringe and a reference resistance device (0.2kPa/L).   
 
Training in this technique was obtained from a tertiary paediatric respiratory team with 
experience in the use of IOS in young children (Professor Janet Stocks, Dr Jane Kirby; 
Portex Respiratory Unit, Institute of Child Health, London).  In addition, the following online 
quality assurance protocol was adopted in collaboration with Dr Jane Kirby.  Support of the 
cheeks to ensure no movement of the mouth (chewing, talking etc.) to minimise upper-
airway compliance; observation of the tidal volume time-based trace to ensure it was stable, 
free from drift with no hyper- or hypoventilation; observation of the impedance at 5Hz to 
ensure consistency throughout the measurement; ensuring no obvious spikes in impedance 
due to swallowing, glottic closure or cough were present. If these criteria were not met, the 
measurement was stopped and the technique reviewed.   
 
On completion of all data collection for the study, two trained operators (STG, JCK) 
assessed all readings.  Essential acceptance criteria for a reading to be included in analyses 
were as follows: at least 10 seconds in duration with a minimum of four tidal breaths; stable, 
regular tidal breaths, free from drift; no obvious abnormalities, looks physiological (i.e. 
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identifying physiological implausible data); coherence >0.4 at 5Hz and >0.7 at 10 Hz.  
Results were rejected if there was evidence of tongue position artefact, (noted by a parallel 
increase in resistance at all frequencies).  For each child, the reported result was the mean 
of 3 to 5 “acceptable” (as defined above) measurements (49). 
 
2.1.4 Allergic sensitisation 
Allergic sensitisation was defined as a skin prick test wheal at least 3mm greater than the 
negative control (glycerine) at 15 minutes, in the context of an appropriate response to the 
positive control (histamine 10%). House dust mite, cat, dog, grass pollen, silver birch pollen 
and alternaria pollen were tested (Stallergenes, Antony, France). 
 
2.1.5 Statistical analysis 
The within-occasion, within-test repeatability, or coefficient of variation (CV), was calculated 
as the standard deviation of each set of measurements as a percentage of the mean.  
Bronchodilator response was measured in two different ways - as the absolute value of the 
difference between measurements (abs), and as a percentage of the initial value (%Init).  
IOS data was explored using histograms and were normally distributed. Unadjusted analysis 
of the difference between groups used the unpaired t-test. Analysis of variance was 
performed with age, height and pre or postnatal environmental tobacco smoke (ETS) 
exposure as covariates. All analyses were performed using SPSS version 19.0 (IBM, 
Chicago USA). A value of p<0.05 was considered statistically significant. 
 
 
 
95 
2.2 Follow up study of a randomised controlled trial of prenatal vitamin 
D supplementation to evaluate its effect on respiratory and allergic 
outcomes in childhood.   
2.2.1 Study subjects 
This was a follow up study of the offspring of women who took part in an ethnically stratified, 
parallel group, randomised controlled trial of vitamin D supplementation in pregnancy at St 
Mary’s Hospital London, a university-affiliated hospital antenatal clinic, between April and 
November 2007.  The original trial was conducted to determine the effects of 
supplementation on the 25(OH)D status of mothers and babies at delivery (418). St. Mary’s 
Hospital Research Ethics Committee approved the study (REC reference 10/H0712/13) and 
all women gave informed consent to participation for themselves and their child. Eligible 
participants were women presenting at 27 weeks gestation for routine glucose challenge test 
from the following ethnic groups: Indian Asian, Middle Eastern, Afro-Caribbean and 
Caucasian. Exclusion criteria were known sarcoidosis, osteomalacia, renal dysfunction or 
tuberculosis. We assessed the offspring of study participants when they reached 3 years 
age, to evaluate subjective and objective measures of health. 
 
2.2.2 Study intervention and randomisation procedure  
Women were randomised at 27 weeks gestation to no treatment (control), 800 IU 
ergocalciferol until delivery (daily), or a single oral dose of 200,000 IU calciferol (bolus). The 
randomisation sequence was generated by an independent person using computer 
generated random number lists in blocks of 15, stratified by ethnicity in a 1:1:1:1 ratio. The 
researcher gave participants a study number on entry to the trial, and treatment was 
allocated from the hospital pharmacy using the randomization list. Women were given 
instructions to swallow the tablets whole and to avoid other multivitamin supplements 
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containing vitamin D.  This trial was conducted before national guidance on routinely 
providing advice on vitamin D intake during pregnancy was introduced in March 2008 (266).  
No adverse effects were reported. 
 
2.2.3 Weaknesses of original study 
Significant weaknesses of the original supplementation trial include the absence of a 
placebo control, which may have led to biased parental reporting and also control women 
taking vitamin D supplements of their own volition.  Although the authors report that 
telephone calls were made during the course of the pregnancy to check for compliance in all 
women on the daily treatment regime, this did not apply to the women in the bolus group, 
and the results of this assessment were not published.  As such adherence was not 
assessed adequately.  These weaknesses would have reduced the magnitude of any effect 
of vitamin D supplementation. 
Also, the process of randomization was not gold standard, such as by an independent 
randomisation service. 
 
2.2.4 Assessment of maternal and childhood vitamin D status, and their 
determinants  
25(OH)D was measured in mothers prior to randomisation, and in offspring at birth (cord 
blood) and at 3 years using a radio-immunoassay (DiaSorin, Stilwater, MN) in a clinical 
biochemistry laboratory that participates in the international Vitamin D external quality 
assessment program (DEQAS). Vitamin D deficiency was defined as 25(OH)D <25nmol/L, 
and insufficiency as 25(OH)D ≥25 but <50nmol/L (213). 
 
Dietary and lifestyle determinants of Vitamin D status were assessed by health 
questionnaire (Appendix 10.3) for mothers and offspring, and by skin colorimeter 
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assessment on mother and child at the 3-year outcome assessment.  Although based on 
known determinants in the literature, validated questionnaires were not used as they were 
assessed as being too long to complete, and thus may have led to questionnaire fatigue for 
the parents.  Determinants assessed included for diet - intake from nutritional supplements, 
mode of infant feeding, duration of breast feeding, age of weaning, observation of a 
restricted diet (vegan or vegetarian), frequency of consumption of certain foods containing 
vitamin D (oily fish, margarine, eggs), and for lifestyle - average length of time spent 
outdoors in daylight hours each day in the last month, use of sunscreen or clothing to protect 
from the sun in sunny weather, length of time watching TV or using a computer each day, 
access to a garden, access to a terrace or balcony and Fitzpatrick score of skin type (236, 
252, 419). In mothers, choice of clothing (no concealed clothing vs all body covered except 
hands and face when outdoors vs all body covered including hands and face when 
outdoors) and use of a sunbed in the last year (252) were assessed. 
 
Skin colour was assessed using reflectance spectroscopy (DSM II Colormeter, Cortex 
Technology, Hadsund, Denmark).  In children a single measurement was taken in each of 
the following areas:  forehead, volar aspect of the forearm and the abdomen just superior to 
the umbilicus.  In mothers a single measurement was taken on the forehead and volar 
aspect of the forearm only. 
 
2.2.5 Assessment of determinants of child health 
Children were characterised by birth weight (using the child’s red book which parents were 
asked to bring with them), gestation, admission to a neonatal unit at birth, immunisation 
status, presence of congenital abnormalities, presence of other health problems and use of 
regular medications.  The following inherited and environmental determinants of child health 
were recorded: ethnic background, age mother and father left full time education, number of 
adults and children in the household, attendance at nursery, number of older and younger 
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siblings, exposure to household pets since birth, exposure to prenatal and postnatal tobacco 
smoke and history of doctor diagnosed eczema, rhinitis or asthma in the mother, father or 
siblings. 
 
2.2.6 Outcome assessment 
2.2.6.1 Subjective outcome measurements reported by parent 
Investigators were blind to original treatment allocation.  To ensure this, parents were 
instructed on their invitation letter not to disclose their treatment group to the research team 
(See appendix xxx).  There were no cases of accidental unblinding.  Children were assessed 
at three years of age using a health questionnaire, which included a number of validated 
assessments.  The primary outcome was prevalence of ‘wheeze ever’ as defined by the 
International Study of Asthma and Allergies in Childhood (ISAAC)(8). Secondary outcomes 
were recurrent wheezing (≥2 episodes of reported wheezing since birth), wheeze in the year 
prior to assessment (ISAAC), wheeze with a positive asthma predictive index (loose 
criteria),(5) reported history of bronchodilator use, eczema ever (ISAAC), eczema in the year 
prior to assessment (ISAAC), allergic rhinitis, history of doctor diagnosed food allergy, 
history of lower respiratory tract infection (LRTI) (any of bronchiolitis, bronchitis, croup, 
pneumonia or an otherwise unspecified chest infection) and history of >4 episodes of upper 
respiratory tract infections (URTI) per year (defined as a positive answer to the question 
‘how often does your child have an upper respiratory tract infection, with at least two of the 
following symptoms:  cough, runny nose and fever?’)  
 
2.2.6.2 Objective assessment of lung function 
IOS was performed as described in section 2.1.3, before and 15 minutes after inhalation of 
400mcg salbutamol sulphate via a large volume spacer  (Volumatic, Allen and Hanbury, 
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Middlesex, UK).  Resonant frequency, area under the reactance curve, and resistance at 10 
and 20 Hz were chosen for primary data analysis.  The IOS system was calibrated twice 
daily using a 3L volume syringe and a reference resistance device (0.2kPa/L).   
 
2.2.6.3 Objective assessment of allergic sensitisation and 
inflammation 
Fully trained personnel undertook allergy skin prick testing in accordance with international 
guidelines. Individual allergens were placed on the forearm of children at the 3-year outcome 
assessment, and disposable lancets were used to undertake the test (ALK-Abello, 
Denmark). House dust mite, alternaria, cladosporium, cat, dog, grass pollen, silver birch 
pollen, peanut, milk and egg were tested; histamine 10mg/ml and glycerine were used as 
positive and negative controls respectively (Stallergenes, Antony, France). Skin prick tests 
were read at 15 minutes, as the mean of the largest wheal diameter and the perpendicular 
diameter. Allergic sensitisation (atopy) was defined as a skin prick test wheal at least 3mm 
greater than the negative control to one or more of the aeroallergens tested, in the context of 
an appropriate response to the positive control.  
 
Exhaled nitric oxide was measured using an offline, tidal breathing technique in accordance 
with the principles recommended by the ATS/ERS (420): measurements were made before 
other lung function tests and before administration of salbutamol; subjects breathed through 
a two-way non-rebreathing mask with partitioned nose and mouth chambers (Series 7975, 
PED SM M/F Mask Yshp, Han Rudolph, Kansas City, USA); subjects breathed normally 
from a source of nitric oxide free air (<5ppb) (NO scrubber, Sievers reorder P/N: AFL 01410-
01, NORTH part no. N7500-2, USA, 40700842 rev E) and exhaled against 5cm H20 
resistance (Model 7100R, flow range 0 to 2 L/sec, SN 710-1227, Han Rudolph, Kansas City, 
USA) to prevent contamination of the sample with nasal NO; the initial 10 exhalations were 
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discarded to allow for washout of dead space of the lungs (421). Five exhalations were 
collected into a NO-inert bag  (Maximum pressure 12 cmH20, Series 6000, P/N CR1735, 
10x10 outside measurement, 1L capacity, Hans Rudolph, Kansas City, USA) connected via 
a three way valve (2100 series 3 way stopcock, Han Rudolph, Kansas City, USA); additional 
samples were collected after 30 seconds of tidal breathing in ambient air; 3 samples were 
collected, with the median value of at least two measurements used for data analysis; 
samples were analysed within 1 hour of collection using the NIOX flex (Aerocrine, Sweden) 
with the following settings - 7 seconds collection time, flow rate of 50mls/s (421), calculation 
segment 50% to 100% of measurement. 
 
Serum total IgE (ImmunoCAP, Phadia, Uppsala, Sweden) and eosinophil count were 
determined on the day of the child’s 3 year assessment. 
 
2.2.6.4 SCORAD assessment 
A SCORAD assessment (422) was performed in children with eczema identified by the 
health questionnaire.  Training in SCORAD assessment was by using the online training 
module, which can be found at http://adserver.sante.univ-nantes.fr/Scorad_Course/.  A 
single investigator made all SCORAD assessments. 
 
2.2.6.5 Assessment of health outcomes via Primary Healthcare 
record analysis 
Primary health care records were obtained from participants’ general practitioners and 
reviewed by a single investigator (RJB), blinded to treatment allocation. Children were 
categorized as having ‘recurrent wheezing’ where ≥2 episodes of either wheezing, or 
respiratory distress treated with bronchodilator were recorded; ‘eczema’ if they had ≥2 
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attendances separated by ≥6 months where either topical corticosteroids were prescribed for 
treatment of an itchy skin rash, or a doctor’s diagnosis of eczema was made; and ‘food 
allergy’ if this diagnosis was recorded in any part of the primary healthcare record.  
 
2.2.6.6 Blood collection 
10mls of blood was collected from each child via venous puncture using local anaesthetic 
cream and appropriate distraction techniques, with a play specialist as needed.  Samples 
were processed as follows:  1ml in EDTA for DNA stored at -80C within one hour of 
collection, 1mls in EDTA for eosinophil count was sent to Imperial College NHS Trust 
Hospital haematology laboratory for automated analysis and 8mls in a 10ml polypropylene 
tube containing 100IU preservative-free heparin collected within one hour and processed for 
flow cytometry and cell culture.  In addition an aliquot of plasma was separated, stored at -
20°C and transported to Northwick Park hospital laboratory for analysis of vitamin D levels, 
and an aliquot was analysed for total IgE level at TDL laboratories (ImmunoCap, Phadia, 
Sweden).   
 
2.2.7 Statistical analysis 
2.2.7.1 Power calculation 
The primary outcome measure was presence of at least one wheezing episode in the first 3 
years of life, which has been reported as occurring in 34% of children (5). With 180 
participants and 80% successful follow up, this study had 80% power with 2-sided alpha of 
0.05 to detect a reduction in wheeze from 34% in the children of non-supplemented mothers, 
(5) to 13% in the supplemented group. This level of risk reduction would be consistent with 
observational studies of maternal vitamin D intake and childhood wheezing (5, 297). 
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2.2.7.2 Data analysis 
All data were double entered onto a database and underwent range checks, data cleaning 
and checking with source documents before database lock. A statistical analysis plan was 
agreed between all the investigators prior to unblinding. Where necessary data were natural 
log transformed for analysis.  All analyses presented here were specified in the statistical 
analysis plan, and no post-hoc analyses were undertaken. For primary analyses, bolus and 
daily vitamin D groups were compared with the control group. We also report subgroup 
analyses of the combined groups versus control, and of children born to mothers with 
vitamin D deficiency (25(OH)D <25nmol/L) at enrolment. Binary outcomes were analysed 
using logistic regression, and continuous outcomes using linear regression. For clinical 
outcomes at age three years, binary outcomes were also analysed using risk ratios for 
unadjusted analysis.  For adjusted analyses, treatment effects were adjusted for mother’s 
ethnic group, presence of household smokers, maternal smoking in pregnancy, exclusive 
breast-feeding to four months, any parental allergic history, any child vitamin 
supplementation, number of children in the household, age mother left full-time education, 
baseline concentration of 25(OH)D in maternal blood, baseline maternal BMI and sex of the 
child. Analyses are based on all participants with complete data.  All analyses were 
performed using SPSS version 19.0 (IBM, Chicago USA). A value of p < 0.05 was 
considered statistically significant. 
 
Adjustment for multiple testing was performed using the Benjamini and Hochberg method 
(423).  This works by evaluating all the p-values from multiple analyses in order of 
significance, and determining whether each one can truly be counted as significant or not.  
For our analyses, there were 28 secondary analyses (14 for the daily group, and 14 for the 
bolus group) and the false discovery rate was controlled at 20%.  
 
Since not all offspring were followed up, sensitivity analyses were performed to determine if 
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this influenced the result for the primary outcome.  Two scenarios were considered – the first 
where no drop-outs wheezed and the second where all drop-outs wheezed. 
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2.3 An evaluation of the effects of prenatal vitamin D supplementation 
on healthcare utilization in the first three years of life  
We asked for consent from the parents of offspring participating in the follow up study of 
prenatal vitamin D supplementation to obtain a copy of their child’s electronic health record 
(e-HR).  Consent was obtained in person or over the telephone, in which case a second 
researcher verified consent.  A complete record was defined as having data for at least 11 
months out 12 for each year, and including all three years since birth. 
 
2.3.1 Primary and secondary outcomes 
The primary outcome was the total cost of unscheduled NHS healthcare utilization across 
primary and secondary care recorded in the e-HR from birth until the child’s third birthday, 
including both visit costs and prescription costs. Scheduled care such as routine 
developmental checks and vaccinations was not included.  Secondary outcomes were as 
follows:  total costs for the first, second and third year of life separately; total primary care 
visit costs, total secondary care visit costs, respiratory costs i.e. healthcare utilisation 
attributed to wheeze, cough, upper respiratory tract infection, lower respiratory tract infection 
and bronchiolitis; food allergy costs, eczema costs; prescription costs attributable to 
wheezing and eczema (separately). 
 
Primary healthcare consultations were classified according to the professional providing the 
service (general practitioner, out of hours service or nurse) and location (surgery, telephone 
or home visit).  Entries without details were classed as ‘primary care; unknown’.  Secondary 
healthcare utilization was classified as new outpatient appointment, follow-up outpatient 
appointment, accident and emergency attendance, ward admission or intensive care unit 
admission.  For admissions, the number of nights in hospital was recorded. Entries 
regarding administrative tasks were not included.  Coding definitions are shown in Table 2.1. 
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Table 2.1 Diagnostic codes for electronic health records 
Outcome Definition.  Any record of the following in the e-HR. 
Wheeze Wheeze or asthma excluding wheeze in the context of bronchiolitis 
Cough   Cough excluding cough in the context of URTI or LRTI 
URTI URTI, pharyngitis, rhinorrhoea, laryngitis, tonsillitis, sinusitis or otitis 
media 
OR 
At least two of fever, sore throat, earache, sticky eye or cough 
LRTI LRTI, chest infection, respiratory infection, bronchitis or pneumonia. 
OR 
Cough with a record of signs of infection such as crackles on 
auscultation 
Bronchiolitis Bronchiolitis 
Food allergy Doctor diagnosed food allergy 
Eczema Eczema or eczematous skin 
URTI (Upper respiratory tract infection), LRTI (Lower respiratory tract infection). 
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2.3.1.1 Visit costs 
Costs were calculated according to standard NHS tariffs for 2009 that include training and, 
where applicable, travel costs and direct care staff costs. As no unit cost was given for 
telephone calls with a practice nurse, this was estimated as follows: a telephone consultation 
with an advanced nurse is six minutes long on average, when applied to the hourly rate for 
client consultation with a GP practice nurse (£34) this gives an average cost of £3.40 per 
call.  A factor of 1.44 was applied to in hours GP utilization to give the estimated out of hours 
cost.  This is based on the mean cost per hour for out of hours GP services being £82.03 
(Inflation adjusted average, (424) which is 44% more than the mean cost per hour for in 
hours GP services of £57.03 (425). For secondary care new and follow-up outpatient 
attendances, a weighted mean of the cost of all types of paediatric referrals for consultant 
led outpatient care was taken, giving an overall mean of £198.60 for a first appointment and 
£155.36 for a follow-up appointment.  Similar methods were used for accident and 
emergency attendances, such that the weighted mean for an A&E attendance leading to 
admission was £129.11, and an A&E attendance without admission £94.93. This cost 
excludes the use of minor injury services and walk-in centres. 
 
2.3.1.2 Prescription costs 
Prescription costs were calculated from the online version of the British National Formulary 
for children 2011 (426). These reflect the cost of drugs issued and not the cost of 
administration associated with delivery to patients.  The price of the pharmaceutical brand 
specified in the record was taken. If no brand was specified the cheapest form of that 
medication with the same mode of delivery was used. Where costs were itemized as a net 
price per measured unit of drug (for example per 100ml), the price was applied proportional 
to the amount prescribed. Where the drug was priced per set volume (for example per tube 
in the case of creams) then the number of tubes required to cover the volume prescribed 
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was calculated. The summation of the medication costs in each record was then subjected 
to deflation calculations using inflation indices (427). As no inflation indices for 2010/11 were 
available at the time of calculation, the indices to deflate 2010 to 2009 were used twice, 
thereby assuming a similar rate of inflation across that time. Deflating prices to 2008/09 
brought them to the same base year as the healthcare utilization costs.  The price of Anusol 
cream and Dentinox oral solution were not available within the BNFC 2010 and were priced 
from Boots pharmacy; each of these were prescribed once.  Whether or not a child was 
prescribed drugs relevant to eczema (emollient creams and bath oils, topical corticosteroids 
with or without antibiotics or antiseptic and calcineurin inhibitors), asthma (inhaled 
corticosteroids, B2 agonists, leukotriene inhibitors and delivery devices) or food allergy 
(adrenaline autoinjectors and antihistamines) was separately recorded. 
 
2.3.2 Accuracy of data analysis 
Two assessors (RJB and MG) independently examined the first three e-HRs (84 
consultations). The kappa score for their assessment of total healthcare utilisation costs was 
0.972, showing excellent agreement.  The remaining records were all analysed by MG. 
 
2.3.3 Statistical analyses 
A database was assembled using Microsoft Excel. Data were explored using histograms and 
the following became normally distributed after natural log transformation:  Total healthcare 
utilization, total visit costs, total prescription costs, total primary care costs, total year 1 costs 
and overall respiratory costs. Levels of 25(OH)D at baseline in the mother, in cord blood and 
at age three years in the child were all normally distributed after natural log transformation.  
0.1 was added to all zero values to allow natural log transformation.  The following data 
remained non-parametrically distributed despite natural log transformation:  Total secondary 
care costs, year 2 and 3 costs, respiratory costs, food allergy costs, eczema costs and 
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prescription costs for eczema and wheezing medications.  
 
For primary analyses, bolus and daily vitamin D groups were compared with the control 
group.  Secondary analysis included bolus and daily vitamin D groups combined (combined 
vitamin D) compared with the control group and the relationship between 25(OH)D levels 
measured in cord blood at delivery and in the child at age three years.  Differences between 
groups were analysed using the Independent student t-test or Mann-Whitney U test 
according to whether the data were normally distributed or not. Analysis of variance was 
performed using potential covariates that have been associated with healthcare utilisation in 
the literature including mother’s age, mother’s age on leaving education, gestational age, 
ethnicity, parity, body mass index (BMI), smoking during pregnancy and mode of delivery 
(415). All analyses were performed using SPSS version 19.0 (IBM, Chicago USA).  A value 
of p<0.05 was considered statistically significant. 
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3 Assessment of lung function in 3 to 5 year old children attending 
a paediatric outpatient department using impulse oscillometry 
3.1 Introduction 
Objective measures of lung function in preschool children are important for evaluating the 
evolution of disease processes and response to interventions during this crucial 
developmental stage (49). However, practical evaluation in young children represents a 
major challenge (49). The ideal pulmonary function test should be applicable at any age, 
simple to perform, safe, reproducible, and sensitive and specific enough to detect changes 
with growth and distinguish clearly between health and disease (49). Impulse oscillometry is 
one technique that simply requires a child to breathe tidally through a mouthpiece for up to 
30 seconds whilst measurements are taken (49). The technique superimposes a small 
external pressure sine wave of a known frequency to the respiratory system, and the 
resulting pressure flow relationship is measured (52).  The ratio of the amplitude of the 
pressure wave, to the amplitude of the resulting flow wave, gives the respiratory impedance 
(Zrs), which represents the overall impediment to flow within the lung (49).   Impedance is 
the complex sum of lung resistance (Rrs) and reactance (Xrs), where Rrs represents 
frictional losses in the proximal and distal airways and lung parenchyma, of which airway 
resistance (Raw) is the most significant (49), and Xrs represents elastic and inertive 
properties within the lung.  
 
Although IOS reference ranges for young children have being published (49, 52, 60), there is 
limited data on the success rate, reproducibility and ability to distinguish between health and 
disease in children aged four years or less. Reported success rate for IOS in 4-year-old 
children range from 21% to 82% (56, 65) in the research setting.  The CV for resistance 
ranges from 6.0% to 11% (61), however, the majority of children included in these studies 
   
were aged over 4 years.  There is evidence that bronchodilator responses measured by IOS 
are greater in children with preschool wheezing compared to controls (59, 68-70, 72). 
Differences in IOS response have been found in preschool children with wheezing enrolled 
in prospective randomised controlled trials of pharmacotherapy (50, 73).  
 
The aims of this study were to determine the success rate of IOS for measuring lung 
function in 3 to 5 year old children, the repeatability (CV) in this age group and the ability of 
IOS to discriminate between children with and without a history of wheezing and/or atopy. 
 
3.2 Methods 
Participants were recruited from a hospital based paediatric outpatient clinic, where they 
completed a questionnaire and had IOS assessment.  Full methods are described in section 
2.1. 
 
3.3 Results 
3.3.1 Subjects 
66 children aged three to five years participated in the study. 64 were recruited from St 
Mary’s paediatric outpatient department and two from the community. Flow of children in the 
study is shown in Figure 3-1, and the demographics of children who provided acceptable 
IOS data, with and without a history of wheeze are shown in Table 3.1.   
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Figure 3-1 Children in the pilot study 
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Table 3.1 Children with and without a history of wheezing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
URTI (Upper respiratory tract infection), IOS (Impulse oscillometry). 
 
 
 
 No wheeze Wheeze 
Male sex, n (%) 11/22 (50.0) 8/15 (53.3) 
Birth weight (g), mean (SD) 3458 (784) 3569 (527) 
Ethnicity, n (%)    
  Asian 5 (22.7) 5 (33.3) 
  Middle Eastern 3 (13.6) 1 (6.7) 
  Black 3 (13.6) 4 (26.7) 
  Other 1 (4.5) 2 (13.3) 
  White 10 (45.5) 3 (20.0) 
Age at time of assessment (months), mean (SD) 49 (7) 50 (6) 
Height (cm), mean (SD) 104 (7) 104 (5) 
Maternal smoking during pregnancy, n (%) 0/22 (0) 1/15 (6.7) 
Presence of household smokers, n (%) 3/22 (13.6) 2/15 (13.3) 
>4 URTI/ year, n (%) 3/22 (13.6) 4/15 (26.7) 
Has your child ever had asthma?  N (%) 0/22 (0.0) 7/15 (46.7) 
Has your child ever had hayfever?  N (%) 4/22 (18.2) 4/15 (26.7) 
Has your child ever had eczema? N (%) 11/22 (50.0) 8/15 (53.3) 
Doctor diagnosed food allergy? N (%) 6/22 (27.3) 8/15 (53.3) 
Atopy, n (%) 7/22 (31.8) 7/15 (46.7) 
Acceptable Pre IOS, n (%) 22/22 (100) 15/15 (100) 
Acceptable post IOS, n (%) 14/22 (63.6) 9/15 (60.0) 
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When baseline measurements from all children were combined for analysis, Z5, R5, R10, 
R15, R20, R25, Fres and AX were all significantly inversely correlated with height (Figure 3-
2).  The relationship between X5 and height did not reach significance. 
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Figure 3-2 Baseline IOS parameters and height   
 
Correlation of A) Impedance at 5Hz (Z5), B) Resistance at 5Hz (R5), C) R10, D) R15, E) 
R20 and F) R25 at baseline with height in children with (black squares) and without (open 
circles) a history of wheezing. Pearson’s correlation coefficient (r). 
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When baseline measurements from all children were combined for analysis, Z5, R5, R10, 
R15, Fres and AX were all significantly inversely correlated with age in months (Table 3.2 
and Figure 3-3).   
 
 
Table 3.2 Baseline IOS parameters (pilot study) with age in months 
 Pearson correlation p 
Z5 -0.51 0.00 
R5 -0.49 0.00 
R10 -0.50 0.00 
R15 -0.37 0.03 
R20 -0.27 0.11 
R25 -0.31 0.07 
X5 0.13 0.45 
Fres -0.34 0.04 
AX -0.54 0.00 
 
Z5 (Impedance at 5Hz), R5 to R25 (resistance at 5 to 
25Hz), X5 (Reactance at 5Hz), Fres (Resonant 
frequency) and AX (Area under the reactance curve). 
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Figure 3-3 Baseline IOS with age in months 
 
 
Correlation of A) Impedance at 5Hz (Z5), B) Resistance at 5Hz (R5), C) R10, D) R15, E) 
R20 and F) R25 at baseline with age in months. Pearson’s correlation coefficient (r). 
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When baseline measurements from all children were combined for analysis, no significant 
differences in any IOS parameter was found between boys and girls (Table 3.3).   
 
 
Table 3.3 Baseline IOS parameters (pilot study) in boys vs girls 
IOS 
Parameter 
n Males 
Mean  SD 
n Females 
Mean  SD 
Mean difference 
(95% CI) 
p 
Z5 19 1.26  0.35 18 1.17  0.26 0.09 (-0.12, 0.29) 0.41 
R5 19 1.21  0.35 18 1.11  0.26 0.09 (-0.12, 0.30) 0.37 
R10 19 0.83  0.22 18 0.83  0.18 0.00 (-0.13, 0.14) 0.96 
R15 19 0.69  0.19 18 0.71  0.18 -0.02 (-0.14, 0.11) 0.80 
R20 19 0.61  0.16 18 0.62  0.17 -0.02 (-0.13, 0.09) 0.77 
R25 19 0.63  0.14 18 0.63  0.13 -0.01 (-0.10, 0.09) 0.90 
RF 19 21.85  2.26 18 21.97  2.76 -0.11 (-1.79, 1.57) 0.89 
AX 19 4.02  1.82 18 3.64  1.41 0.38 (-0.71, 1.47) 0.49 
Z5 (Impedance at 5Hz), R5 to R25 (resistance at 5 to 25Hz), X5 (Reactance at 5Hz), Fres 
(Resonant frequency) and AX (Area under the reactance curve). 
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When baseline measurements from all children were combined for analysis, significant 
differences were found between children of different ethnic groups as follows:  White and 
Black children for R10, R15, R20, R25 and Fres; White and Asian children for R15, R20 and 
Fres; Asian and Middle Eastern children for Fres; Black and Middle Eastern children for Fres 
(Figure 3-4). 
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Figure 3-4  Baseline IOS parameters (pilot study) by different ethnic groups 
 
Baseline IOS in children of different ethnic origins. A) Impedance at 5Hz (Z5), B) Resistance 
at 5Hz (R5), C) R10, D) R15, E) R20, F) R25, G) AX and H) Fres. 
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3.3.2 Success rate of IOS in preschool children 
Acceptable baseline IOS data was acquired for 37/66 (56%) of participating children. 
Bronchodilator response was measured in 23/66 (35%). Boys and girls were equally able to 
perform IOS, with 18/31 females (58.1%) and 19/35 males (54.3%) providing baseline data 
of acceptable quality.  Success rates were 18/36 (50%) for three year olds and 19/30 (63%) 
for 4 year olds. Using a cut off of 42 months, success rates were higher for older children 
with 8/21 (38.1%) successful aged ≤ 42 months and 29/45 (64.4%) successful >42 months 
(Pearson Chi Squared, p=0.045).  However, there was no difference in median age in 
months between children who were and were not successful in providing acceptable quality 
data (Mann-Whitney U Test, p=0.19) 
 
3.3.3 Repeatability of measurements  
CV was acceptable for most parameters, but over 20% for X5 and AX (Table 3.4). There 
were no significant differences between wheezers and non-wheezers for CV (Table 3.5). 
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Table 3.4 Coefficient of variation for impulse oscillometry measurements  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Baseline 
Median (IQR) (%) 
Post bronchodilator 
Median (IQR) (%) 
Z5 8.84 (5.81, 10.86) 7.60 (5.44, 9.17) 
R5 8.50 (6.21, 11.82) 8.38 (6.36, 9.70) 
R10 6.93 (4.31, 8.44) 6.45 (4.52, 8.84) 
R15 7.31 (4.27, 9.93) 6.82 (5.67, 9.82) 
R20 7.92 (5.56, 10.11) 7.54 (5.25, 11.59) 
R25 6.24 (4.97, 10.63) 6.46 (4.32, 11.30) 
X5 20.59 (64.27, 8.83) 14.47 (32.33, 9.62) 
Fres 4.31 (2.59, 6.21) 3.50 (1.78, 6.09) 
AX 12.90 (8.04, 19.69) 12.10 (8.33, 19.56) 
Z5 (Impedance at 5Hz), R5 to R25 (resistance at 5 to 25Hz), 
X5 (Reactance at 5Hz), Fres (Resonant frequency) and AX 
(Area under the reactance curve). 
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Table 3.5 Coefficient of variation for impulse oscillometry in children with and without wheezing 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Non-wheezers 
Median (IQR) (%) 
Wheezers 
Median (IQR) (%) 
p 
Z5 8.88 (5.53, 11.89) 8.34 (6.22, 10.60) 0.64 
R5 9.77 (6.21, 13.18) 8.16 (5.39, 11.42) 0.35 
R10 6.81(4.31, 8.44) 6.93 (3.63, 11.20) 0.80 
R15 8.33 (4.08, 9.93) 7.22 (4.92, 11.24) 0.70 
R20 9.03 (4.08, 9.62) 7.60 (5.61, 10.35) 0.92 
R25 6.09 (4.06, 9.62) 7.76 (5.33, 11.02) 0.30 
X5 16 (8.58, 64.27) 31.13 (15.68, 77.89) 0.45 
Fres 4.99 (2.59, 6.34) 3.21 (2.55, 5.40) 0.29 
AX 15.45 (9.55, 23.92) 11.13 (6.61, 19.69) 0.30 
Z5 (Impedance at 5Hz), R5 to R25 (resistance at 5 to 25Hz), X5 
(Reactance at 5Hz), Fres (Resonant frequency) and AX (Area under 
the reactance curve). 
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3.3.4 Ability to discriminate between groups 
3.3.4.1 Differences in baseline lung function  
Data for baseline IOS parameters in children with and without history of wheeze are 
presented in Figure 3-5 and Table 3.6, and for atopic sensitisation, atopic wheeze, any ETS 
exposure and frequent URTI in Tables 3.7 to 3.10. Children with wheezing had significantly 
higher baseline Fres than non-wheezers in adjusted analyses only.  There were no 
differences in baseline lung function between groups for atopy, atopic wheezing, any ETS 
exposure or history of frequent URTI.   
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Figure 3-5 Baseline lung function in children with and without a history of wheezing 
 
Baseline A) Impedance at 5Hz (Z5), B) Resistance at 5Hz (R5), C) R10, D) R15, E) R20, F) 
R25, G) Resonant frequency (Fres) and H) Area under the reactance curve (AX) in children 
with (black squares) and without (black circles) a history of wheezing.  Horizontal bars 
represent means and p values are for adjusted analyses. 
 
 
126 
Table 3.6 Baseline lung function in preschool children with and without a history of wheeze 
IOS Parameter n No wheeze 
Mean ± SD 
n Wheeze 
Mean ± SD 
Mean difference 
(95% CI) 
p n 1Adjusted mean 
difference (95% CI) 
p 
Z5 (kPa.s.L) 22 1.20 ± 0.38 15 1.24 ± 0.17 0.05 (-0.16, 0.26) 0.66 37 0.05 (-0.12, 0.22) 0.58 
R5 (kPa/Ls-1) 22 1.13 ± 0.38 15 1.20 ± 0.18 0.07 (-0.15, 0.28) 0.53 37 0.07 (-0.11, 0.25) 0.45 
R10 (kPa/Ls-1) 22 0.81 ± 0.21 15 0.85 ± 0.19 0.04 (-0.10, 0.18) 0.58 37 0.03 (-0.09, 0.15) 0.60 
R15 (kPa/Ls-1) 22 0.67 ± 0.18 15 0.73 ± 0.18 0.06 (-0.07, 0.18) 0.35 37 0.04 (-0.07, 0.15) 0.46 
R20 (kPa/Ls-1) 22 0.59 ± 0.16 15 0.65 ± 0.16 0.06 (-0.05, 0.17) 0.30 37 0.04 (-0.07, 0.15) 0.45 
R25 (kPa/Ls-1) 22 0.62 ± 0.14 15 0.65 ± 0.13 0.03 (-0.06, 0.13) 0.48 37 0.03 (-0.07, 0.12) 0.55 
Fres (Hz) 22 21.34 ± 2.17 15 22.74 ± 2.75 1.41 (-0.24, 3.05) 0.09 37 0.87 (-0.50, 2.24) 0.20 
AX (kPa/L) 22 3.88 ± 1.99 15 3.78 ± 0.92 -0.10 (-1.22, 1.02) 0.86 37 -0.13 (-0.99, 0.73) 0.76 
Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency), AX (Area under the  
reactance curve).  1Adjusted for age, height, sex and ethnicity. 
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Table 3.7 Baseline lung function in preschool children with and without atopic skin sensitisation 
IOS Parameter n Non-atopic 
Mean ± SD 
n Atopic 
Mean ± SD 
Mean difference 
(95% CI) 
p n 1Adjusted mean 
difference (95% CI) 
p 
Z5 (kPa.s.L) 23 1.25 ± 0.33 14 1.15 ± 0.25 -0.10 (-0.31, 0.11) 0.34 37 -0.01 (-0.18, 0.17) 0.96 
R5 (kPa/Ls-1) 23 1.20 ± 0.34 14 1.10 ± 0.26 -0.10 (-0.32, 0.11) 0.33 37 -0.01 (-0.20, 0.18) 0.90 
R10 (kPa/Ls-1) 23 0.83 ± 0.22 14 0.82 ± 0.18 -0.01 (-0.15, 0.13) 0.88 37 0.06 (-0.06, 0.18) 0.30 
R15 (kPa/Ls-1) 23 0.69 ± 0.19 14 0.71 ± 0.16 0.02 (-0.11, 0.15) 0.75 37 0.06 (-0.06, 0.178) 0.29 
R20 (kPa/Ls-1) 23 0.61 ± 0.17 14 0.63 ± 0.15 0.03 (-0.09, 0.14) 0.65 37 0.05 (-0.06, 0.17) 0.34 
R25 (kPa/Ls-1) 23 0.63 ± 0.15 14 0.63 ± 0.12 -0.00 (-0.10, 0.09) 0.95 37 0.03 (-0.07, 0.13) 0.51 
Fres (Hz) 23 21.61 ± 2.68 14 22.40 ± 2.11 0.80 (-0.91, 2.51) 0.35 37 1.01 (-0.43, 2.44) 0.16 
AX (kPa/L) 23 3.97 ± 1.81 14 3.62 ± 1.29 -0.35 (-1.47, 0.78) 0.54 37 0.25 (-0.65, 1.16) 0.57 
Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency), AX (Area under the 
reactance curve).  1Adjusted for age, height and sex and ethnicity. 
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Table 3.8 Baseline lung function in preschool children with and without atopic wheeze 
IOS Parameter n Non atopic wheeze 
Mean ± SD 
n Atopic wheeze 
Mean ± SD 
Mean difference 
(95% CI) 
p n 1Adjusted mean 
difference (95% CI) 
p 
Z5 (kPa.s.L) 30 1.21 ± 0.33 7 1.23 ±0.20 0.02 (-0.25, 0.28) 0.90 37 0.05 (-0.15, 0.25) 0.62 
R5 (kPa/Ls-1) 30 1.15 ± 0.33 7 1.18 ± 0.20 0.03 (-0.24, 0.30) 0.84 37 0.06 (-0.16, 0.27) 0.59 
R10 (kPa/Ls-1) 30 0.82 ± 0.20 7 0.87 ± 0.20 0.05 (-0.13, 0.22) 0.60 37 0.06 (-0.08, 0.20) 0.38 
R15 (kPa/Ls-1) 30 0.69 ± 0.18 7 0.74 ± 0.20 0.05 (-0.11, 0.20) 0.54 37 0.05 (-0.08, 0.19) 0.42 
R20 (kPa/Ls-1) 30 0.61 ± 0.16 7 0.65 ± 0.19 0.04 (-0.10, 0.18) 0.54 37 0.05 (-0.08, 0.18) 0.45 
R25 (kPa/Ls-1) 30 0.63 ± 0.13 7 0.65 ± 0.15 0.02 (-0.09, 0.14) 0.69 37 0.04 (-0.07, 0.15) 0.50 
Fres (Hz) 30 21.65 ± 2.49 7 23.02 ± 2.28 1.37(-0.72, 3.46) 0.19 37 1.11 (-0.53, 2.75) 0.18 
AX (kPa/L) 30 3.81 ± 1.76 7 3.97 ± 0.93 0.16 (-1.25, 1.56) 0.82 37 0.32 (-0.71, 1.35) 0.53 
Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency), AX (Area under the reactance 
 curve).  1Adjusted for height and age, sex and ethnicity 
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Table 3.9 Baseline lung function in preschool children with and without any ETS exposure 
IOS Parameter n No ETS 
Mean ± SD 
n Any ETS 
Mean ± SD 
Mean difference 
(95% CI) 
p n 1Adjusted mean 
difference (95% CI) 
p 
Z5 (kPa.s.L) 32 1.24 ± 0.31 5 1.04 ± 0.25 -0.20 (-0.49, 0.10) 0.88 37 -0.07 (-0.32, 0.18) 0.59 
R5 (kPa/Ls-1) 32 1.19 ± 0.31 5 1.00 ± 0.25 -0.19 (-0.49, 0.12) 0.18 37 -0.05 (-0.32, 0.21) 0.68 
R10 (kPa/Ls-1) 32 0.83 ± 0.20 5 0.80 ± 0.22 -0.04 (-0.24, 0.16) 0.22 37 0.02 (-0.15, 0.20) 0.78 
R15 (kPa/Ls-1) 32 0.70 ± 0.18 5 0.68 ± 0.21 -0.02 (-0.19, 0.16) 0.86 37 0.02 (-0.15, 0.19) 0.80 
R20 (kPa/Ls-1) 32 0.62 ± 0.16 5 0.61 ± 0.20 -0.01 (-0.17, 0.15) 0.87 37 0.02 (-0.14, 0.19) 0.80 
R25 (kPa/Ls-1) 32 0.64 ± 0.13 5 0.60 ± 0.16 -0.03 (-0.17, 0.10) 0.60 37 -0.00 (-0.14, 0.14) 0.98 
Fres (Hz) 32 21.90 ± 2.35 5 21.96 ± 3.56 0.06 (-2.40, 2.52) 0.96 37 0.55 (-1.55, 2.65) 0.60 
AX (kPa/L) 32 3.99 ± 1.67 5 2.86 ± 0.87 -1.13 (-2.69, 0.43) 0.15 37 -0.44 (-1.72, 0.84) 0.49 
ETS (Pre or postnatal environmental tobacco smoke exposure), Z5 (Impedance at 5Hz),  
R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency), AX (Area under the reactance curve). 
1Adjusted for height, age, sex and ethnicity. 
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Table 3.10 Baseline lung function in preschool children with and without frequent URTI 
IOS Parameter n 4 URTI/yr 
Mean ± SD 
n >4 URTI/yr 
Mean ± SD 
Mean difference 
(95% CI) 
p n 1Adjusted mean 
difference (95% CI) 
p 
Z5 (kPa.s.L) 30 1.18 ±0.27 7 1.38 ± 0.42 0.21 (-0.05, 0.46) 0.11 37 0.05 (-0.17, 0.27) 0.67 
R5 (kPa/Ls-1) 30 1.12 ± 0.28 7 1.32 ± 0.42 0.19 (-0.07, 0.45) 0.14 37 0.04 (-0.20, 0.27) 0.75 
R10 (kPa/Ls-1) 30 0.80 ± 0.18 7 0.95 ± 0.24 0.15 (-0.02, 0.32) 0.07 37 0.03 (-0.12, 0.18) 0.67 
R15 (kPa/Ls-1) 30 0.67 ± 0.17 7 0.81 ± 0.18 0.14 (-0.004, 0.29) 0.06 37 0.03 (-0.12, 0.18) 0.65 
R20 (kPa/Ls-1) 30 0.59 ± 0.15 7 0.73 ± 0.16 0.14 (0.004, 0.27) 0.04 37 0.05 (-0.09, 0.19) 0.49 
R25 (kPa/Ls-1) 30 0.61 ± 0.12 7 0.73 ± 0.15 0.12 (0.01, 0.23) 0.03 37 0.06 (-0.06, 0.18) 0.30 
Fres (Hz) 30 21.71 ± 2.61 7 22.77 ± 1.71 1.06 (-1.05, 3.18) 0.31 37 -0.83 (-2.64, 0.98) 0.36 
AX (kPa/L) 30 3.66 ± 1.38 7 4.59 ± 2.40 0.93 (-0.43, 2.30) 0.18 37 0.07 (-1.06, 1.19) 0.91 
URTI (Upper respiratory tract infection), Yr (Year), Z5 (Impedance at 5Hz),  
R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency), AX (Area under the reactance curve). 
1Adjusted for height, age, sex and ethnicity. 
 
 
131 
3.3.4.2 Bronchodilator response  
The response to administration of 400mcg of salbutamol in children with and without a 
history of wheeze is shown in Figure 3-6 and Table 3.11.  Results for atopy, atopic 
wheezing, any ETS exposure and frequent URTI are given in Tables 3.12 to 3.15.  In 
adjusted and unadjusted analyses, children with a history of wheezing had significantly 
greater bronchodilator response in R25 compared to children with no history of wheezing.   
There were no significant differences in bronchodilator responses when data was 
dichotomized by atopic status, atopic wheezing, any ETS exposure or frequent URTI. 
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Figure 3-6 Bronchodilator responses in children with and without a history of wheezing 
 
Percentage change in lung function measured before and 15 minutes after inhalation of 
400mcg salbutamol for A) Impedance at 5Hz (Z5), B) Resistance at 5Hz (R5), C) R10, D) 
R15, E) R20, F) R25, G) Resonant frequency (Fres) and H) Area under the reactance curve 
(AX) in children with (black squares) and without (open circles) a history of wheezing.  
Horizontal lines represent means and p values are for adjusted analyses.  
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Table 3.11 Bronchodilator response in children with and without a history of wheezing 
IOS 
Parameter 
n No wheeze 
Mean ± SD 
n Wheeze 
Mean ± SD 
Mean difference 
(95% CI) 
p n 1Adjusted mean 
difference (95% CI) 
p 
Z5 %Init 14 -7.13 ± 15.92 9 -15.28  ± 8.69 -8.15 (-20.26, 3.95) 0.18 23 2.47 (-16.79, 21.71) 0.79 
R5 %Init 14 -5.66 ± 17.80 9 -14.87 ± 7.56 -9.21 (-22.33, 3.91) 0.16 23 3.53 (-17.17, 24.23) 0.72 
R10 %Init 14 -3.74 ± 11.97 9 -11.48 ± 7.69 -7.74 (-17.10, 1.63) 0.10 23 0.37 (-13.98, 14.71) 0.96 
R15 %Init 14 -1.61 ± 10.68 9 -8.61 ± 8.87 -7.00 (-15.91, 1.91) 0.12 23 0.00 (-13.95, 13.96) 1.00 
R20 %Init 14 -0.36 ± 9.86 9 -7.89 ± 8.73 -7.53 (-15.93, 0.86) 0.08 23 -3.50 (-17.26, 10.25) 0.59 
R25 %Init 14 -1.24 ± 8.46 9 -9.67 ± 7.71 -8.43 (-15.70, -1.16) 0.03 23 -7.19 (-18.37, -4.00) 0.19 
Fres %Init 14 -5.09  ± 10.81 9 -7.84 ± 7.91 -2.75 (-11.46, 5.97) 0.52 23 3.20 (-11.62, 18.01) 0.65 
AX %Init 14 -19.39 ± 32.08 9 -27.45 ± 24.26 -8.06 (-34.13, 18.02) 0.53 23 15.69 (-28.77, 60.16) 0.46 
Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency),  
AX (Area under the reactance curve), %Init (percentage change in parameter 15 minutes after 400 mcg inhaled salbutamol). 
1Adjusted for height, age, sex and ethnicity. 
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Table 3.12 Bronchodilator response in children with and without a history of atopy 
IOS 
Parameter 
n Non atopic 
Mean ± SD 
n Atopic 
Mean ± SD 
Mean difference 
(95% CI) 
p n 1Adjusted mean 
difference (95% CI) 
p 
Z5 %Init 17 -9.02  14.77 6 -13.99  11.49 -4.97 (-18.86, 8.91) 0.47 23 -4.86 (-21.78, 12.07) 0.55 
R5 %Init 17 -7.69  15.95 6 -13.74  12.73 -6.05 (-21.10, 9.01) 0.41 23 -3.38 (-21.78, 15.01) 0.70 
R10 %Init 17 -6.48  11.72 6 -7.60  9.59 -1.12 (-12.23, 9.99) 0.84 23 1.35 (-11.38, 14.07) 0.82 
R15 %Init 17 -4.76  10.81 6 -3.18  10.01 1.58 (-8.92, 12.07) 0.76 23 4.61, (-7.50, 16.73) 0.43 
R20 %Init 17 -3.80  9.93 6 -1.91  10.86 1.90 (-8.14, 11.93) 0.70 23 3.29 (-8.92, 15.50) 0.57 
R25 %Init 17 -4.66  8.82 6 -4.20  10.49 0.47 (-8.66, 9.59) 0.92 23 0.63 (-9.96, 11.21) 0.90 
Fres %Init 17 -5.12  10.06 6 -9.14  8.60 -4.02 (-13.63, 5.59) 0.39 23 0.98 (-14.23, 12.28) 0.88 
AX %Init 17 -18.65  29.36 6 -33.58  27.06 -14.92 (-43.39, 13.55) 0.29 23 -15.71 (-55.01, 23.59) 0.41 
Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency),  
AX (Area under the reactance curve), %Init (percentage change in parameter 15 minutes after 400 mcg inhaled salbutamol). 
1Adjusted for height, age, sex and ethnicity. 
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Table 3.13 Bronchodilator response in children with and without a history of atopic wheezing 
IOS 
Parameter 
n No atopy or 
wheeze 
Mean ± SD 
n Atopic wheeze 
Mean ± SD 
Mean difference 
(95% CI) 
p n 1Adjusted mean 
difference (95% CI) 
p 
Z5 %Init 19 -9.61  15.12 4 -13.71  5.50 4.10 (-12.09, 20.29) 0.60 23 -2.11 (-21.27, 17.05) 0.82 
R5 %Init 19 -8.26  16.48 4 -14.03  3.87 5.77 (-11.76, 23.30) 0.50 23 -1.49 (-22.17, 19.20) 0.88 
R10 %Init 19 -6.41  11.83 4 -8.49  6.54 2.07 (-10.77, 14.92) 0.74 23 0.46 (-13.81, 14.74) 0.95 
R15 %Init 19 -4.32  11.00 4 -4.49  8.25 0.18 (-12.00, 12.36) 0.98 23 1.82 (-12.03, 15.66) 0.78 
R20 %Init 19 -2.79  10.27 4 -5.75  9.24 2.96 (-8.63, 14.55) 0.60 23 -3.59 (-17.27, 10.09) 0.58 
R25 %Init 19 -3.73  9.10 4 -8.42  8.77 4.69 (-5.67, 15.05) 0.36 23 -5.83 (-17.21, 5.55) 0.29 
Fres %Init 19 -6.07  10.42 4 -6.64  5.95 0.58 (-10.75, 11.91) 0.92 23 1.60 (-13.23, 16.42) 0.82 
AX %Init 19 -21.93  29.97 4 -25.48  27.27 3.55 (-30.31, 37.42) 0.83 23 1.38 (-43.76, 46.51) 0.95 
Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency), AX (Area under the 
reactance curve), %Init (percentage change in parameter 15 minutes after 400 mcg inhaled salbutamol). 
1Adjusted for height, age, sex and ethnicity. 
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Table 3.14 Bronchodilator response in children with and without a history of any ETS exposure 
IOS 
Parameter 
n No ETS 
exposure 
Mean ± SD 
n Any ETS 
exposure 
Mean ± SD 
Mean difference 
(95% CI) 
p n 1Adjusted mean 
difference (95% CI) 
p 
Z5 %Init 20 -11.32  14.59 3 -3.63  5.49 7.69 (-10.31, 25.70) 0.38 23 6.75 (-11.87, 25.37) 0.45 
R5 %Init 20 -10.40  15.80 3 -1.72  7.14 8.68 (-10.88, 28.24) 0.37 23  8.46 (-11.46, 28.38) 0.39 
R10 %Init 20 -7.56  11.35 3 -1.50  7.74 6.07 (-8.17, 20.30) 0.39 23 6.00 (-7.72, 19.71) 0.36 
R15 %Init 20 -5.24  10.47 3 1.58  9.36 6.82 (-6.54, 20.17) 0.30 23 7.00 (-6.15, 20.16) 0.27 
R20 %Init 20 -4.47  9.58 3 4.44  10.83 8.91 (-3.59, 21.40) 0.15 23 9.68 (-2.85, 22.51) 0.12 
R25 %Init 20 -5.71  8.76 3 3.24  8.01 8.95 (-2.24, 20.14) 0.11 23 10.38 (0.26, 20.58) 0.06 
Fres %Init 20 -6.61  10.32 3 -3.25  1.84 3.36 (-9.30, 16.02) 0.59 23 4.37 (-10.13, 18.87) 0.53 
AX %Init 20 -22.57  31.04 3 -22.41  8.15 0.16 (-38.00, 38.32) 0.99 23 -3.37 (-48.40, 40.93) 0.86 
ETS (Pre or postnatal environmental tobacco smoke exposure), Z5 (Impedance at 5Hz),  
R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency), AX (Area under the reactance curve),  
%Init (percentage change in parameter 15 minutes after 400 mcg inhaled salbutamol). 
1Adjusted for height, age, sex and ethnicity. 
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Table 3.15 Bronchodilator response in children with and without a history of frequent URTI 
IOS 
Parameter 
n 4 URTI/yr 
Mean ± SD 
n >4 URTI/yr 
Mean ± SD 
Mean difference 
(95% CI) 
p n 1Adjusted mean 
difference (95% CI) 
p 
Z5 %Init 18 -8.66 ± 14.64 5 -16.30 ± 9.85 -7.65 (-22.22, 6.92) 0.29 23 0.09 (-19.40, 19.57) 0.99 
R5 %Init 18 -7.22 ± 16.02 5 -16.62 ± 9.18 -9.39 (-25.12, 6.33) 0.23 23 -0.10 (-21.11, 20.91) 0.99 
R10 %Init 18 -6.00 ± 11.74 5 -9.56 ± 8.20 -3.57 (-15.29, 8.16) 0.53 23 4.18 (-10.10, 18.47) 0.54 
R15 %Init 18 -3.95 ± 10.92 5 -5.76 ± 9.25 -1.81 (-12.97, 9.35) 0.74 23 6.41 (-7.19, 20.01) 0.33 
R20 %Init 18 -3.27 ± 10.27 5 -3.42 ± 9.91 -0.15 (-10.87, 10.57) 0.98 23 7.06 (-6.38, 20.50) 0.28 
R25 %Init 18 -4.95 ± 9.24 5 -3.06 ± 9.08 1.89 (-7.79, 11.57) 0.69 23 6.23 (-5.26, 17.72) 0.26 
RF %Init 18 -5.76 ± 9.89 5 -7.62 ± 9.82 -1.85 (-12.23, 8.53) 0.71 23 -0.83 (-15.89, 14.24) 0.91 
AX %Init 18 -20.45 ± 31.29 5 -30.11 ± 18.93 -9.66 (-40.50, 21.18) 0.52 23 2.65 (-43.14, 48.43) 0.90 
URTI (Upper respiratory tract infection), Yr (year), Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), 
Fres (Resonant frequency), AX (Area under the reactance curve), %Init (percentage change in parameter 15 
minutes after 400 mcg inhaled salbutamol). 
1Adjusted for pre and postnatal environmental tobacco smoke exposure, height and age. 
   
3.4 Discussion 
We have found that in a convenience sample of children aged three and four years attending 
outpatient clinic, acceptable IOS data could be acquired in just over half.  When acceptable 
quality readings are taken, the technique is repeatable with low CV for most measurements. 
We found significant differences in IOS parameters between children from different ethnic 
groups, particularly between White and Black children.  No significant differences in lung 
function were found between children with and without a history of wheezing, atopy, 
environmental tobacco smoke exposure and frequent URTI.   
 
Our success rates are not as high as Klug et al who reported reporting 65% and 82% for 
children aged 3 and 4 years respectively (56), but much greater than Guilbert et al who 
reported a 21% success rate for children aged 4 years (65).  A number of factors could 
account for the difference. Klug et al used a specially designed facemask to minimise upper 
airway artefact.  Our quality criteria are more stringent.  If we had included all readings, 
regardless of quality, our success would have increased to 71%.  Although IOS is described 
as a simple, non-invasive test, children get bored, stick their tongues in the mouthpiece, 
swallow, and chew and make an incomplete seal.  All these manoeuvres lead to data 
corruption.  Whilst these issues are identified in ATS/ERS guidelines on IOS, there are no 
uniformly agreed criteria for acceptance of an individual reading.  It is possible that poor 
operator technique led to poor quality data.  This is hard to quantify but in undertaking this 
study training was undertaken with an experienced IOS practitioner. The setting may have 
been important.  Children were recruited from a hospital outpatient clinic and a high 
proportion were attending the asthma/ allergy clinic.  This may bias towards children familiar 
with using mouthpieces and respiratory devices such as spacers leading to increased 
compliance compared to the general population, however we found no difference in the 
repeatability between children with and without a history of wheezing, suggesting this is not 
   
the case.  Alternatively, because children and families where attending outpatients they may 
have been tired or less cooperative than usual leading to reduced compliance compared to 
children attending for research purposes only (56).  
 
Our CV for resistance compares favourably with other published studies (61). As found by 
others (58, 66), CV for X5 and AX was much higher, suggesting it may not be possible to 
reliably measure these two parameters in preschool IOS assessment. 
 
Our finding of ethnic variation in impulse oscillometry measurements is of great interest.  
Whilst such differences have been described for spirometry, (428, 429), to our knowledge 
only one study has described such differences for impulse oscillomtery in preschool children 
by comparing reference ranges in Caucasians and Mexicans(430).  However, this finding 
should be viewed with caution, as it is possible that confounding factors such socio-
economic background, which may differ between ethnic groups in this convenience sample, 
could explain the difference.  
 
In keeping with other studies (65, 67, 68, 70), we found no differences in baseline respiratory 
resistance between children with and without a history of wheezing.  However unlike the 
majority of other studies, we found no differences respiratory resistance between children 
with and without a history of wheezing (59, 68-71) (Table 3.16).  
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Table 3.16 Bronchodilator responses for asthmatic/wheezy children vs controls 
Study R5 R10 R20 R25 R35 X5 Fres AX 
Nielsen (59) ✓ ✕ - - - ✓ - - 
Marotta (68) ✓ ✓ - - - ✕ ✕ - 
Song (69) ✓ ✓ ✓ - ✓ ✕ ✕ - 
Komarov (70) ✓ ✓ ✕ - - ✓ - ✓ 
Shin (72) ✓ ✕ - - - ✓ - ✓ 
This study ✕ ✕ x x - ✕ ✕ ✕ 
✓= significantly greater response in asthmatics/ wheezy children than controls;  
✕ = no difference;  - = not measured 
 
The explanation for this finding is not clear. Perhaps the heterogeneity of the groups, 
including the variation of ethnicity, meant that true differences in lung function between 
children with wheeze and no wheeze, were masked.  This study may have been 
underpowered to detect a significant difference. 
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4 Effect of prenatal vitamin D supplementation on parentally 
reported outcomes 
4.1 Introduction 
Several observational studies have suggested a protective effect of higher maternal vitamin 
D intake during pregnancy on risk of wheezing (175, 272, 289), asthma and allergic rhinitis 
(298), and eczema (289) in offspring. However, dietary intake of vitamin D makes a relatively 
small contribution to overall vitamin D status, and apparent effects of vitamin D intake may 
be confounded by other correlated nutrients. These studies did not report outcomes in 
relation to maternal serum 25-hydroxyvitamin D (25(OH)D) concentration,  the gold standard 
measure of vitamin D status (210, 431), which takes account of skin synthesis, our primary 
source of vitamin D.  Observational studies based on early life 25(OH)D levels have 
conflicting results; for wheezing, one study found reduced cumulative wheeze by 5 years in 
offspring of vitamin D deficient mothers (290) but three studies found no relationship (145, 
292, 293); For asthma, five studies found no effect by 6 years of age (145, 290-293) but one 
study an increased risk by age 9 years (287); For allergic rhinitis and eczema no relationship 
has been found (145, 287, 291).  The case for protection against early respiratory infection is 
more convincing, with observational studies showing a protective effect of higher levels 
against infection in the first three months of life (290), or by 1 year of age (292, 294). 
 
There are plausible biological mechanisms for these associations. Developmental 
programming of lung function and immune responses occurs during pregnancy (75, 432). 
Developmental deficiency of vitamin D in rats induces alterations in immune and early lung 
development (400, 433).  In human in-vitro studies, 1,25(OH)D has potent 
immunomodulatory effects (434).  1,25(OH)D has the ability to enhance the production of 
naturally occurring antimicrobial peptides, such as cathelicidin, in macrophages and airway 
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epithelial cells which may have a role in protection against respiratory infections (227, 357). 
 
Current recommendations in the United Kingdom are for provision of 10 µg/day (400 IU/day) 
to all pregnant women (266). Vitamin D insufficiency is nevertheless very common during 
pregnancy (242, 252, 435), and it has been proposed that prenatal vitamin D 
supplementation may prevent childhood wheezing and asthma (269). We assessed children 
whose mothers had taken part in a randomised controlled trial of prenatal vitamin D 
supplementation, to determine whether supplementation prevented wheezing, allergic 
disease or respiratory infection in the first 3 years of life (418). 
 
4.2  Methods 
This was a follow up study of the offspring of women who took part in an ethnically stratified, 
parallel group, randomised controlled trial of vitamin D supplementation in pregnancy at St 
Mary’s Hospital London.  Full methods are described in section 2.2. 
 
4.3  Results 
4.3.1 Study participants 
In the original trial 180 women were recruited who delivered 181 infants. There was one twin 
pregnancy of whom the first-born was included in analysis.  There were 4 deaths, all in the 
control group: One stillbirth at 41 weeks, one death aged two days (no further details 
available), one death aged 16 hours from meconium aspiration and one child born with 
congenital abnormalities who died post-operatively aged 17 months. We successfully 
followed up 158/180 (88%) of infants at age 3. 129/180 (72%) agreed to a review of their 
primary care record. Participant flow is shown in Figure 4-1.  
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Figure 4-1 Participant flow through the study 
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The characteristics of the children and their mothers in each randomisation group were 
similar at baseline (Table 4.1).  
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Table 4.1 Study participants  
 Control 
(n=50) 
Daily vitamin D 
(n=56) 
Bolus vitamin D 
(n=52) 
Combined vitamin D 
(n=108) 
 
Baseline maternal 25(OH)D < 25nmol/L, n/N (%) 24/50 (48) 25/56 (45) 22/52 (42) 47/108 (44)  
Male sex, n/N (%) 27/50 (54) 32/56 (57) 26/52 (50) 58/108 (55)  
Birth weight (g), mean (SD) 3268 (585) 3321 (525) 3290 (467) 3307 (497)  
Ethnicity, n (%)       
  Asian 12 (24) 15 (27) 13 (25) 28 (26)  
  Middle Eastern 13 (26) 14 (25) 14 (26) 28 (26)  
  Black 12 (24) 14 (25) 13 (25) 27 (25)  
  White 13 (26) 13 (23) 12 (24) 25 (23)  
GA at delivery (weeks), mean (SD) 40 (1) 39 (2) 40 (1) 39 (2)  
Nulliparous mother, n/N (%) 23/50 (46) 20/56 (36) 21/52 (40) 41/108 (38)  
Vaginal delivery, n/N (%) 29/50 (58) 35/56 (63) 28/52 (54) 63/108 (58)  
Maternal smoking during pregnancy, n/N (%) 2/48 (4) 3/55 (5) 0/46 (0) 3/101 (3)  
Presence of household smokers, n/N (%) 16/48 (33) 15/55 (27) 17/46 (37) 32/101 (32)  
Number of children in household, mean (SD) 2 (1) 2 (1) 2 (1) 2 (1)  
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Age mother left full time education, mean (SD) 20 (3) 20 (4) 21 (4) 21 (4)  
Child in nursery, n/N (%) 27/48 (56) 36/55 (65) 20/45 (44) 57/101 (56)  
Cat or dog in household, n/N (%) 4/48 (8) 5/54 (9) 4/46 (9) 9/100 (9)  
Maternal Fitzpatrick skin score grade 3-6, n/N (%) 28/44 (64) 33/49 (67) 28/43 (65) 61/92 (66)  
Maternal regular vitamin intake at three years, n/N (%) 9/46 (20) 16/53 (30) 16/45 (36) 32/98 (33)  
At least one parent with allergic disease, n/N (%) 23/45 (51) 35/53 (66) 21/45 (47) 56/98 (57)  
Exclusively breast-fed for 4 months, n/N (%) 22/48 (46) 20/54 (37) 23/44 (52) 43/98 (44)  
Any child vitamin supplementation, n/N (%) 30/48 (63) 34/55 (62) 30/46 (65) 64/101 (63)  
Completed immunizations to date, n/N (%) 48/49 (98) 54/55 (98) 43/47 (91) 97/102 (95)  
Age at time of assessment (months), median (IQR) 37.9 (36.9, 39.9) 37.1 (36.5, 38.8) 37.4 (36.5, 39.5) 37.3 (36.5, 39.0)  
Child Fitzpatrick skin score grade 3-6, n (%) 29/42 (69) 34/48 (71) 29/43 (67) 63/91 (69)  
Child BMI Z score age 3, mean (SD) 0.51 (1.48) 0.35 (1.15) 0.62 (1.15) 0.47 (1.15)  
Child outdoors > 1 hour/day, n/N (%) 32/48 (67) 34/53 (64) 33/45 (73) 67/98 (68)  
Child TV/ computer > 2 hours/day, n/N (%) 24/48 (50) 18/53 (34) 17/45 (38) 35/98 (36)  
Child 25(OH)D (nmol/L) age 3, median (IQR) 42 (27, 68) 35 (21, 66) 42 (30, 93) 41 (26, 72)  
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As previously reported (418), median cord 25(OH)D levels at delivery were significantly 
higher in supplemented children compared to the control group [control 17nmol/l 
(interquartile range (IQR) 14-22); daily dose 26nmol/l (IQR 17-45); p<0.001; bolus dose 
25nmol/l (IQR 18-34); p<0.001)].  
 
4.3.2 Effect of prenatal vitamin D supplementation on parent reported 
wheezing, allergic disease and respiratory infections.   
We found no significant difference in the primary outcome of ‘wheeze ever’ between 
treatment groups (daily vs. control Table 4.2, bolus vs. control Table 4.3).   
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Table 4.2 Parentally reported outcomes at age three years.  Daily vitamin D versus control 
 
Control 
(%) 
Daily Vitamin D 
(%) 
RR 
(95% CI) 
p OR 
(95% CI) 
p aOR† 
(95% CI) 
p 
Wheeze ever 14/50 (28) 11/56 (20) 0.70 (0.35, 1.40) 0.36 0.63 (0.26, 1.55) 0.31 0.61 (0.20, 1.85) 0.39 
Recurrent wheezing 7/50 (14) 8/56 (14) 1.02 (0.40, 2.61) 1.00 1.02 (0.34, 3.06) 0.97 1.35 (0.35, 5.22) 0.66 
Wheezing in the last year 8/50 (16) 8/56 (14) 0.89 (0.36, 2.20) 1.00 0.88 (0.30, 2.54) 0.81 1.14 (0.32, 4.13) 0.84 
Wheeze with positive API 7/50 (14) 6/56 (11) 0.77 (0.28, 2.13) 0.77 0.74 (0.23, 2.36) 0.61 0.63 (0.13, 3.20) 0.58 
Any bronchodilator use 4/49 (8) 10/56 (18) 2.23 (0.75, 6.67) 0.16 2.45 (0.72, 8.37) 0.15 2.03 (0.43, 9.55) 0.37 
Eczema ever 15/49 (31) 15/54 (28) 0.91 (0.50, 1.66) 0.83 0.87 (0.37, 2.04) 0.75 0.59 (0.20, 1.77) 0.35 
Eczema in the last year 7/49 (14) 11/55 (20) 1.40 (0.59, 3.33) 0.60 1.50 (0.53, 4.23) 0.44 1.79 (0.45, 7.09) 0.41 
Atopy 7/27 (26) 4/36 (11) 0.41 (0.13, 1.27) 0.18 0.36 (0.09, 1.38) 0.13 0.43 (0.05, 3.82) 0.45 
Allergic rhinitis 7/49 (14) 7/55 (13) 0.89 (0.34, 2.36) 1.00 0.88 (0.28, 2.70) 0.82 0.25 (0.03, 2.09) 0.20 
Food allergy diagnosis 3/49 (6) 8/55 (15) 2.38 (0.67, 8.46) 0.21 2.61 (0.65, 10.45) 0.16 16.42 (0.74, 362.37) 0.08 
> 4 URTI/year 7/50 (14) 11/55 (20) 1.43 (0.60, 3.40) 0.45 1.54 (0.55, 4.33) 0.42 1.52 (0.40, 5.81) 0.54 
LRTI ever 11/50 (22) 14/54 (26) 1.18 (0.59, 2.35) 0.65 1.24 (0.50, 3.07) 0.64 0.95 (0.31, 2.94) 0.93 
Primary health care records         
   Recurrent wheeze 3/31 (10) 4/36 (11) 1.15 (0.28, 4.74) 1.00 1.17 (0.24, 5.67) 0.85 0.29 (0.03, 4.27) 0.40 
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   Eczema  6/31 (19) 5/36 (14) 0.72 (0.24, 2.12) 0.74 0.67 (0.18, 2.46) 0.55 0.63 (0.10, 4.05) 0.63 
   Food allergy  2/31 (7) 2/36 (6) 0.86 (0.13, 5.76) 1.00 0.85 (0.11, 6.44) 0.88 - - 
RR=Risk ratio, aOR (adjusted odds ratio), API (Asthma predictive index), URTI (upper respiratory tract infection), LRTI (lower respiratory tract 
infection) 
1Adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in pregnancy, exclusive breast-feeding to four months, 
any parental allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education, 
baseline concentration of 25(OH)D in maternal blood, maternal baseline BMI and sex of child. 
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Table 4.3 Parentally reported outcomes at age three years. Bolus vitamin D versus control 
 
Control 
(%) 
Bolus Vitamin D 
(%) 
RR 
(95% CI) 
p OR 
(95% CI) 
p aOR† 
(95% CI) 
p 
Wheeze ever 14/50 (28) 15/52 (29) 1.03 (0.56, 1.91) 1.00 1.04 (0.44, 2.47) 0.93 1.88 (0.61, 5.83) 0.27 
Recurrent wheezing 7/50 (14) 9/52 (17) 1.24 (0.50 (3.07) 0.65 1.29 (0.44, 3.77) 0.65 5.88 (0.99, 34.79) 0.05 
Wheezing in the last year 8/50 (16) 9/52 (17) 1.08 (0.45, 2.58) 0.86 1.10 (0.39, 3.12) 0.86 2.34 (0.57, 9.72) 0.24 
Wheeze with positive API 7/50 (14) 9/51 (18) 1.26 (0.51, 3.12) 0.79 1.32 (0.45, 3.86) 0.62 3.77 (0.86, 16.56) 0.08 
Any bronchodilator use 4/49 (8) 14/48 (29) 3.57 (1.27, 10.09) 0.008* 4.63 (1.40, 15.34) 0.008* 7.89 (1.67, 37.22) 0.01 
Eczema ever 15/49 (31) 15/48 (31) 1.02 (0.56, 1.85) 1.00 1.03 (0.44, 2.44) 0.95 0.98 (0.35, 2.80) 0.98 
Eczema in the last year 7/49 (14) 9/48 (19) 1.31 (0.53, 3.24) 0.59 1.39 (0.47, 4.08) 0.55 2.24 (0.51, 9.86) 0.29 
Atopy 7/27 (26) 7/32 (22) 0.84 (0.34, 2.11) 0.77 0.80 (0.24, 2.66) 0.72 0.34 (0.06, 2.04) 0.24 
Allergic rhinitis 7/49 (14) 4/46 (9) 0.61 (0.19, 1.94) 0.53 0.57 (0.16, 2.10) 0.40 - - 
Food allergy diagnosed 3/49 (6) 4/47 (9) 1.36 (0.32, 5.78) 0.72 1.43 (0.30, 6.75) 0.65 2.25 (0.29, 17.29) 0.44 
> 4 URTI/year 7/50 (14) 9/48 (19) 1.34 (0.54, 3.31) 0.59 1.42 (0.48, 4.17) 0.53 2.15 (0.57, 8.07) 0.26 
LRTI ever 11/50 (22) 17/47 (36) 1.64 (0.86, 3.14) 0.18 2.01 (0.82, 4.92) 0.12 5.19 (1.55, 17.40) 0.01 
Primary health care record         
Recurrent wheeze 3/31 (10) 6/34 (18) 1.82 (0.50, 6.68) 0.48 2.00 (0.46, 8.80) 0.35 2.06 (0.37, 11.67) 0.41 
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Eczema 6/31 (19) 5/34 (15) 0.76 (0.26, 2.24) 0.74 0.72 (0.20, 2.64) 0.62 0.62 (0.11, 3.57) 0.59 
Food allergy 2/31 (7) 0/34 (0) 0.0 (-, -) 0.22 - - - - 
RR=Risk ratio, aOR (adjusted odds ratio), API (Asthma predictive index), URTI (upper respiratory tract infection), LRTI (lower respiratory tract 
infection) 
1Adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in pregnancy, exclusive breast-feeding to four months, 
any parental allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education, 
baseline concentration of 25(OH)D in maternal blood, maternal baseline BMI and sex of child. 
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There was also no difference between groups in prevalence of eczema.  We found 
significantly increased bronchodilator use and higher prevalence of LRTI’s in the offspring of 
the bolus group, but this did not remain significant after adjusting for multiple testing at a 
20% threshold.  Also shown are complete unadjusted and adjusted analyses of these 
outcomes for offspring of mothers with baseline vitamin D deficiency (daily vs. control Table 
4.4; bolus vs control, Table 4.5).   
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Table 4.4 Parentally reported outcomes at age three years in offspring of mothers with baseline vitamin D deficiency.  Daily vitamin D versus control.   
 Control Daily vitamin D RR OR p aOR† p 
 (%) (%) (95% CI) (95% CI)  (95% CI)  
Wheeze ever 7/24 (29.2) 4/25 (16) 0.60 (0.20, 1.77) 0.46 (0.12, 1.85) 0.27 0.23 (0.03, 2.08) 0.19 
Recurrent wheezing 4/24 (16.7) 3/25 (12.0) 0.72 (0.18, 2.89) 0.68 (0.14, 3.43) 0.64 3.48 (0.12, 103.5) 0.47 
Wheezing in the last year 5/24 (20.8) 3/25 (12.0) 0.58 (0.15, 2.15) 0.52 (0.11, 2.46) 0.40 0.55 (0.06, 5.01) 0.60 
Wheeze with positive API 4/24 (16.7) 3/25 (12.0) 0.72 (0.18, 2.89) 0.68 (0.14, 3.43) 0.64 3.40 (0.04, 308.9) 0.59 
Any bronchodilator use 2/24 (8.3) 4/25 (16.0) 1.92 (0.39, 9.54) 2.10 (0.35, 12.67) 0.42 - - 
Eczema ever 8/24 (33.3) 7/24 (29.2) 0.88 (0.38, 2.03) 0.82 (0.24, 2.80) 0.76 0.22 (0.02, 2.71) 0.24 
Eczema in the last year 4/24 (16.7) 5/25 (20.0) 1.20 (0.37, 3.94) 1.25 (0.29, 5.35) 0.76 0.29 (0.02, 4.48) 0.38 
Atopy 4/13 (30.8) 1/14 (7.1) 0.23 (0.03, 1.82) 0.17 (0.02, 1.82) 0.11 - - 
Allergic rhinitis 3/24 (12.5) 3/25 (12.0) 0.96 (0.21, 4.30) 0.96 (0.17, 5.27) 0.96 - 0.77 
Food allergy diagnosis 2/24 (0.0) 3/25 (8.0) 1.44 (0.26, 7.88) 1.50 (0.23, 9.87) 0.67 - - 
> 4 URTI/year 3/24 (12.5) 6/25 (24.0) 1.92 (0.54, 6.82) 2.21 (0.48, 10.09) 0.30 - - 
LRTI ever 7/24 (29.2) 6/24 (25.0) 0.86 (0.34, 2.18) 0.81 (0.23, 2.90) 0.75 0.06 (0.00, 1.19) 0.07 
Primary health care record         
   Recurrent wheeze 1/17 (5.9) 2/16 (12.5) 2.13 (0.21, 21.24) 2.29 (0.19, 28.00) 0.51 - - 
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   Eczema 3/17 (17.6) 2/16 (12.5) 0.71 (0.14, 3.70) 0.67 (0.10, 4.62) 0.68 - - 
   Food allergy  0/17 (0.0) 1/16 (6.3) - - - - - 
RR=Risk ratio, aOR (adjusted odds ratio), API (Asthma predictive index), URTI (upper respiratory tract infection), LRTI (lower respiratory tract 
infection) 
1Adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in pregnancy, exclusive breast-feeding to four months, 
any parental allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education, 
baseline concentration of 25(OH)D in maternal blood, maternal baseline BMI and sex of child 
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Table 4.5 Parentally reported outcomes at age three years in offspring of mothers with baseline vitamin D deficiency. Bolus vitamin D versus control  
 Control Bolus vitamin D RR OR p aOR† p 
 (%) (%) (95% CI) (95% CI)  (95% CI)  
Wheeze ever 7/24 (29.2) 7/22 (31.8) 1.09 (0.46, 2.61) 1.13 (0.32, 3.98) 0.85 3.83 (0.37, 39.56) 0.26 
Recurrent wheezing 4/24 (16.7) 5/22 (22.7) 1.36 (0.42, 4.44) 1.47 (0.34, 6.37) 0.61 43.36 (0.72, 2610) 0.07 
Wheezing in the last year 5/24 (20.8) 5/22 (22.7) 1.09 (0.36, 3.27) 1.12 (0.28, 4.54) 0.88 3.15 (0.29, 34.70) 0.35 
Wheeze with positive API 4/24 (16.7) 3/21 (14.3) 0.86 (0.22, 3.40) 0.83 (0.16, 4.24) 0.83 - - 
Any bronchodilator use 2/24 (8.3) 5/19 (26.3) 3.16 (0.69, 14.52) 3.93 (0.67, 23.10) 0.11 - - 
Eczema ever 8/24 (33.3) 7/19 (36.8) 1.11 (0.49, 2.50) 1.17 (0.33, 4.12) 0.81 1.60 (0.12, 20.86) 0.72 
Eczema in the last year 4/24 (16.7) 5/19 (26.3) 1.58 (0.49, 5.08) 1.79 (0.41, 7.86) 0.44 - - 
Atopy 4/13 (30.8) 3/13 (23.1) 0.75 (0.21, 2.71) 0.68 (0.12, 3.87) 0.66 - - 
Allergic rhinitis 3/24 (12.5) 1/19 (5.3) 0.42 (0.05, 3.73) 0.39 (0.04, 4.07) 0.42 - - 
Food allergy diagnosis 2/24 2/19 1.26 (0.20, 8.16) 1.29 (0.17, 10.15) 0.81 - - 
> 4 URTI/year 3/24 (12.5) 6/19 (31.6) 2.53 (0.72, 8.81) 3.23 (0.69, 15.20) 0.13 - - 
LRTI ever 7/24 (29.2) 7/19 (36.8) 1.26 (0.54, 2.98) 1.42 (0.39, 5.11) 0.59 5.95 (0.71, 49.76) 0.10 
Primary health care record         
   Recurrent wheeze 1/17 (5.9) 3/13 (23.1) 3.92 (0.46, 33.52) 4.80 (0.44, 52.76) 0.17 - - 
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   Eczema 3/17 (17.6) 4/13 (30.8) 1.74 (0.47, 6.47) 2.07 (0.37, 11.53) 0.40 - - 
   Food allergy  0/17 0/13 - - - - - 
RR=Risk ratio, aOR (adjusted odds ratio), API (Asthma predictive index), URTI (upper respiratory tract infection), LRTI (lower respiratory tract 
infection). 
1Adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in pregnancy, exclusive breast-feeding to four months, 
any parental allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education, 
baseline concentration of 25(OH)D in maternal blood, maternal baseline BMI and sex of child. 
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We found no significant difference in the primary outcome of ‘wheeze ever’, or for any 
secondary outcomes.  
  
Also shown are unadjusted and adjusted analyses of these outcomes for the two groups 
combined (all offspring, Table 4.6; offspring of mothers with baseline vitamin D deficiency, 
Table 4.7).  
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Table 4.6 Parentally reported outcomes at age three years.  Combined vitamin D groups versus control  
 Control 
(%) 
Combined vitamin D 
(%) 
RR 
(95% CI) 
p OR 
(95% CI) 
p aOR† 
(95% CI) 
p 
Wheeze ever 14/50 (28) 26/108 (24) 0.86 (0.49, 1.50) 0.69 0.82 (0.38, 1.74) 0.60 0.90 (0.38, 2.15) 0.82 
Recurrent wheezing 7/50 (14) 17/108 (16) 1.12 (0.50, 2.54) 1.00 1.15 (0.44, 2.97) 0.77 1.53 (0.52, 4.55) 0.44 
Wheezing in the last year 8/50 (16) 17/108 (16) 0.98 (0.46, 2.13) 1.00 0.98 (0.39, 2.45) 0.97 1.23 (0.43, 3.50) 0.70 
Wheeze with positive API 7/50 (15) 15/107 (14) 1.00 (0.44, 2.30) 1.00 1.00 (0.38, 2.64) 1.00 1.46 (0.47, 4.56) 0.51 
Any bronchodilator use 4/49 (8) 24/104 (23) 2.83 (1.04, 7.71) 0.03* 3.37 (1.10, 10.34) 0.03* 3.36 (0.98, 11.53) 0.06 
Eczema ever 15/49 (31) 30/102 (29) 0.96 (0.57, 1.61) 1.00 0.75 (0.35, 1.62) 0.47 0.82 (0.35, 1.91) 0.64 
Eczema in the last year 7/49 (14) 20/103 (19) 1.36 (0.62, 3.00) 0.50 1.34 (0.52, 3.47) 0.55 1.98 (0.66, 5.92) 0.22 
Atopy 7/27(26) 11/68 (16) 0.62 (0.27, 1.44) 0.38 0.56 (0.19, 1.66) 0.30 0.33 (0.08, 1.42) 0.14 
Allergic rhinitis 7/49 (14) 11/101 (12) 0.76 (0.31, 1.85) 0.60 0.63 (0.22, 1.78) 0.38 0.17 (0.02, 1.23) 0.08 
Food allergy diagnosis 3/49 (6) 12/102 (12) 1.92 (0.57, 6.50) 0.39 1.81 (0.48, 6.85) 0.38 2.88 (0.56, 14.12) 0.19 
> 4 URTI/year 7/50 (14) 20/103 (19) 1.39 (0.63, 3.06) 0.50 1.43 (0.55, 3.68) 0.46 1.54 (0.53, 4.42) 0.43 
LRTI ever 11/50 (22) 31/101 (31) 1.40 (0.77, 2.54) 0.34 1.47 (0.64, 3.37) 0.37 1.95 (0.77, 4.94) 0.16 
Primary health care records         
    Recurrent wheeze  3/31 (10) 10/70 (14) 1.48 (0.44, 5.00) 0.75 1.56 (0.40, 6.10) 0.52 1.30 (0.28,  6.07) 0.74 
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    Eczema 6/31 (19) 10/70 (14) 0.74 (0.29, 1.85) 0.56 0.46 (0.23, 2.12) 0.52 0.70 (0.19, 2.61) 0.59 
    Food allergy 2/31 (6) 2/70 (3) 0.44 (0.07, 3.00) 0.58 0.43 (0.06, 3.18) 0.58 0.06 (0.00, 35.17) 0.38 
RR=Risk ratio, aOR (adjusted odds ratio), API (Asthma predictive index), URTI (upper respiratory tract infection), LRTI (lower respiratory tract 
infection). 
1Adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in pregnancy, exclusive breast-feeding to four months, 
any parental allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education, 
baseline concentration of 25(OH)D in maternal blood, maternal baseline BMI and sex of child. 
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Table 4.7 Parentally reported outcomes at age three years in offspring of mothers with baseline vitamin D deficiency.  Combined vitamin D versus control 
 Control Combined vitamin D RR OR p aOR† p 
 (%) (%) (95% CI) (95% CI)  (95% CI)  
Wheeze ever 7/24 (29) 11/47 (23) 0.80 (0.36, 1.80) 0.74 (0.25, 2.25) 0.60 0.96 (0.22, 4.32) 0.96 
Recurrent wheezing 4/24 (17) 8/47 (17) 1.02 (0.34, 3.05) 1.03 (0.28, 3.82) 0.97 2.16 (0.39, 12.13) 0.38 
Wheezing in the last year 5/24 (21) 8/47 (17) 0.82 (0.30, 2.23) 0.78 (0.23, 2.71) 0.69 1.10 (0.22, 5.42) 0.91 
Wheeze with positive API 4/24 (17) 6/46 (13) 0.78 (0.24, 2.51) 0.75 (0.19, 2.96) 0.68 3.10 (0.38, 25.52) 0.29 
Any bronchodilator use 2/24 (8) 9/44 (21) 2.46 (0.58, 10.46) 2.83 (0.56, 14.33) 0.20 24.49 (0.97, 616.5) 0.05 
Eczema ever 8/24 (33) 14/43 (33) 0.98 (0.48, 1.99) 0.97 (0.33, 2.79) 0.95 1.05 (0.22, 5.10) 0.95 
Eczema in the last year 4/24 (17) 10/44 (23) 1.36 (0.48, 3.89) 1.47 (0.41, 5.31) 0.56 1.75 (0.32, 9.66) 0.52 
Atopy 4/13 (31) 4/27 (15) 0.48 (0.14, 1.63) 0.39 (0.08, 1.91) 0.24 - - 
Allergic rhinitis 3/24 (13) 4/44 (9) 0.73 (0.18, 2.99) 0.70 (0.14, 3.42) 0.66 3.34 (0.06, 187.41) 0.56 
Food allergy diagnosis 2/24 (8.3) 5/44 (11.4) 1.36 (0.29, 6.51) 1.41 (0.25, 7.88) 0.69 0.32 (0.00, 26.52) 0.62 
> 4 URTI/year 3/24 (13) 12/44 (27) 2.18 (0.68, 6.99) 2.63 (0.66, 10.43) 0.16 7.01 (0.95, 151.93) 0.06 
LRTI ever 7/24 (29) 13/43 (30) 1.04 (0.48, 2.24) 1.05 (0.35, 3.15) 0.93 1,72 (0.35, 8.32) 0.50 
Primary health care record         
   Recurrent wheeze 1/17 (6) 5/29 (17) 2.93 (0.37, 23.05) 3.33 (0.36, 31.26) 0.27 - - 
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   Eczema 3/17 (18) 6/29 (21) 1.17 (0.34, 4.09) 1.22 (0.26, 5.67) 0.80 0.68 (0.06, 7.78) 0.76 
   Food allergy  0/17 (0) 1/29 (3) - - - - - 
RR=Risk ratio, aOR (adjusted odds ratio), API (Asthma predictive index), URTI (upper respiratory tract infection), LRTI (lower respiratory tract 
infection). 
1Adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in pregnancy, exclusive breast-feeding to four months, 
any parental allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education, 
baseline concentration of 25(OH)D in maternal blood, maternal baseline BMI and sex of child. 
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We found no significant difference in the primary outcome of ‘wheeze ever’, or for eczema or 
any of the secondary outcomes.  
 
Since 22 offspring were not followed up, sensitivity analyses were performed to determine if 
this influenced the result for the primary outcome.  Two scenarios were considered – the first 
where no drop-outs wheezed and the second where all drop-outs wheezed.  There was no 
significant difference between groups in wheezing prevalence for either of these scenarios 
(Table 4.8). 
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Table 4.8 Sensitivity analysis for primary outcome ‘wheeze ever’ using imputation for missing data 
 Control Treatment group RR OR p 
 (% wheeze) (% wheeze) (95% CI) (95% CI)  
Scenario assuming no drop-outs wheezed      
Control vs Combined 14/60 (23) 26/120 (22) 0.93 (0.52, 1.64) 0.91 (0.43, 1.90) 0.80 
Control vs Daily 14/60 (23) 11/60 (18) 0.79 (0.39, 1.59) 0.74 (0.30, 1.79) 0.50 
Control vs Bolus 14/60 (23) 15/60 (25) 1.07 (0.57, 2.02) 1.10 (0.48, 2.53) 0.83 
Scenario assuming all drop-outs wheezed      
Control vs Combined 24/60 (40) 38/120 (32) 0.79 (0.53, 1.19) 0.70 (0.37, 1.32) 0.27 
Control vs Daily 24/60 (40) 15/60 (25) 0.63 (0.37, 1.07) 0.50 (0.23, 1.09) 0.08 
Control vs Bolus 24/60 (40) 23/60 (38) 0.96 (0.61, 1.50) 0.93 (0.45, 1.94) 0.85 
RR=Risk ratio, OR=Odds ratio, CI= Confidence intervals 
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For 123 children assessed at 3 years, cord 25(OH)D levels were available. After natural log 
transformation, we found no difference between cord blood 25(OH)D levels in children with 
and without a history of wheeze, eczema, any LRTI or >4 episodes of URTI per year (Figure 
4-2 and Table 4.9).  There was also no correlation between Ln cord blood 25(OH)D level 
and Ln Total IgE at age three years for 68 children (Beta coefficient = -0.05, p=0.72).  
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Figure 4-2 Cord vitamin D levels and parentally reported outcomes at age three years  
Ln Cord 25(OH)D at birth and A) Wheeze ever, B) Eczema ever, C) Lower respiratory tract 
infection (LRTI) ever and D) Frequency of upper respiratory tract infection (URTI) per year in 
offspring at age three years.  Horizontal bars represent means and p values adjusted 
analyses. 
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Table 4.9 Ln Cord vitamin D levels and parentally reported outcomes at age 3 years 
Outcome n Outcome absent n Outcome present Unadjusted Mean p Adjusted1 mean p 
  Mean ± SD  Mean ± SD Difference (95% CI)  Difference (95% CI)  
Wheeze 88 3.20 ± 0.52 34 3.07 ± 0.43 -0.13 (-0.33, 0.07) 0.19 -0.07 (-0.26, 0.11) 0.43 
Atopy 59 3.19 ± 0.49 14 3.28 ± 0.44 0.08 (-0.20, 0.37) 0.56 0.10 (-0.17, 0.37) 0.47 
Eczema 82 3.14 ± 0.51 34 3.17 ± 0.48 0.03 (-0.23, 0.17) 0.74 0.05 (-0.13, 0.23) 0.56 
Any LRTI 84 3.17 ± 0.52 31 3.16 ± 0.45 -0.007 (-0.20, 0.22) 0.95 -0.10 (-0.29, 0.09) 0.30 
> 4 URTI/year 95 3.19 ± 0.52 22 3.03 ± 0.41 -0.16 (-0.40, 0.07) 0.17 -0.11 (-0.32, 0.11) 0.33 
LRTI (Lower respiratory tract infection), URTI (Upper respiratory tract infection). 
1Adjusted for treatment group, mother’s ethnic group, presence of household smokers, maternal smoking in pregnancy, exclusive breast-
feeding to four months, any parental allergic history, any child vitamin supplementation, number of children in the household, age mother left 
full-time education and baseline concentration of 25(OH)D in maternal blood. 
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4.4  Discussion 
In this randomised controlled trial of vitamin D supplementation in late pregnancy in a 
relatively deficient mixed race population, daily supplementation with 800 IU ergocalciferol or 
a single bolus dose of 200,000 IU cholecalciferol from 27 weeks gestation did not prevent 
parentally reported wheezing, allergic disease or respiratory tract infections in the first three 
years of life. We were unable to confidently exclude an effect on some secondary outcome 
measures such as atopy at 3 years, where statistical power was limited. Our results suggest 
that the most likely explanation for the finding of decreased wheezing risk in offspring of 
mothers with a higher vitamin D intake during pregnancy in observational studies (175, 289, 
297, 298), is confounding by other dietary or lifestyle factors associated with vitamin D 
intake.   
 
Our study has a number of limitations. First, we relied on a subjective primary outcome 
measure and participants were not blind to treatment allocation, which introduces a risk of 
reporter bias. Investigators were, however, kept blind to treatment allocation until database 
lock. Moreover the results of subjective primary outcome measures are supported by the 
results of both our secondary objective outcome assessments and a blinded assessment of 
prospectively recorded healthcare records. Second, this was a small study with limited 
statistical power, particularly for detecting differences in objective outcomes. Our power 
calculation was based on the study by Camargo et al (297), which estimated a risk reduction 
for recurrent wheezing from 34% to 13% comparing mothers with the highest quartile of daily 
vitamin D intake (median 724 IU) to those in the lowest quartile of intake (median 356 IU).  
However the prevalence of wheeze in our control group was 28% thus reducing the power of 
the study. Third, we did not assess vitamin D receptor polymorphisms or other potentially 
important genotypic variations. It is possible that vitamin D supplementation is effective for 
preventing wheezing or atopy in the presence of specific maternal or infant genotypes, as 
suggested by others (285). Fourth, women from four ethnic groups were enrolled in this 
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study, with significant differences in baseline vitamin D levels between Caucasian women 
and all other ethnic groups (data not shown).  Previous observational studies have 
predominantly studied Caucasians (297).  Although randomisation in this trial was stratified 
by ethnicity, and we included baseline vitamin D in our adjusted model, it is possible that this 
source of heterogeneity could have masked positive findings.  Fifth, supplementation with 
vitamin D only started at 27 weeks of gestation.  It is known that immune cells develop much 
earlier in fetal life (436), and that airway development to the respiratory bronchioles is 
complete by 16 weeks gestation, (437).  It may be that supplementation earlier in pregnancy, 
or indeed pre-conception, is necessary for protection against childhood wheezing.   
 
We are also unable to exclude the possibility that vitamin D supplementation at a higher 
dose, might protect against early childhood wheezing. Although the vitamin D doses used in 
this trial were greater than the current recommended intake for pregnant women of 400 
IU/day during pregnancy in the United Kingdom (266, 403), and 600 IU in the United States 
(438), only a small percentage of offspring had cord 25(OH)D levels in the sufficient range 
(13% daily group, 3% bolus group). It has recently been shown that doses of 4000 IU of 
vitamin D daily are safe and effective for short term treatment of vitamin D deficiency during 
pregnancy (439), although the long term effects on child health have not been studied. Two 
on-going trials, the Vitamin D Prenatal Asthma Reduction Trial (NCT00920621), and 
ABCvitaminD (NCT00856947) are specifically exploring the effects of earlier and higher 
dose prenatal vitamin D supplementation on child health.  
 
Although our findings of increased bronchodilator use and increased LRTI in offspring of 
mothers who received a bolus dose of vitamin D became non-significant after adjusting for 
multiple testing, this is an important adverse outcome to consider. The principle that non-
physiological dosing regimens of vitamin D may be harmful is established in other settings, 
with two randomised controlled trials in adults finding high dose bolus vitamin D is 
associated with increased risk of fractures (440, 441) and/or falls (440). With evidence of a U 
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shaped, or reverse J shaped relationship between 25(OH)D levels and health outcomes in 
adults suggesting both lower and upper limits for healthy 25(OH)D levels (438, 442), these 
findings should sound a note of caution in relation to high dose bolus vitamin D treatment in 
pregnancy.  These outcomes should be carefully assessed in the ongoing randomised 
controlled trials of vitamin D supplementation in pregnancy. 
 
Two recent observational studies that documented prenatal vitamin D status by measuring 
cord blood 25(OH)D concentration, found relationships with allergic sensitisation and/or 
wheezing in early childhood (290, 291). When we analysed our own data on cord blood 
25(OH)D concentration and wheezing, atopy and frequency of respiratory infection in the 
first three years, no significant relationship was found. While our interventions did result in at 
least 50% higher cord blood 25(OH)D concentrations compared with no treatment, cord 
blood levels were still significantly lower in the intervention groups than in these studies. The 
results of our randomised controlled trial do not support a strong causal relationship between 
low prenatal vitamin D status within the deficient/insufficient range and increased risk of 
allergic sensitization or wheezing in early childhood. We are unable to confidently exclude a 
similar relationship in more vitamin D sufficient populations (290). 
 
The findings of our study are specific to a population of vitamin D deficient women (half had 
baseline 25(OH)D levels below 25nmol/L) and two specific forms of prenatal vitamin D 
supplementation. The doses of supplementation were chosen pragmatically, were not 
stratified based on individual vitamin D status or genotype, and response to treatment was 
not monitored before delivery. The study population was not selected for allergy or asthma 
risk and, as a mixed race urban population, is representative of many populations of 
pregnant women worldwide (443).  Although these findings cannot automatically be 
generalised to other populations of pregnant women, one might expect prenatal vitamin D 
supplementation to show its clearest clinical effects in a deficient population such as this.  
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In summary we found no evidence for a protective effect of prenatal vitamin D 
supplementation from 27 weeks gestation on parentally reported childhood wheezing and 
allergic disease in the first 3 years of life. Given the modest effects on cord blood vitamin D 
achieved by these interventions, the safety and efficacy of higher dose prenatal vitamin D 
supplementation strategies need to be explored.  Given our finding of increased 
bronchodilator use and increased LRTI in offspring of mothers who received a bolus dose of 
vitamin D, (in this case a single dose of 200,000 units at 27 weeks gestation), the use of 
such regimens should be viewed with caution.
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5 Effect of prenatal vitamin D on atopy, inflammation and lung 
function 
5.1  Introduction 
Both vitamin D deficiency (269) and supplementation (268) have been proposed as a cause 
of the asthma epidemic. Epidemiological evidence based on long term follow up of birth 
cohort studies can be found to support both hypotheses, with studies showing protective 
(174, 175, 177, 298), no effect (290-293) and harmful effects (287) of higher early life vitamin 
D status on childhood wheezing. For allergic sensitisation, although three studies have found 
no association with skin prick test sensitivity (175, 288, 293), in another study both high 
(100nmol/L) and low (<50nmol/L) cord levels of 25(OH)D were associated with increased 
skin prick test sensitivity and IgE levels at 5 years (291), an effect that may be genetically 
determined (285).   Two studies have investigated spirometry and exhaled nitric oxide as 
outcomes, and found no association (175, 293). 
 
There is plausible biological data to support a relationship between early life vitamin D status 
and atopic sensitisation, allergic inflammation and lung function in early childhood.  
Developmental deficiency of vitamin D in rats induces alterations in immune and early lung 
development (400, 433).  Failure of VDR knockout mice to develop experimental allergic 
airway disease suggests vitamin D is necessary for Th-2 driven lung inflammation to occur 
(346, 347).  In mouse models, 1,25(OH)2D inhibits airway inflammation (348), and irradiation 
with UVB light prior to sensitization blunts airway hyper-responsiveness and inflammation 
(349).  Animal data suggest that alveolarisation may be influenced in part by a complex 
growth axis which involves 1,25(OH)2D3. The VDR is expressed during late intrauterine life 
in rate pulmonary tissues (312, 313).  Rat lung fibroblasts are capable of metabolising 
25(OH)D to 1,25(OH)2D suggesting a paracrine system for vitamin D (316, 317). 1,25(OH)2D 
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significantly increases proliferation of rat perinatal lung fibroblasts (318) and inhibits 
apoptosis of lipid laden interstitial lung fibroblasts (323). 
In human in-vitro work, the VDR has been detected in human foetal lung fibroblasts from 16 
weeks gestation, (332, 333) and in alveolar type two cells from the second trimester (334).  
1,25(OH)D has a marked inhibitory effect on adaptive immune cells (233).  In cord blood, 
1,25(OH)D inhibits differentiation of naïve T cells into Th1 and Th2 cells (385).  1,25(OH)D is 
a potent promoter of tolerogenic dendritic cells and regulatory T cells (386). In-vivo data from 
a cross-sectional survey of over seven thousand white British 45 year olds suggest a non-
linear relationship between 25(OH)D status and total IgE levels, with both low (<25nmol/L) 
and excess (>135nmol/L) levels associated with elevated IgE (301). Data from adult studies 
suggest 1,25(OH)2D may have a role in protection against airway remodelling (345). 
 
The aim of this study was to determine if prenatal vitamin D supplementation influenced 
objective markers of atopic sensitisation and inflammation (skin prick test reactivity, total IgE, 
exhaled nitric oxide, peripheral eosinophil count) and lung function in offspring at three years 
of age. 
 
5.2  Methods 
This was a follow up study of the offspring of women who took part in a randomised 
controlled trial of vitamin D supplementation in pregnancy at St Mary’s Hospital London.  Full 
methods are described in section 2.2.   
 
5.3  Results 
For patient selection see section 2.2.1. Of the 180 offspring, IOS data of acceptable quality 
for analysis was available for 51 (28%), IgE results for 86 (48%), eNO levels for 62 (34%) 
and eosinophil count for 80 (44%).  
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5.3.1 Effect of prenatal vitamin D supplementation on atopy 
We found no significant difference in atopy between treatment groups, but confidence 
intervals were wide (Offspring of all mothers, Table 5.1; Offspring of mothers with baseline 
25(OH)D <25nmol/L, Table 5.2). 
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Table 5.1 Atopy at age three years.  Daily, bolus and combined groups vs control 
 
Control 
(%) 
Intervention 
group (%) 
Unadjusted OR 
(95% CI) 
p n aOR1 
(95% CI) 
p 
Daily vs control 7/27 (26) 4/36 (11) 0.36 (0.09, 1.38) 0.13 60 0.36 (0.05, 2.94) 0.34 
Bolus vs control 7/27 (26) 7/32 (22) 0.80 (0.24, 2.66) 0.72 56 0.31 (0.05, 1.83) 0.20 
Combined vs control 7/27(26) 11/68 (16) 0.55 (0.18, 1.62) 0.27 90 0.29 (0.07, 1.16) 0.08 
aOR (adjusted odds ratio). 
1Adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in  
pregnancy, exclusive breast-feeding to four months, any parental allergic history, any child 
vitamin supplementation, number of children in the household, age mother left full-time  
education and baseline concentration of 25(OH)D in maternal blood.  
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Table 5.2 Atopy at age three years in offspring of mothers with baseline vitamin D deficiency. Daily, bolus and combined groups vs control 
 
Control 
(%) 
Intervention 
group (%) 
Unadjusted OR 
(95% CI) 
p n aOR1 
(95% CI) 
p 
Daily vs control 4/13 (30.8) 1/14 (7.1) 0.17 (0.02, 1.82) 0.11 - - - 
Bolus vs control  4/13 (30.8) 3/13 (23.1) 0.68 (0.12, 3.87) 0.66 - - - 
Combined vs control 4/13 (31) 4/27 (15) 0.39 (0.08, 1.91) 0.24 - - - 
aOR (adjusted odds ratio) not done as numbers insufficient. 
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When results for atopy were analysed by Ln cord 25(OH)D levels, no association was 
found in unadjusted and adjusted analyses (mean ± SD Ln cord 25(OH)D, 3.19 ± 0.49 in 59 
non-atopic children vs 3.28 ± 0.44 in 14 atopic children, (adjusted mean difference 0.10; 
95% CI, -0.16,0.37; p=0.44) (Fig 5-1).  Represented as the geometric mean gives 24.29 ± 
1.64 nmol/L in non-atopic children vs 26.58 ± 1.55 nmol/L in atopic children, (multiplicative 
mean difference 1.11; 95% CI, 1.17-1.15; p = 0.44). 
 
 
 
Figure 5-1 Ln cord 25(OH)D levels and atopic status at age three years 
 
Horizontal bars represent means and p values adjusted analyses. 
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5.3.2 Effect of parental vitamin D supplementation on allergic inflammation 
We found no significant difference in adjusted and unadjusted analysis between groups in 
total IgE, exhaled nitric oxide or eosinophil count assessed at age 3 years (Figure 5-2). 
   
Figure 5-2 Allergic inflammation at age three years.  Daily and bolus vitamin D vs control. 
 
A) Ln IgE, B) exhaled nitric oxide (eNO) and C) Ln % eosinophil count.  Control versus daily 
vitamin D or bolus vitamin D.  Horizontal bars represent medians, and p values represent 
adjusted analysis. 
  
   179 
When data were analysed for the two forms of prenatal vitamin D supplementation 
combined, there was no significant difference between groups (Table 5.3). 
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Table 5.3 Measures of allergic inflammation at age three years. Combined vitamin D groups versus control 
Outcome n Control 
Mean ± SD 
n Combined 
vitamin D 
Mean ± SD 
Unadjusted mean 
difference 
(95% CI) 
p n Adjusted1 mean 
difference 
(95% CI) 
p 
Ln IgE 27 3.74 ± 1.29 59 3.44  ± 1.52 -0.30 (-0.97, 0.37) 0.38 82 -0.39 (-1.15, 0.36) 0.30 
IgE‡ (kU/L) 27 42.1 ± 3.62 59 31.20 ± 4.57 0.74 (0.38, 1.45) 0.38 82 0.68 (0.32, 1.43) 0.30 
eNO (ppb) 20 23.50 ± 12.71 42 19.30 ± 9.28 -4.18 (-9.88, 1.52) 0.15 58 -3.34 (-9.44, 2.75) 0.28 
Ln Eos 27 1.11 ± 0.70 53 1.01 ± 0.69 -0.10 (-0.43, 0.22) 0.53 76 -0.25 (-0.61, 0.11) 0.18 
Eos§ (%) 27 3.03 ± 2.01 53 2.75 ± 1.99 0.90 (0.65, 1.25) 0.53 76 0.78 (0.54, 1.12) 0.18 
eNO (exhaled nitric oxide), Eos (eosinophil count as a % of total white cell count) 
1Adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in pregnancy,  
exclusive breast-feeding to four months, any parental allergic history, any child vitamin supplementation,  
number of children in the household, age mother left full-time education and baseline concentration of  
25(OH)D in maternal blood.  
‡Ln IgE result transformed into geometric mean ± SD and multiplicative mean difference with 95% CI  
§Ln Eos result transformed into geometric mean ± SD and multiplicative mean difference with 95% CI 
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When results for Total IgE, eNO and eosinophil counts were analysed by Ln cord 25(OH)D 
levels, no associations were found (Figure 5-4; Table 5.4). 
 
Figure 5-3 Ln Cord vitamin D levels and markers of inflammation at age three years 
 
Adjusted correlation (Beta coefficient, β) between Ln cord 25(OH)D levels and A) Ln Total 
IgE, B) exhaled nitric oxide (eNO) and C) Ln eosinophil % at age three years.  
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Table 5.4 Ln Cord 25(OH)D levels and markers of inflammation at age three years. 
Outcome n β p n Adjusted1 β p 
Ln Total IgE (kU/L) 68 -0.05 0.72 65 0.02 0.91 
eNO (ppb) 47 -0.05 0.73 44 0.04 0.83 
Ln Eosinophils (%) 62 0.03 0.81 59 0.01 0.95 
β (Beta coefficient) 
1Adjusted for treatment group, mother’s ethnic group, presence of household smokers, 
maternal smoking in pregnancy, exclusive breast-feeding to four months, any parental 
allergic history, any child vitamin supplementation, number of children in the household, age 
mother left full-time education and baseline concentration of 25(OH)D in maternal blood.  
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5.3.3 Effect of prenatal vitamin D supplementation on lung function and 
bronchodilator responsiveness 
We found no significant difference between groups in either baseline respiratory resistance 
or BDR for R10, R20, Fres or AX (Baseline lung function, Figure 5-5; BDR, Figure 5-6).  
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Figure 5-4 Baseline lung function at age three years.  Daily and bolus groups vs control.  
Baseline A) Resistance at 10Hz (R10), B) R20, C) Resonant frequency (Fres) and D) Area 
under the reactance curve (AX).  Control versus daily vitamin D or bolus vitamin D. 
Horizontal bars represent medians, p values are for adjusted analysis. 
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Figure 5-5 Bronchodilator response at age three years.  Daily and bolus groups vs control.   
 
Percentage change in lung function measured before and 15 minutes after inhalation of 400 
mcg salbutamol for A) resistance at 10Hz (R10), B) R20, D) Resonant frequency (Fres) and 
D) Area under the reactance curve (AX).  Control versus daily vitamin D or bolus vitamin D. 
Horizontal bars represent medians and p value are for adjusted analyses. 
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When data were analysed for the two forms of prenatal vitamin D supplementation 
combined, there was no significant difference between groups (Table 5.5).  
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Table 5.5 Baseline lung function and bronchodilator response at age three years. Combined vitamin D groups versus control.  
IOS parameter n Control 
Mean ± SD 
n Combined 
vitamin D 
Mean ± SD 
Unadjusted mean 
difference (95% CI) 
p n Adjusted1 mean 
difference (95% CI) 
p 
R10 (kPa/L.s-1) 13 0.97  ± 0.14 38 0.93 ± 0.16 -0.04 (-0.14, 0.06) 0.44 49 -0.06 (-0.18, 0.07) 0.35 
R20 (kPa/L.s-1) 13 0.82 ± 0.12 38 0.77 ± 0.13 -0.05 (-0.13, 0.04) 0.26 49 -0.05 (-0.15, 0.05) 0.36 
Fres  (Hz) 13 25.0 ± 2.17 38 24.8 ± 3.28 -0.28 (-2.25, 1.68) 0.77 49 -0.58 (-2.95, 1.79) 0.62 
AX (kPa/L) 13 3.89 ± 1.59 38 3.90 ± 1.69 0.02 (-1.06, 1.10) 0.97 49 -0.43 (-1.69, 0.80) 0.48 
R10 %Init 10 -10.66 ± 8.12 29 -9.74 ± 10.50 -0.91 (-8.33, 6.50) 0.80 37 -0.12 (-6.90, 6.67) 0.97 
R20 %Init 10 -6.37 ± 10.52 29 -5.89 ± 9.31 -0.48 (-7.62, 6.67) 0.89 37 -1.26 (-8.69, 6.16) 0.73 
Fres %Init 10 -12.07 ± 8.59 29 -10.92 ± 11.22 -1.15 (-9.05, 6.76) 0.77 37 0.59 (-8.41, 9.59) 0.89 
AX% Init 10 -34.20 ± 23.30 29 -31.94 ± 26.92 -2.26 (-21.64, 17.12) 0.81 37 4.02 (-19.76, 27.81) 0.73 
Baseline R10 and R20 (Resistance at 10 and 20 Hz), Fres (Resonant frequency) and AX (Area under the reactance curve). Parameters 
labelled %Init represent the percentage change from baseline, 15 minutes after inhalation of 400 mcg of salbutamol.  
1Adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in pregnancy, exclusive breast-feeding to four months, 
any parental allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education, 
baseline concentration of 25(OH)D in maternal blood and sex, age and height of offpsring 
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When results for lung function were analysed by Ln cord 25(OH)D levels, no associations 
were found (Baseline lung function, Figure 5-7; BDR Figure 5-8; All data Table 5.6). 
 
Figure 5-6 Ln Cord 25(OH)D levels and baseline lung function at age three years. 
 
Adjusted correlation (Beta coefficient, β) between Ln cord 25(OH)D levels and A) Resistance 
at 10Hz (R10), B) R20, C) Resonant frequency (Fres) and D) Area under the reactance 
curve (AX) at age three years.  
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Figure 5-7 Ln Cord 25(OH)D levels and bronchodilator response at age three years.   
 
Percentage change in lung function measured before and 15 minutes after inhalation of 400 
mcg of salbutamol for A) Resistance at 10Hz (R10), B) R20, C) Resonant frequency (Fres) 
and D) Area under the reactance curve (AX).   
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Table 5.6 Ln cord 25(OH)D levels and lung function at age three years. 
Parameter n β p n Adjusted1 β p 
R10 (kPa/(L.s-1) 40 -0.02 0.91 38 -0.08 0.68 
R20 (kPa/(L.s-1) 40 -0.01 0.97 38 0.06 0.76 
Fres  (Hz) 40 0.05 0.75 38 -0.04 0.84 
AX (kPa/L) 40 -0.05 0.76 38 -0.22 0.27 
R10 %Init 31 -0.08 0.68 29 0.09 0.70 
R20 %Init 31 -0.10 0.58 29 -0.08 0.76 
Fres %Init 31 -0.30 0.11 29 -0.12 0.65 
AX %Init 31 -0.03 0.88 29 0.17 0.51 
β (Beta coefficient).  Baseline R10 and R20 (Resistance at 10 and 20 Hz), Fres (Resonant 
frequency) and AX (Area under the reactance curve).  Parameters labelled %Init represent 
the percentage change from baseline 15 minutes after inhalation of 400 mcg of salbutamol.  
1Adjusted for treatment group, mother’s ethnic group, presence of household smokers, 
maternal smoking in pregnancy, exclusive breast-feeding to four months, any parental 
allergic history, any child vitamin supplementation, number of children in the household, age 
mother left full-time education, baseline concentration of 25(OH)D in maternal blood and 
age, sex and height of the child. 
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5.4  Discussion 
In this randomised controlled trial of vitamin D supplementation in late pregnancy in a 
relatively deficient mixed race population, daily supplementation with 800 IU ergocalciferol or 
a single bolus dose of 200,000 IU cholecalciferol from 27 weeks gestation did not influence 
atopic sensitisation, IgE levels, exhaled nitric oxide or lung function in offspring at age three 
years. 
 
These results are in agreement with observational data from most birth cohort studies (175, 
288, 293).  However, in one study, both low (<50nmol/L) and high (100nmol/L) levels cord 
25(OH)D levels were associated with increased atopic sensitisation and IgE levels at 5 years 
(291), an effect that may be genetically determined (285).  When we analysed our own data 
on cord blood 25(OH)D concentration and objective markers of atopy, inflammation and lung 
function at age first three years, no significant relationships were found. However, while our 
interventions did result in at least 50% higher cord blood 25(OH)D concentrations compared 
with no treatment, cord blood levels were still significantly lower in the intervention groups 
than in this study (291). 
 
The results of our randomised controlled trial do not support a causal relationship between 
low prenatal vitamin D status within the deficient/insufficient range and increased risk of 
allergic sensitization or inflammation, or improved lung function in early childhood. We are 
unable to confidently exclude a similar relationship in more vitamin D sufficient populations.
 
 
192 
6 Effect of prenatal vitamin D on healthcare utilisation in offspring 
6.1  Introduction  
The economic burden of allergic disease is an increasing problem, especially in developed 
countries within northern latitudes. In the United Kingdom, allergic conditions account for up 
to 6% of primary care utilization, 70,000 hospital admissions a year and 10% of the primary 
care prescribing costs, representing a direct burden of over a billion pounds per anum (402).  
Primary prevention of asthma and allergic disorders is a high priority. 
Early life vitamin D deficiency is common (403), and has been proposed as a cause of the 
asthma epidemic (269), based on observational studies finding an increased risk of 
wheezing in the offspring of mothers with lower intake of vitamin D during pregnancy (175, 
176, 289, 297). Vitamin D supplementation during pregnancy is safe in higher doses in 
studies with short term follow up (404) and inexpensive, and thus represents an attractive 
public health intervention for asthma prevention.  
 
In the United Kingdom, all children registered with a general practice have an electronic 
health record (e-HR). This is a contemporaneous record of all health care utilisation from 
that practice. Use of primary out of hours services (OOH) or secondary healthcare is also 
recorded, providing a discharge summary is sent to the child’s general practice, and the data 
electronically entered. When children move practices, the e-HR follows the child via the local 
health authority.  In this way the e-HR forms a complete record of a child’s healthcare 
utilisation from birth. 
 
Determinants of a child’s overall healthcare utilisation are their underlying health status (406-
410), parent mental health and family functioning (411-413), and socioeconomic predictors 
(age and ethnicity of the child, family income, area of residence, parental educational 
attainment and social class) (406, 410, 414, 415), although some studies found no effect of 
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social class (407, 408).  For hospital utilisation, predictors include socioeconomic position at 
the time of birth, mother’s age, mother’s age on leaving education, gestational age, ethnicity, 
parity, maternal BMI, maternal smoking during pregnancy and mode of delivery (415).  
 
We hypothesized that prenatal vitamin D supplementation during pregnancy would reduce a 
child’s healthcare utilisation during the first three years of life.   
 
6.2  Methods 
We analysed the child health records of the offspring of mothers who participated in the 
prenatal vitamin D supplementation study.  Full methods are described in section 2.3. 
 
6.3  Results 
Of the 180 offspring from the original trial, 159 participated in the questionnaire and we 
successfully obtained 130 e-HRs from their GP’s. 31 had incomplete data and could not be 
used, leaving 99/180 (55%) infants with complete e-HR data for analysis.  An additional 12 
records were incomplete but had at least one year’s health data for analysis. Incomplete 
records were due to inadequate GP summaries or where the patient had moved GP practice 
over the last three years and we were unable to obtain the old or new records. Only records 
with complete data were used for primary analysis.  The characteristics of children with 
complete records in each randomization group are shown in Table 6.1. 
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 Table 6.1 Characteristics of children with complete e-HR data 
 Control (n=31) Daily (n=36) Bolus (n=32) 
Male sex, n (%) 14/31 (45) 22/36 (61) 16/32 (50) 
Gestational age, weeks (SD) 39.92 (1.28) 39.34 (1.69) 39.72 (1.66) 
Delivery by caesarean section, n (%)  10/31 (32) 10/36 (28) 10/32 (31) 
Maternal Ethnicity, n (%) 
   Asian 
   Middle Eastern  
   Black  
   Caucasian  
6/31 (19) 
11/31 (35) 
5/31 (16) 
9/31 (29) 
10/36 (28) 
8/36 (22) 
8/36 (22) 
10/36 (28) 
9/32 (28) 
6/32 (19) 
8/32 (25) 
9/32 (28) 
Maternal age at booking, years (SD) 30 (7) 32 (6) 32 (6) 
Maternal highest education, years (SD) 20 (3) 20 (4) 20 (3) 
Family history of atopy, n (%) 13/29 (45) 23/35 (63) 15/31 (48) 
Maternal smoking in pregnancy, n (%) 1/31 (3) 3/36 (8) 0/31 (0) 
Number children in household, n (SD) 2 (1) 2 (1) 3 (1) 
Multiparous, n (%) 19/31 (61) 27/36 (75) 20/32 (63) 
Maternal BMI > 30 at booking, n (%) 9/31 (29) 4/36 (11) 4/32 (12.5) 
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6.3.1 Effect of prenatal vitamin D supplementation on health care utilization 
There was no significant difference in the primary outcome measure, total healthcare utilisation, 
between treatment groups (Figure 6-1).  
 
Figure 6-1 Effect of prenatal vitamin D randomisation on total healthcare utilisation in the first three years of life. 
 
   Horizontal bars represent medians and p values are for adjusted analyses. 
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We found no significant difference in secondary outcomes between offspring in the daily treatment 
group compared to controls (Table 6.2).  There was weak evidence that secondary care health 
utilisation costs (p=0.048) and year 3 costs (p=0.045) were reduced in the bolus group (Table 6.3).  
When treatment groups were combined for analysis, no difference was found from controls (Table 
6.4). 
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Table 6.2.Healthcare utilisation in the first three years of life. Daily vitamin D versus control. 
 n Control 
Mean ± SD or 
Median (IQR) 
n Daily 
Mean ± SD or 
Median (IQR) 
Mean difference 
(95% CI) 
p n Adjusted1 mean 
difference (95% 
CI 
p 
Ln total cost 31 7.07 ± 0.99 36 7.08 ± 0.99 0.02 (-0.47, 0.50) 0.95 53 0.07 (-0.48, 0.62) 0.81 
Ln all Visits 31 7.03 ± 0.99 36 7.02 ± 1.01 -0.01 (-0.50, 0.47) 0.95 53 0.02 (-0.53, 0.58) 0.93 
Ln prescription cost 31 3.23 ± 1.83 36 3.57 ± 1.12 0.34 (-0.40, 1.08) 0.36 53 0.50 (-0.36, 1.36) 0.25 
Ln year 1 cost 31 5.66 ± 2.02 36 5.95 ± 1.49 0.29 (-0.56, 1.15) 0.50 53 0.51 (-0.46, 1.48) 0.30 
Year 2 cost 31 247 (103, 607) 36 248 (123, 487) - 0.92 - - - 
Year 3 cost 31 239 (103, 552) 36 212 (96, 463) - 0.57 - - - 
Ln primary care cost 31 5.96 ± 0.98 36 6.11 ± 0.62 0.14 (-0.25, 0.54) 0.47 53 0.29 (-0.15, 0.72) 0.20 
Secondary care cost 31 632 (206, 1853) 36 368 (155, 1502) - 0.42 - - - 
Wheeze cost 31 0 (0, 0) 36 0 (0, 0) - 0.71 - - - 
Cough cost 31 0 (0, 36) 36 0 (0, 36) - 0.26 - - - 
URTI cost 31 180 (36, 324) 36 150 (54, 234) - 0.78 - - - 
LRTI cost 31 0 (0, 0) 36 0 (0, 0) - 0.75 - - - 
Bronchiolitis cost 31 0 (0, 0) 36 0 (0, 0) - 0.89 - - - 
Ln overall resp cost 31 5.14 ± 1.83 36 4.95 ± 1.65 -0.19 (-1.15, 0.76) 0.69 53 0.10 (-1.06, 1.26) 0.86 
Food allergy cost 31 0 (0, 0) 36 0 (0, 0) - 0.35 - - - 
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Eczema cost 31 0 (0, 88) 36 0 (0, 36) - 0.62 - - - 
URTI (Upper respiratory tract infection), LRTI (Lower respiratory tract infection).   
1Adjusted for mother’s age, mother’s age on leaving education and gestational age as potential covariates, and ethnicity (Caucasian, Asian, 
Middle Eastern, Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or caesarean) as potential cofactors. 
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Table 6.3 Healthcare utilization in the first three years of life. Bolus vitamin D versus control. 
 n Control 
Mean ± SD or 
Median (IQR) 
n Bolus 
Mean ± SD or 
Median (IQR) 
Mean difference p n Adjusted1 mean 
difference 
p 
Ln total cost* 31 7.07 ± 0.99 31 6.61 ± 1.06 -0.46 (-0.97, 0.06) 0.08 49 -0.34 (-0.90, 0.22) 0.23 
Ln all visit costs 31 7.03 ± 0.99 32 6.56 ±1.08 0.47(-0.99, 0.05) 0.08 49 -0.36 (-0.93, 0.21) 0.21 
Ln all prescription cost 31 3.23 ± 1.82 32 3.11 ±1.53 0.11 (-0.96, 0.73) 0.79 49 0.21 (-0.67, 1.10) 0.63 
Ln year 1 cost 31 5.66 ± 2.02 32 5.41 ±1.27 0.25 (-1.09, 0.60) 0.56 49 0.02 (-0.86, 0.90) 0.96 
Year 2 cost 31 247 (103, 607) 32 202 (101, 603) - 0.75 - - - 
Year 3 cost 31 239 (103, 552) 32 142 (36, 333) - 0.04 - - - 
Ln primary care cost 31 5.96 ± 0.98 32 5.95 ±0.82 0.02 (-0.47, 0.44) 0.95 49 0.01 (-0.45, 0.47) 0.98 
Secondary care cost 31 632 (206, 1853) 32 313 (0, 848) - 0.04 - - - 
Wheeze visit cost 31 0 (0, 0) 32 0 (0, 0) - 0.22 - - - 
Cough visit cost 31 0 (0, 36) 32 0 (0, 36) - 0.59 - - - 
URTI visit cost 31 180 (36, 324) 32 108 (72, 255) - 0.91 - - - 
LRTI visit cost 31 0 (0, 0) 32 0 (0, 36) - 0.31 - - - 
Bronchiolitis visit cost 31 0 (0, 0) 32 0 (0, 0) - 0.59 - - - 
Ln overall resp cost 31 5.14 ± 1.84 32 4.92 ±2.15 -0.22 (-1.23, 0.79) 0.66 49 -0.17 (-1.31, 0.97) 0.77 
Food allergy cost 31 0 (0, 0) 32 0 (0, 0) - 1.00 - - - 
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Eczema cost 31 0 (0, 88) 32 0 (0, 36) - 0.77 - - - 
URTI (Upper respiratory tract infection), LRTI (Lower respiratory tract infection).   
1Adjusted for mother’s age, mother’s age on leaving education and gestational age as potential covariates, and ethnicity (Caucasian, Asian, 
Middle Eastern, Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or caesarean) as potential cofactors. 
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Table 6.4 Healthcare utilization costs in the first three years of life. Combined vitamin D versus control. 
 n Control 
Mean ± SD 
or Median (IQR) 
n Combined 
Mean ± SD 
or Median (IQR) 
Mean difference 
 
p n Adjusted* 
mean difference 
p 
Ln total cost* 31 7.07 ± 0.99 68 6.86 ± 1.05 -0.21 (-0.65, 0.24) 0.36 84 -0.16 (-0.64, 0.33) 0.52 
Ln all visit cost 31 7.03 ± 0.99 68 6.80 ± 1.06 -0.24 (-0.67, 0.22) 0.31 84 -0.19 (-0.68, 0.30) 0.45 
Ln all prescription cost 31 3.23 ± 1.82 68 3.35 ± 1.36 0.13 (-0.53, 0.78) 0.70 84 0.29 (-0.40, 0.98) 0.41 
Ln year 1 total cost 31 5.66 ± 2.02 68 5.70 ± 1.39 0.04 (-0.66, 0.73) 0.91 84 0.22 (-0.53, 0.97) 0.56 
Year 2 total cost 31 247 (103, 607) 68 244 (108, 558) - 0.81 - - - 
Year 3 total cost 31 239 (103, 552) 68 168 (60, 430) - 0.14 - - - 
Ln primary care visit cost 31 5.96 ± 0.98 68 6.03 ± 0.72 0.07 (-0.28, 0.42) 0.70 84 0.15 (-0.22, 0.51) 0.42 
Secondary care visit cost 31 632 (206, 1853) 68 316 (103, 1050) - 0.11 - - - 
Wheeze visit cost 31 0 (0,0) 68 0 (0, 0) - 0.37 - - - 
Cough visit cost 31 0 (0, 36) 68 0 (0, 36) - 0.33 - - - 
URTI visit cost 31 180 (36, 324) 68 130 (72, 252) - 0.82 - - - 
LRTI visit cost 31 0 (0, 0) 68 0 (0, 24) - 0.68 - - - 
Bronchiolitis visit cost 31 0 (0, 0) 68 0 (0, 0) - 0.70 - - - 
Ln overall resp cost 31 5.14 ± 1.84 68 4.93 ± 2.08 -0.21 (-1.07, 0.66) 0.64 84 -0.02 (-0.99, 0.95) 0.97 
Food allergy cost 31 0 (0, 0) 68 0 (0, 0) - 0.50 - - - 
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Eczema cost 31 0 (0, 88) 68 0 (0, 36) - 0.90 - - - 
URTI (Upper respiratory tract infection), LRTI (Lower respiratory tract infection).   
1Adjusted for mother’s age, mother’s age on leaving education and gestational age as potential covariates, and ethnicity (Caucasian, Asian, 
Middle Eastern, Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or caesarean) as potential cofactors. 
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6.3.2 Effect of randomisation on number of prescriptions for eczema and 
asthma  
There was no difference in the number of prescriptions issued for medicated skin creams 
[Median 1.0 IQR (0.0, 2.0) combined vitamin D versus 0.0 (0.0, 2.0) controls; p=0.27] or 
wheezing medications [Median 0.0 IQR (0.0, 1.0) combined vitamin D versus 0.0 (0.0, 0.0) 
controls; p=0.42].   
Prescribing data were dichotomized according to whether any prescription was made in the 
first three years of life.  There was weak evidence that offspring of mothers who received 
bolus vitamin D were more likely to have been prescribed a wheezing medication (p=0.05), 
and that offspring of mothers who received daily vitamin D were more likely to have been 
prescribed an eczema medication (p=0.04) (Table 6.5).   
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Table 6.5 Any prescription for wheezing or eczema.  Daily, bolus and combined groups vs controls.  
 Control 
n (%) 
Treatment 
group, n (%) 
Unadjusted OR 
(95%CI) 
p n aOR1 
(95% CI) 
p 
Wheezing medications        
  Daily vs controls 4/31 (12.9) 8/36 (22.2) 1.93 (0.66, 1.97) 0.32 66 3.19 (0.57, 17.77) 0.19 
  Bolus vs controls 4/31 (12.9) 11/32 (34.4) 3.54 (0.98, 12.70) 0.05 62 4.07 (0.98, 16.84) 0.05 
  Combined vs controls 4/31 (12.9) 19/68 (27.9) 2.62 (0.81, 8.49) 0.11 96 3.08 (0.85, 11.24) 0.09 
Eczema medications        
  Daily vs controls 14/31 (45.2) 22/36 (61.1) 1.91 (0.72, 5.06) 0.19 66 3.60 (1.05, 12.34) 0.04 
  Bolus vs controls 14/31 (45.2) 15/32 (46.9) 1.07 (0.40, 2.89) 0.89 62 2.13 (0.60, 7.53) 0.24 
  Combined vs controls 14/31 (45.2) 37/68 (54.4) 1.45 (0.62, 3.40) 0.39 96 2.22 (0.82, 6.02) 0.12 
aOR (Adjusted odds ratio).  1Adjusted for mother’s age, mother’s age on leaving education and gestational age as  
potential covariates, and ethnicity (Caucasian, Asian, Middle Eastern, Black), parity, BMI>30, smoking during pregnancy 
 and mode of delivery (vaginal, instrumental or caesarean) as potential cofactors. 
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6.3.3 Effect of 25(OH)D level on health care utilization 
Of the 99 offspring with complete e-HR data, cord levels of 25(OH)D2 were available for 79, 
and levels at age three years for 65. There was no correlation between either of these 
measures with any healthcare utilisation outcome (Both analyses Figure 6-2; Ln Cord 
25(OH)D, Table 6.6; Ln Childhood 25(OH)D, Table 6.7). 
 
Figure 6-2 Cord and childhood 25(OH)D levels and total healthcare utilisation in the first three years of 
life. 
 
Adjusted correlation (Beta coefficient, β) between 25(OH)D levels measured at A) Birth and 
B) Age three years, and total health care utilisation by age three years.   
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Table 6.6 Cord 25(OH)D levels and healthcare utilisation in the first three years of life.   
Outcome n β or  p n Adjusted1 β p 
Ln total healthcare 79 -0.06 0.58 76 -0.02 0.89 
Ln all visit cost 79 -0.07 0.54 76 -0.01 0.93 
Ln all prescription cost 79 -0.03 0.78 76 0.12 0.36 
Ln year 1 cost 79 -0.07 0.57 76 0.01 0.94 
Year 2 cost 79 -0.04 0.76 - - - 
Year 3 cost 79 0.07 0.57 - - - 
Ln primary care cost 79 -0.01 0.96 76 0.12 0.36 
Secondary care cost 79 -0.06 0.62 - - - 
Wheeze cost 79 0.01 0.95 - - - 
Cough cost 79 -0.003 0.98 - - - 
UTRI cost 79 -0.09 0.42 - - - 
LRTI cost 79 0.12 0.28 - - - 
Bronchiolitis cost 79 -0.07 0.55 - - - 
Ln Overall Resp cost 79 -0.10 0.35 76 -0.05 0.74 
Food allergy cost 79 -0.02 0.86 - - - 
Eczema cost 79 0.18 0.12 - - - 
β (Beta coefficient),  (Spearmans correlation coefficient), URTI (Upper respiratory tract 
infection, LRTI (Lower respiratory tract infection). 
1Adjusted for treatment group, mother’s age, mother’s age on leaving education and 
gestational age as potential covariates, and ethnicity (Caucasian, Asian, Middle Eastern, 
Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or 
caesarean) as potential cofactors.  
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Table 6.7 Childhood 25(OH)D levels and healthcare utilisation in the first three years of life. 
Outcome n β or  p n Adjusted1 β p 
Ln total healthcare 65 -0.08 0.52 63 -0.07 0.68 
Ln all visit cost 65 -0.09 0.49 63 -0.08 0.66 
Ln all prescription cost 65 0.02 0.88 63 -0.007 0.97 
Ln year 1 cost 65 -0.06 0.63 63 -0.05 0.76 
Year 2 cost 65 -0.08 0.52 - - - 
Year 3 cost 65 -0.15 0.24 - - - 
Ln primary care cost 65 0.02 0.86 63 0.12 0.93 
Secondary care cost 65 -0.05 0.70 - - - 
Wheeze cost 65 0.05 0.72 - - - 
Cough cost 65 0.07 0.56 - - - 
UTRI cost 65 -0.16 0.21 - - - 
LRTI cost 65 -0.09 0.50 - - - 
Bronchiolitis cost 65 -0.01 0.94 - - - 
Ln overall Resp cost 65 -0.20 0.11 63 -0.14 0.45 
Food allergy cost 65 - - - - - 
Eczema cost 65 0.02 0.86 - - - 
β (Beta coefficient),  (Spearmans correlation coefficient), URTI (Upper respiratory tract 
infection, LRTI (Lower respiratory tract infection). 
1Adjusted for treatment group, mother’s age, mother’s age on leaving education and 
gestational age as potential covariates, and ethnicity (Caucasian, Asian, Middle Eastern, 
Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or 
caesarean) as potential cofactors.  
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6.4 Discussion 
To our knowledge, this is the first randomized controlled trial of prenatal vitamin D 
supplementation to have assessed healthcare utilisation in offspring.  We evaluated the 
overall evidence that prenatal vitamin D supplementation, at two specific doses, can reduce 
health care utilisation in the first three years of life. We found no consistent evidence for a 
treatment effect. Furthermore, we found no evidence that prenatal vitamin D status is 
inversely associated with healthcare utilization, which suggests that the very high prevalence 
of prenatal vitamin D deficiency seen in many populations across the world may not have 
major health implications for children in the short term.  
 
These data contrast with studies in other populations, which have suggested an inverse 
relationship between cord blood vitamin D level and child health outcomes (290).  There are 
a number of possible explanations for this.  First, healthcare utilization as an outcome is 
rather crude, with large health effects required to influence global healthcare utilisation. 
However, the national framework for health provision in the UK provides a powerful resource 
of objective information, the merit of which has been validated on systematic review (444, 
445). When prevalence based on diagnosis and prescribing patterns are taken together, as 
has been done here, the reliability of this resource further increases (446). Second, this is a 
relatively small study. However, the high nature of the p-values and narrow confidence 
intervals taken with the lack of effect from confounders on multivariate analysis lends 
strength to our conclusions from this relatively small data set. Overall these data suggest 
that a clinically meaningful relationship between vitamin D in cord-blood or at three years of 
age and healthcare utilization is unlikely.  Third, the timing and dose of vitamin D in our 
study. While our interventions did result in at least 50% higher cord blood 25(OH)D 
concentrations compared with no treatment, cord blood levels were significantly lower in our 
intervention groups [daily dose 26nmol/l (IQR 17-45); bolus dose 25nmol/l (IQR 18-34)] than 
in studies that have found protective effects of higher early life 25(OH)D levels on wheezing 
  
or respiratory tract infections in early childhood [Camargo 44nmol/L (IQR 29-78) (290); 
Morales 73.75nmol/L (IQR 56.3-92.8) (292); Belderbos 82nmol/L (SE 3.5nmol/L) (294)]. 
 
Other limitations of this study include the following. The follow up rate of only 55% of the 
original offspring could have led to selection bias. Analyses with imputation for missing data 
were not undertaken due to the relatively small sample size.   This was a diverse ethnic 
group. Variation in healthcare use has been reported between ethnic minorities in the UK, 
with lower levels of asthma diagnosis and treatment in those from the Indian subcontinent 
(447, 448) but higher frequency of consultation (449, 450). However, multivariate analysis of 
our data showed that although maternal ethnicity correlated to vitamin D level there was no 
relationship between maternal ethnicity and our measures of healthcare utilization. 
 
Interestingly we found weak evidence that secondary care health utilisation costs and year 3 
costs were reduced in the bolus group only.  This contrasts with our earlier finding of 
increased LRTI and bronchodilator use in the bolus group as a parentally reported outcome 
when children attended for research assessment. This disparity may be a consequence of 
the different follow up rates for the outcomes (55% for healthcare utilisation and 88% for 
parentally reported outcomes), and may also reflect underlying differences between the 
sample population who attended for assessment at three years, and the sample population 
we had for electronic health record data. 
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7 Assessment of lung function in 3 year old children whose mothers 
participated in a vitamin D supplementation trial during pregnancy using 
impulse oscillometry 
7.1 Introduction 
Like other investigators (59, 68-70, 72), our pilot study found that IOS could determine 
differences in lung function between children with and without a history of respiratory 
symptoms.  We found that children with a history wheeze had significantly higher Fres and 
greater BDR.  However, this study was limited by the relatively small sample size. As such 
the lung function results for children in the prenatal vitamin D follow up study were analysed 
to determine if the findings were replicable. 
7.2  Methods 
As for the pilot study (section 2.1). In addition, treatment allocation (daily, bolus or 
combined) was added as a cofactor in adjusted analyses.  
7.3  Results 
7.3.1 Success rate of IOS in preschool children 
Acceptable baseline IOS data was acquired for 51/105 (48.6%) of children who attended for 
physical assessment, and a bronchodilator response in 39/105 (37.1%).  The mean age of 
children able to perform successful IOS was 37.5 (SD 1.5) months.   
 
7.3.2 Repeatability of measurements  
CV was acceptable for most parameters, but commonly over 17% for X5 and AX (Table 7.1). 
  211 
               Table 7.1 Coefficient of variation for impulse oscillometry measurements 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter Pre 
Median (IQR) (%) 
Post 
Median (IQR) (%) 
Z5 7.56 (4.43, 11.85) 8.23 (5.50, 10.75) 
R5 5.72 (3.94, 8.46) 8.53 (6.27, 11.08) 
R10 5.72 (3.94, 8.46) 6.30 (4.38, 9.17) 
R15 6.01 (3.53, 9.05) 6.09 (4.32, 8.88) 
R20 6.19 (3.76, 9.78) 6.42 (4.61, 9.40) 
R25 6.78 (4.55, 9.73) 7.09 (4.59, 9.36) 
X5 23.52 (15.04, 37.74) 28.72 (19.44, 57.14) 
Fres 4.70 (3.31, 8.50) 6.54 (4.65, 8.99) 
AX 17.44 (9.91, 26.83) 19.46 (13.23, 25.22) 
Z5 (Impedance at 5Hz), R5 to R25 (resistance at 5 to 25Hz), 
X5 (Reactance at 5Hz), Fres (Resonant frequency) and AX 
(Area under the reactance curve). 
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7.3.2.1 Differences between ethnic groups 
When baseline measurements from all children were combined for analysis, no significant 
differences were found between children of different ethnic groups as follows (Figure 7-1). 
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Figure 7-1 Baseline IOS parameters (main study) by different ethnic groups 
 
Baseline IOS in children of different ethnic origins. A) Impedance at 5Hz (Z5), B) Resistance 
at 5Hz (R5), C) R10, D) R15, E) R20, F) R25, G) AX and H) Fres. 
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7.3.2.2 Differences in baseline lung function  
There were no group differences between children with and without wheeze, atopic skin 
sensitisation, atopic wheezing, pre or postnatal ETS exposure or frequent URTI for baseline 
lung function (Tables 7.2 to 7.6).  
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Table 7.2 Baseline lung function in children with and without a history of wheeze (offspring of prenatal vitamin D study). 
IOS Parameter n No wheeze 
Mean ± SD 
n Wheeze 
Mean ± SD 
Mean difference 
(95% CI) 
p n Adjusted1 mean 
difference (95% CI) 
p 
Z5 (kPa.s.L) 36 1.26 ± 0.23 15 1.23 ± 0.28 -0.03 (-0.18, 0.12) 0.65 51 -0.05 (-0.21, 0.10) 0.50 
R5 (kPa/Ls-1) 36 1.21 ± 0.23 15 1.16 ± 0.25 -0.05 (-0.19, 0.10) 0.51 51 -0.07 (-0.22, 0.09) 0.39 
R10 (kPa/Ls-1) 36 0.96 ± 0.16 15 0.90 ± 0.13 -0.06 (-0.15, 0.04) 0.25 51 -0.07 (-0.17, 0.03) 0.18 
R15 (kPa/Ls-1) 36 0.88 ± 0.15 15 0.81 ± 0.11 -0.06 (-0.15, 0.02) 0.15 51 -0.08 (-0.17, 0.01) 0.08 
R20 (kPa/Ls-1) 36 0.80 ± 0.13 15 0.74 ± 0.10 -0.06 (-0.14, 0.02) 0.11 51 -0.08 (-0.16, 0.00) 0.06 
R25 (kPa/Ls-1) 36 0.77 ± 0.13 15 0.71 ± 0.10 -0.06 (-0.13, 0.01) 0.11 51 -0.07 (-0.15, 0.00) 0.06 
Fres (Hz) 36 24.72 ± 3.18 15 25.09 ± 2.67 0.37 (-1.51, 2.25) 0.69 51 0.17 (-1.83, 2.18) 0.86 
AX (kPa/L) 36 3.79 ± 1.44 15 4.15 ± 2.11 0.36 (-0.66, 1.39) 0.48 51 0.36 (-0.73, 1.44) 0.51 
Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency) and AX (Area under the reactance curve). 
1Adjusted for age, height, sex, ethnicity and randomisation. 
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Table 7.3 Baseline lung function in children with and without atopic skin sensitisation (offspring of prenatal vitamin D study). 
IOS Parameter n Non-atopic 
Mean ± SD 
n Atopic 
Mean ± SD 
Mean difference 
(95% CI) 
p n Adjusted1 mean 
difference (95% CI) 
p 
Z5 (kPa.s.L) 38 1.24 ± 0.24 12 1.30 ± 0.26 0.06 (-0.10, 0.22) 0.49 50 0.05 (-0.11, 0.22) 0.53 
R5 (kPa/Ls-1) 38 1.19 ± 0.23 12 1.24 ± 0.26 0.04 (-0.11, 0.20) 0.59 50 0.04 (-0.12, 0.21) 0.59 
R10 (kPa/Ls-1) 38 0.94 ± 0.14 12 0.97 ± 0.20 0.03 (-0.07, 0.14) 0.52 50 0.04 (-0.07, 0.15) 0.48 
R15 (kPa/Ls-1) 38 0.85 ± 0.12 12 0.88 ± 0.19 0.03 (-0.07, 0.12) 0.55 50 0.06 (-0.03, 0.14) 0.20 
R20 (kPa/Ls-1) 38 0.78 ± 0.11 12 0.80 ± 0.17 0.02 (-0.06, 0.11) 0.59 50 0.03 (-0.06, 0.12) 0.52 
R25 (kPa/Ls-1) 38 0.76 ± 0.11 12 0.77 ± 0.16 0.01 (-0.07, 0.10) 0.72 50 0.02 (-0.06, 0.10) 0.64 
Fres (Hz) 38 24.50 ± 2.85 12 25.98 ± 3.46 1.49 (-0.51, 3.49) 0.14 50 1.46 (-0.65, 3.57) 0.17 
AX (kPa/L) 38 3.78 ± 1.76 12 4.36 ± 1.29 0.58 (-0.53, 1.68) 0.30 50 0.49 (-0.68, 1.65) 0.40 
Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency) and AX (Area under the reactance curve). 
1Adjusted for age, height, sex, ethnicity and randomisation. 
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Table 7.4 Baseline lung function in children with and without atopic wheeze (offspring of prenatal vitamin D study). 
IOS Parameter n No atopy 
or wheeze 
Mean ± SD 
n Atopy and 
wheeze 
Mean ± SD 
Mean difference 
(95% CI) 
p n Adjusted1 mean 
difference (95% CI) 
p 
Z5 (kPa.s.L) 46 1.25 ± 0.24 4 1.29 ± 0.29 0.03 (-0.22, 0.29) 0.80 50 -0.02 (-0.29, 0.25) 0.89 
R5 (kPa/Ls-1) 46 1.20 ± 0.24 4 1.22 ± 0.26 0.02 (-0.23, 0.26) 0.90 50 -0.04 (-0.31, 0.23) 0.79 
R10 (kPa/Ls-1) 46 0.95 ± 0.16 4 0.91 ± 0.13 -0.03 (-0.20, 0.13) 0.68 50 -0.05 (-0.23, 0.13) 0.55 
R15 (kPa/Ls-1) 46 0.86 ± 0.14 4 0.82 ± 0.10 -0.05 (-0.20, 0.10) 0.51 50 -0.06 (-0.22, 0.10) 0.44 
R20 (kPa/Ls-1) 46 0.79 ± 0.13 4 0.74 ± 0.08 -0.05 (-0.19, 0.08) 0.46 50 -0.06 (-0.20, 0.08) 0.39 
R25 (kPa/Ls-1) 46 0.76 ± 0.12 4 0.71 ± 0.07 -0.05 (-0.18, 0.08) 0.44 50 -0.06 (-0.20, 0.07) 0.35 
Fres (Hz) 46 24.82 ± 3.12 4 25.20 ± 2.18 0.38 (-2.84, 3.60) 0.81 50 0.50 (-4.01 3.02) 0.78 
AX (kPa/L) 46 3.87 ± 1.67 4 4.50 ± 1.70 0.63 (-1.12, 2.38) 0.47 50 0.35 (-1.56, 2.26) 0.72 
Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency) and AX (Area under the reactance curve). 
1Adjusted for age, height, sex, ethnicity and randomisation. 
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Table 7.5 Baseline lung function in children with and without any ETS exposure (offspring of prenatal vitamin D study). 
IOS Parameter n No ETS 
Mean ± SD 
n Any ETS 
Mean ± SD 
Mean difference 
(95% CI) 
p n Adjusted1 mean 
difference (95% CI) 
p 
Z5 (kPa.s.L) 34 1.28 ± 0.25 17 1.19 ± 0.22 -0.09 (-0.23, 0.05) 0.20 51 -0.09 (-0.23, 0.06) 0.23 
R5 (kPa/Ls-1) 34 1.22 ± 0.24 17 1.15 ± 0.23 -0.08 (-0.22, 0.06) 0.27 51 -0.07 (-0.21, 0.07) 0.32 
R10 (kPa/Ls-1) 34 0.96 ± 0.16 17 0.90 ± 0.14 -0.06 (-0.15, 0.03) 0.20 51 -0.06 (-0.15, 0.04) 0.22 
R15 (kPa/Ls-1) 34 0.88 ± 0.15 17 0.82 ± 0.12 -0.06 (-0.14, 0.02) 0.16 51 -0.06 (-0.14, 0.02) 0.16 
R20 (kPa/Ls-1) 34 0.80 ± 0.13 17 0.74 ± 0.11 -0.06 (-0.13, 0.02) 0.12 51 -0.06 (-0.13, 0.02) 0.12 
R25 (kPa/Ls-1) 34 0.78 ± 0.12 17 0.72 ± 0.11 -0.06 (-0.13, 0.02) 0.12 51 -0.05 (-0.13, 0.02) 0.13 
Fres (Hz) 34 25.22 ± 3.21 17 24.06 ± 2.49 -1.15 (-2.94, 0.63) 0.20 51 -1.07 (-2.90, 0.76) 0.24 
AX (kPa/L) 34 4.06 ± 1.64 17 3.58 ± 1.67 -0.47 (-1.46, 0.51) 0.34 51 -0.45 (-1.45, 0.55) 0.37 
ETS (Pre or postnatal environmental tobacco smoke exposure), Z5 (Impedance at 5Hz), R5 to R25 
(Resistance at 5-25Hz), Fres (Resonant frequency) and AX (Area under the reactance curve). 
1Adjusted for age, height, sex, ethnicity and randomisation. 
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Table 7.6 Baseline lung function in children with and without frequent URTI (offspring of prenatal vitamin D study). 
IOS Parameter n 4 URTI/yr 
Mean ± SD 
n >4 URTI/yr 
Mean ± SD 
Mean difference 
(95% CI) 
p n Adjusted1 mean 
difference (95% CI) 
p 
Z5 (kPa.s.L) 39 1.25 ± 0.24 12 1.26 ± 0.24 0.01 (-0.15, 0.17) 0.93 51 -0.02 (-0.18, 0.14) 0.79 
R5 (kPa/Ls-1) 39 1.20 ± 0.24 12 1.20 ± 0.23 0.00 (-0.15, 0.16) 0.96 51 -0.02 (-0.18, 0.14) 0.79 
R10 (kPa/Ls-1) 39 0.94 ± 0.14 12 0.95 ± 0.20 0.00 (-0.10, 0.11) 0.93 51 -0.01 (-0.12 0.09) 0.80 
R15 (kPa/Ls-1) 39 0.85 ± 0.12 12 0.87 ± 0.19 0.02 (-0.07, 0.11) 0.68 51 -0.00 (-0.10 0.09) 0.99 
R20 (kPa/Ls-1) 39 0.78 ± 0.11 12 0.79 ± 0.18 0.02 (-0.07, 0.10) 0.69 51 -0.00 (-0.09, 0.08) 0.96 
R25 (kPa/Ls-1) 39 0.75 ± 0.11 12 0.77 ± 0.16 0.02 (-0.06, 0.10) 0.69 51 0.00 (-0.08, 0.08) 0.98 
Fres (Hz) 39 24.80 ± 2.87 12 24.91 ± 3.58 0.11 (-1.91, 2.13) 0.91 51 -0.20 (-2.31, 1.90) 0.85 
AX (kPa/L) 39 3.92 ± 1.74 12 3.82 ± 1.40 -0.10 (-1.21, 1.00) 0.85 51 0.22 (-1.37, 0.92) 0.70 
URTI (Upper respiratory tract infection), Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres 
(Resonant frequency) and AX (Area under the reactance curve). 
1Adjusted for age, height, sex, ethnicity and randomisation. 
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7.3.2.3 Bronchodilator response  
The response to administration of 400mcg of salbutamol in children with and without a 
history of wheezing, atopy, atopic wheezing, pre or postnatal ETS exposure and frequent 
URTI are given in Tables 7.7 to 7.11. There was no evidence for differences in BDR 
between these groups, other than weak evidence that atopic children had a smaller BDR for 
R25 compared to non-atopic children (p=0.05). 
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Table 7.7 Bronchodilator response in children with and without a history of wheezing (offspring of prenatal vitamin D study). 
IOS 
Parameter 
n No wheeze 
Mean ± SD 
n Wheeze 
Mean ± SD 
Mean difference 
(95% CI) 
p n Adjusted1 mean 
difference (95% CI) 
p 
Z5 %Init 26 -11.85 ± 13.99 13 -11.10 ± 7.95 0.75 (-7.75, 9.26) 0.86 39 -0.12 (-8.18, 7.94) 0.98 
R5 %Init 26 -10.25 ± 14.85 13 -9.94 ± 8.25 0.31 (-8.69, 9.31) 0.94 39 -0.59 (-8.59, 7.77) 0.89 
R10 %Init 26 -9.65 ± 11.24 13 -10.63 ± 6.60 -0.99 (-7.85, 5.88) 0.77 39 -1.80 (-7.07, 3.47) 0.49 
R15 %Init 26 -8.11 ± 10.66 13 -9.05 ± 6.54 -0.94 (-7.49, 5.62) 0.77 39 -1.18 (-6.16, 3.79) 0.63 
R20 %Init 26 -5.96 ± 10.62 13 -6.11 ± 7.09 -0.15 (-6.77, 6.47) 0.96 39 0.19 (-5.28, 5.66) 0.95 
R25 %Init 26 -3.69 ± 10.11 13 -3.71 ± 7.68 -0.02 (-6.48, 6.45) 1.00 39 -0.00 (-5.45, 5.45) 1.00 
Fres %Init 26 -12.26 ± 11.30 13 -9.12 ± 8.76 3.14 (-4.12, 10.39) 0.39 39 3.01 (-4.84, 10.86) 0.44 
AX %Init 26 -34.26 ± 25.84 13 -29.05 ± 26.27 5.20 (-12.68, 23.08) 0.56 39 3.61 (-15.16, 22.38) 0.70 
Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency), AX (Area under the reactance curve), %Init 
(percentage change in parameter 15 minutes after 400 mcg inhaled salbutamol). 
1Adjusted for age, height, sex, ethnicity and randomisation. 
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Table 7.8 Bronchodilator responses in children with and without a history of atopy (offspring of prenatal vitamin D study). 
IOS 
Parameter 
n Non-atopic 
Mean ± SD 
n Atopic 
Mean ± SD 
Mean difference 
(95% CI) 
p n Adjusted1 mean 
difference  (95% CI) 
p 
Z5 %Init 29 -11.93 ± 12.42 9 -9.06 ± 11.69 2.87 (-6.62, 12.36) 0.54 38 -2.19 (-11.37, 6.99) 0.63 
R5 %Init 29 -10.66 ± 12.95 9 -6.98 ± 13.01 3.68 (-6.35, 13.72) 0.46 38 -1.88 (-11.42, 7.67) 0.69 
R10 %Init 29 -10.78 ± 9.94 9 -5.88 ± 8.42 4.90 (-2.55, 12.35) 0.19 38 0.09 (-5.98, 6.16) 0.98 
R15 %Init 29 -9.23 ± 9.49 9 -4.50 ± 8.20 4.73 (-2.40, 11.87) 0.19 38 -0.30 (-6.01, 5.40) 0.91 
R20 %Init 29 -7.00 ± 9.65 9 -1.58 ± 7.81 5.42 (-1.75, 12.60) 0.13 38 0.67 (-5.58, 6.91) 0.83 
R25 %Init 29 -5.09 ± 8.82 9 2.01 ± 8.77 7.09 (0.28, 13.91) 0.04 38 2.92 (-3.20, 9.05) 0.34 
Fres %Init 29 -10.21 ± 11.44 9 -14.07 ± 7.21 -3.87 (-12.11, 4.37) 0.35 38 -5.69 (-14.46, 3.08) 0.20 
AX %Init 29 -31.32 ± 27.43 9 -34.22 ± 21.47 -2.90 (-23.19, 17.40) 0.77 38 -9.19 (-30.47, 12.09) 0.39 
Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency), AX (Area under the reactance curve), %Init 
(percentage change in parameter 15 minutes after 400 mcg inhaled salbutamol). 
1Adjusted for age, height, sex, ethnicity and randomisation. 
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Table 7.9 Bronchodilator responses in children with and without a history of atopic wheezing (offspring of prenatal vitamin D study). 
IOS 
Parameter 
n No atopy or 
wheeze 
Mean ± SD 
n Atopic 
wheeze 
Mean ± SD 
Mean difference 
(95% CI) 
p n Adjusted1 mean 
difference  (95% CI) 
p 
Z5 %Init 35 -11.54 ± 12.58 3 -7.87 ± 4.96 3.67 (-11.32, 18.66) 0.62 38 -5.47 (-20.64, 9.70) 0.47 
R5 %Init 35 -10.09 ± 13.29 3 -6.33 ± 7.05 3.76 (-12.13, 19.65) 0.63 38 -6.02 (-21.76, 9.71) 0.44 
R10 %Init 35 -9.86 ± 9.89 3 -6.85 ± 8.67 3.01 (-8.98, 14.99) 0.61 38 -4.59 (-14.52, 5.34) 0.35 
R15 %Init 35 -8.30 ± 9.43 3 -5.86 ± 9.28 2.44 (-9.06, 13.94) 0.67 38 -3.41 (-12.80, 5.98) 0.46 
R20 %Init 35 -5.94 ± 9.64 3 -3.13 ± 7.61 2.81 (-8.83, 14.45) 0.63 38 -1.76 (-12.13, 8.60) 0.73 
R25 %Init 35 -3.79 ± 9.27 3 1.10 ± 8.59 4.89 (-6.38, 16.16) 0.38 38 1.50 (-8.80, 11.81) 0.77 
Fres %Init 35 -11.16 ± 11.04 3 -10.62 ± 4.23 0.54 (-12.61, 13.69) 0.93 38 -3.64 (-18.56, 11.28) 0.62 
AX %Init 35 -32.43 ± 26.93 3 -27.08 ± 6.41 5.35 (-26.64, 37.33) 0.74 38 -9.88 (-45.48, 25.72) 0.58 
Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency), AX (Area under the reactance curve), %Init 
(percentage change in parameter 15 minutes after 400 mcg inhaled salbutamol). 
1Adjusted for age, height, sex, ethnicity and randomisation. 
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Table 7.10 Bronchodilator responses in children with and without a history of environmental tobacco exposure (offspring of 
prenatal vitamin D study). 
IOS 
Parameter 
n No ETS 
exposure 
Mean ± SD 
n ETS exposure 
Mean ± SD 
Mean difference 
(95% CI) 
p n Adjusted1 mean 
difference  (95% CI) 
p 
Z5 %Init 26 -11.77 ± 11.50 13 -11.28 ± 13.98 0.49 (-8.02, 8.99) 0.91 39 1.02 (-6.64, 8.68) 0.79 
R5 %Init 26 -10.55 ± 12.05 13 -9.34 ± 14.96 1.21 (-7.78, 10.20) 0.79 39 1.71 (-6.22, 9.65) 0.66 
R10 %Init 26 -10.21 ± 8.46 13 -9.50 ± 12.56 0.71 (-6.16, 7.58) 0.84 39 0.66 (-4.38, 5.71) 0.79 
R15 %Init 26 -8.72 ± 7.97 13 -7.83 ± 12.13 0.89 (-5.67, 7.44) 0.79 39 0.47 (-4.27, 5.22) 0.84 
R20 %Init 26 -6.54 ± 8.78 13 -4.96 ± 11.09 1.58 (-5.02, 8.18) 0.63 39 0.56 (-4.23, 6.15) 0.71 
R25 %Init 26 -4.10 ± 9.33 13 -2.88 ± 9.46 1.22 (-5.23, 7.67) 0.70 39 0.51 (-4.67, 5.69) 0.84 
Fres %Init 26 -12.37 ± 11.70 13 -8.89 ± 7.46 3.48 (-3.75, 10.72) 0.34 39 4.08 (-3.32, 11.47) 0.27 
AX %Init 26 -31.17 ± 27.74 13 -35.22 ± 22.04 -4.04 (-21.96, 13.87) 0.65 39 -1.93 (-19.82, 15.96) 0.83 
ETS (Pre or postnatal environmental tobacco smoke exposure), Z5 (Impedance at 5Hz), R5 to R25 (Resistance 
at 5-25Hz), Fres (Resonant frequency), AX (Area under the reactance curve), %Init (percentage change in 
parameter 15 minutes after 400 mcg inhaled salbutamol). 
1Adjusted for age, height, sex, ethnicity and randomisation. 
 
  225 
Table 7.11 Bronchodilator response in children with and without a history of frequent URTI (offspring of prenatal vitamin D study). 
IOS 
Parameter 
n 4 URTI/year 
Mean ± SD 
n >4 URTI/year 
Mean ± SD 
Mean difference 
(95% CI) 
p n Adjusted1 mean 
difference  (95% CI) 
p 
Z5 %Init 31 -12.22 ± 12.59 8 -9.22 ± 10.94 3.00 (-6.88, 12.88) 0.54 39 -0.84 (-10.30, 8.61) 0.86 
R5 %Init 31 -10.73 ± 13.22 8 -7.87 ± 12.16 2.87 (-7.60, 13.33) 0.58 39 -1.46 (-11.26, 8.35) 0.76 
R10 %Init 31 -10.89 ± 9.13 8 -6.44 ± 12.31 4.45 (-3.43, 12.34) 0.26 39 0.61 (-5.62, 6.83) 0.84 
R15 %Init 31 -9.28 ± 8.59 8 -5.11 ± 12.16 4.17 (-3.36, 11.70) 0.27 39 0.46 (-5.40, 6.32) 0.87 
R20 %Init 31 -6.68 ± 9.27 8 -3.43 ± 10.55 3.25 (-4.41, 10.90) 0.40 39 0.60 (-5.82, 7.01) 0.85 
R25 %Init 31 -4.34 ± 9.14 8 -1.19 ± 9.96 3.15 (-4.32, 10.62) 0.40 39 0.67 (-5.73, 7.06) 0.83 
Fres %Init 31 -11.77 ± 11.09 8 -9.04 ± 8.09 2.74 (-5.77, 11.24) 0.52 39 0.57 (-8.73, 9.87) 0.90 
AX %Init 31 -33.89 ± 27.78 8 -27.22 ± 15.95 6.67 (-14.18, 27.53) 0.52 39 0.09 (-22.00, 22.17) 0.99 
URTI (Upper respiratory tract infection), Z5 (Impedance at 5Hz), R5 to R25 (Resistance at 5-25Hz), Fres (Resonant frequency), AX (Area 
under the reactance curve), %Init (percentage change in parameter 15 minutes after 400 mcg inhaled salbutamol). 
1Adjusted for age, height, sex, ethnicity and randomisation. 
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7.4 Discussion 
We have found that in a study of preschool children aged three years, measurement of 
baseline lung function or response to bronchodilator with IOS was unable to discriminate 
between children with and without a history of wheezing. Furthermore, unlike in our pilot 
study, no differences in impulse oscillometry were found between ethnic groups.   
 
There are a number of possibilities as to why no differences between ethnic groups were 
found in this analysis.  The pilot study was a convenience sample from outpatients, and so 
there may have been many sources of bias accentuating ethnic differences in lung function 
which were not present in the offspring of the randomized trial. 
 
For baseline lung function, this is in keeping with other studies (65, 67, 68, 70). For BDR, 
only one other study has similar findings (67), with the majority finding increased BDR in 
wheezy children compared to controls (59, 68-71). Our pilot study found increased BDR for 
R25 in wheezy children.   There are a number of possible explanations for these differences.  
First, offspring of mothers who received a bolus of 200,000 IU of vitamin D in pregnancy had 
increased bronchodilator use compared to controls, and thus it is possible the intervention 
itself influenced the result.  Second, the intervention selected mothers from four ethnic 
groups, which may have made it harder to discern small differences between groups (429).  
Third, in the pilot study, and positive studies in the literature, children with wheeze were 
recruited from hospital based asthma clinics.  This may have resulted in selecting cases with 
a more severe wheezing phenotype.  We note that the one study finding no difference in 
BDR between children with and without asthma recruited from a Kindergarten (451).  Fourth, 
we looked for differences between children with and without any episode of wheeze as 
opposed to ‘asthma’.  Although diagnosing asthma in children under six years of age is of 
limited utility (13), using more stringent criteria may have selected out children with more 
severe lung impairment that would have enabled us to discern differences. However, we did 
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not find any differences when evaluating atopic wheezers separately.  Fifth, the mean age of 
children in this study was 37 months, considerably lower than published studies which range 
from 4.1 to 7.7 years.  Finally, although a larger group than the pilot study, this was still a 
relatively small sample compared to the majority of published studies. 
 
Our study used consistent methodology.  However, lung function was performed by two 
different operators in the pilot (UB) and main study (SG). For bronchodilator responses, the 
number of study subjects is relatively small compared to other studies.  We used a stringent 
process to check and maintain quality of data.  Whilst this led to the analysis of high quality 
data, which is reflected in our low CVs for most parameters, this also meant a significant 
proportion of IOS data was not analysed.  At present there are no standards for post 
acquisition IOS quality control in preschool children. 
 
In conclusion, in this study of preschool children of mixed ethnicity who are the offspring of 
an intervention trial of prenatal vitamin D supplementation, IOS was unable to discriminate 
between children with and without a history of wheezing.   Further research should evaluate 
the role of IOS in assessing longitudinal changes to therapy in individual children.
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8 Discussion 
8.1 Assessment of lung function in preschool children using impulse 
oscillometry 
8.1.1 Summary of findings 
1. Acceptable IOS data acquired in 56% of children (pilot study) and 49% (follow up 
study).  In the pilot study, IOS was more successful in children aged over 42 months.  
The CVs were acceptable, ranging from 3.5 to 8.8%, except for AX and X5 which 
were considerably higher. 
2. No significant differences in baseline impulse oscillometry measurements between 
children with and without wheeze, atopy, ETS exposure or frequent URTI.  
3. In the pilot study, ethnic differences in lung function were found that were not 
replicated in the main study population. 
 
8.1.2  Consistency with other studies 
The majority of studies have found increased BDR in wheezy children compared to controls 
(59, 68-71). The most likely explanation for us not consistently observing this difference are 
that unlike studies in the literature, children in both the pilot study and vitamin D follow up 
study came from a wide range of ethnicities, which may have made it harder to discern small 
differences between groups (429).  Second, studies that found a difference in BDR in 
children with and without asthma all recruited from hospital based clinics, which may have 
lead to selecting wheezy children with a more ‘severe’ phenotype. In the study that found no 
difference in BDR, children were recruited from a community based Kindergarten (451), to 
which the vitamin D follow up offspring may be more similar to.   
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8.1.3  Strengths and weaknesses of the data 
Our study used consistent methodology.  However, lung function was performed by two 
different operators in the pilot (UB) and main study (SG). For bronchodilator responses, the 
number of study subjects is relatively small compared to other studies.  We used a stringent 
process to check and maintain quality of data.  Whilst this led to the analysis of high quality 
data, which is reflected in our low CVs for most parameters, this also meant a significant 
proportion of IOS data was not analysed.  At present there are no standards for post 
acquisition IOS quality control in preschool children. 
 
8.1.4  Implications for future research and clinical practice 
We have shown that IOS can be performed reliably in children as young as 3 years, and is 
acceptable in terms of repeatability.  However, more research is required to understand the 
correlation between measured parameters and clinical outcomes in preschool children. 
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8.2  Effect of prenatal vitamin D on child health  
8.2.1 Summary of findings 
1. No effect of prenatal vitamin D supplementation on parentally reported wheezing. 
2. Increased bronchodilator use and increased LRTI in offspring of mothers who 
received a bolus dose of vitamin D (although this result became non-significant after 
adjusting for multiple testing) 
3. No effect of prenatal vitamin D supplementation on atopic sensitisation, IgE levels, 
exhaled nitric oxide or lung function measured by IOS in offspring at age three years 
4. No consistent evidence for a treatment effect on healthcare utilisation. 
5. No correlation between cord 25(OH)D levels and wheezing or any other outcome.  
 
8.2.2  Consistency with other studies 
Our results are in agreement with observational studies that have found no relationship 
between cord or maternal gestational 25(OH)D levels and these outcomes (145, 175, 288, 
290-293).   
 
When we analysed our own data on cord blood 25(OH)D concentration and parentally 
reported child health and objective markers of atopy, inflammation and lung function at age 
first three years, no significant relationships were found. However, while our interventions 
did result in at least 50% higher cord blood 25(OH)D concentrations compared with no 
treatment, cord blood levels were still significantly lower in the intervention groups than in 
studies that found significant relationships (291).  If prenatal supplementation with vitamin D 
is to make a difference, one might expect to more clearly see an effect in such a deficient 
population. 
 
  231 
8.2.3  Strengths and weaknesses of the study 
The key strength of this study is that we have comprehensively assessed child health using 
a range of overlapping techniques including validated parental questionnaire, objective 
assessment of biological parameters and analysis of prospectively recorded primary 
healthcare records for clinical outcomes and total healthcare utilisation.  Reassuringly, 
results are consistent across these fields.  However, our study has a number of limitations, 
as have been described previously.  Perhaps the most important limitations are first, this 
was a small study with limited statistical power apart from for the primary outcome of 
wheezing.  Second, we did not assess vitamin D receptor polymorphisms or other potentially 
important genotypic variations. It is possible that vitamin D supplementation is effective for 
preventing wheezing in the presence of specific maternal or infant genotypes, as suggested 
by others (285). Third, the effectiveness of the intervention.  It is possible that vitamin D 
supplementation at a higher dose, or earlier in pregnancy might protect against early 
childhood wheezing.  Finally, the ethnic variability may have led to more ‘noise’ between 
groups making small differences in outcomes harder to discern. 
 
8.2.4  Implications for future research and clinical practice 
Although our data excludes a large effect on preschool wheezing, given the modest effects 
on cord blood vitamin D achieved by these interventions, the safety and efficacy of higher 
dose prenatal vitamin D supplementation strategies need to be explored.  Two on-going 
trials, the Vitamin D Prenatal Asthma Reduction Trial (NCT00920621), and ABCvitaminD 
(NCT00856947) are specifically exploring the effects of earlier and higher dose prenatal 
vitamin D supplementation on child health.  Given our finding of increased bronchodilator 
use and increased LRTI in offspring of mothers who received a bolus dose of vitamin D, (in 
this case a single dose of 200,000 units at 27 weeks gestation), the use of  such regimens 
should be viewed with caution. 
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10 Appendices 
10.1 Pilot study participant information sheet 
Participant Information Sheet 
 
 
We would like to invite you to take part in a research study. Before deciding you need to 
understand why the research is being done and what it involves.  Please take time to read 
the following information carefully. Talk to others about the study if you wish.  Ask us if there 
is anything that is not clear or if you would like more information. 
 
Part I tells you about the purpose of the study and what will happen if you take part. 
Part II gives you more detailed information about the conduct of the study. 
 
Part I 
What is the study about? 
In the UK, one in three children become wheezy before they are three. These illnesses 
reduce quality of life for children and families, and our understanding of these illnesses is 
quite limited. Recently a new method has been developed for testing young children’s lung 
function, and we would like to develop this method to help us understand why wheezing in 
young children happens. We wish to use this method to test lung function in 60 young 
children and compare this with information about any illnesses they have had.  
 
Why has my child been invited to take part? 
We are inviting pre-school children who are currently not suffering from any infection or 
acute illness, and who are attending St Mary’s hospital as a patient, relative or visitor to take 
part in this study.   
  
Do we have to take part? 
It is up to you to decide.  We will answer any questions that you have, and give you time to 
decide.  We will then ask you to sign a consent form to show that you have agreed to take 
part.  You are free to withdraw from the study at any time, without giving a reason.  If you 
withdraw from the study it will not affect your usual medical care in any way. 
 
What will happen if we agree to take part? 
We will ask you some questions about your child’s health, and examine your child’s skin and 
chest. We will ask your child to breathe in and out of a tube attached to a machine for 1 
minute, to measure their lung function. We will then give them a medicine to inhale called 
salbutamol (ventolin) and repeat the breathing test 15 minutes later. Salbutamol is a 
medicine which helps children with asthma breathe more easily, and is very safe.  To give 
the medicine, your child simply breathes in and out of a plastic box filled with salbutamol 
spray for a few seconds.  
 
 
Your child will also have: 
The Effects of Prenatal Vitamin D Supplementation on Child Health:  Pilot study 
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1. An allergy skin test. This is a test for allergy where small drops of liquid are placed on the 
child’s forearm or back, and a painless scratch is made through each drop into the surface of 
the skin.  15 minutes later the appearance of the skin is observed for signs of an allergic 
reaction.  We will discuss the results with you, and of course let your GP know and ask them 
to arrange appropriate follow up where necessary. 
2. Nose test. This is a test for allergy in the nose – we will place a small piece of paper in your 
child’s nose and leave it there for 2 minutes. After removing the paper we will look at the fluid 
which the paper has absorbed for signs of allergy. 
 
The whole assessment will take approximately 30 minutes. 
 
What else will we have to do? 
Nothing – once the above assessment is completed no further tests or participation is needed. 
 
Are there any disadvantages to taking part in this study? 
The main disadvantage is the time taken. Allergy skin tests and the nose test can cause 
some itchiness at the time of the test which settles within a few minutes.   
 
Are there any benefits to taking part in this study? 
We cannot promise the study will help you, but we hope the information we get from the 
study will help lead to an intervention that can prevent some children from developing 
asthma.  
If we discover any health problems during the assessment, such as allergies, we will give 
you the written results so that you can contact your general practitioner and arrange 
appropriate medical treatment or assessment. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you or your child might have suffered will be addressed.  The detailed information on 
this is given in part 2. 
 
Will taking part in the study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information about you and your child 
will be handled in confidence.  The details are included in part 2. 
 
Part 2 
What will happen if I don’t want to carry on with the study? 
If you withdraw from the study, or change your mind, any stored tissue samples that can be 
identified as yours will be destroyed if you wish.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the 
researchers who will do their best to answer your questions.  If you remain unhappy and 
wish to complain formally, you can do this through the NHS complaints procedure which is 
called PALS (Patient Advice and Liaison Service.)   
 
What if something goes wrong? 
Imperial College London holds insurance policies which apply to this study.  If you 
experience serious and enduring harm or injury as a result of taking part in this study, you 
may be eligible to claim compensation without having to prove that Imperial College is at 
fault.  This does not affect your legal rights to seek compensation. 
  
If you are harmed due to someone’s negligence, then you may have grounds for a legal 
action.  Regardless of this, if you wish to complain, or have any concerns about any aspect 
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of the way you have been treated during the course of this study then you should 
immediately inform the Investigator (Dr Stephen Goldring, contact details at end of this 
leaflet).  The normal National Health Service complaint complaints mechanisms are also 
available to you.  If you are still not satisfied with the response, you may contact the Imperial 
AHSC Joint Research Office.   
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential, and any information about you which leaves the hospital will have your 
name and address removed so that you cannot be recognised.   
 
Involvement of your General Practitioner 
We will inform your General Practitioner of your child’s involvement in this brief study, and if 
we identify any important health problem we will give you and your GP a written copy of the 
results so that you can discuss them with your GP.  
 
What will happen to the nose samples? 
All samples will be labelled with a code with no identifying information about you. 
Some tests will be done straight away.  We know that samples from children are a precious 
resource.  We try and collect as little as possible, and also use as little as possible, so that 
when this study is finished we can store what’s left and use the samples for future ethically 
approved research. At any time you wanted, you could ask for these samples to be 
destroyed. 
 
Will any genetic (DNA analysis) tests be done? 
No. 
 
What will happen to the results of the research study? 
Results of this study will be published in the scientific peer-reviewed literature, and 
presented at national and international congresses relevant to asthma and allergic disease. 
Results will also be disseminated to asthma patients via the funder Asthma UK.  Patients will 
not be identifiable in any report, publication or presentation unless you have given your 
consent. 
 
Who is organising and funding the research? 
The research is co-ordinated by Imperial College London and has been funded by Asthma 
UK, a national organisation that supports research into the causes of asthma.   
It has also been reviewed and given a favourable opinion by the St Mary’s Hospital ethics 
committee. None of the investigators performing the research or participants taking part will 
benefit financially from the study. 
 
 
Who has reviewed the study? 
Service users were involved in the design of this research.  The funders, Asthma UK, have 
peer reviewed the study, and it has also been reviewed by the St Mary’s hospital research 
and ethics committee.   
 
Further information and contact details 
If you would like more information or to discuss anything in this leaflet, please contact the 
study coordinator Dr Stephen Goldring, who will be happy to discuss any aspect of this 
study.   
 
Dr Stephen Goldring 
Paediatrician and Clinical Research Fellow 
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Department of Paediatrics 
Imperial College London 
Norfolk Place 
London, W2 1PG 
Tel:  0207 594 3990 
Fax: 0207 594 3984 
Mobile:  07792 923 957 
Email:  sgoldring@nhs.net 
 
 
This information can be made available in other languages and formats if requested.  
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10.2 Pilot study consent form 
Consent Form for Parents/ Guardian 
 
 
  Please 
initial 
1. I confirm that I have read and understand the information Sheet dated 
03/03/10, for the above study.  I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily.   
  
□ 
2.  I understand that my child’s participation is voluntary, and that I am free to 
withdraw consent for my child at any time, without giving any reason and 
without my child’s medical care or legal rights being affected. 
 
□ 
3.  I understand that relevant sections of any of my child’s medical notes and 
data collected during the study, may be looked at by responsible individuals 
from Imperial College London, from  Imperial College Healthcare NHS Trust 
and from  regulatory authorities, where it is relevant to my taking part in this 
research.  I give permission for these individuals to access my child’s 
records.  
 
□ 
4. I agree to my child’s general practitioner being informed of my child’s 
participation in the study 
 
□ 
5. I agree to the use of my child’s nasal samples as described in the patient 
information sheet 
 
□ 
7.  I agree to the use of my child’s samples in any future ethically-approved 
studies. 
 
□ 
8.   I agree to my child taking part in the above study. 
 □ 
 
 
________________________     ____________________     ________________ 
Name of Parent/ Guardian     Date      Signature 
 
_________________________   
Name of Child     
 
_________________________     ____________________     ________________ 
Name of Person taking consent     Date      Signature 
 
 
When completed:  1 for parent, 1 for researcher site file, 1 to be posted to GP (if consent given)  
The Effects of Prenatal Vitamin D Supplementation on Child Health:  Pilot study 
Protocol Version 1.0   31/12/09.  Consent form version 2, 03/03/10 
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10.3 Pilot study – general health questionnaire 
 
1.Patient Name:  
 
2. Hospital No:  
 
     
 
3.  Patient Code:  
 
 
4. Contact Details (preferable telephone number details): 
 
         Address:………………………………………………………………. 
                     ……………………………………………………………….. 
                    ………………………………………………………………… 
                   …………………………………………………………………. 
                   …………………………………………………………………. 
 
        Telephone……………………………………………………………… 
 
        Email………………………………………………………………………. 
 
 
5. DOB:                    /                     /   
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6. Sex:       Male        /        Female 
 
 
7. Ethnicity:  Middle Eastern     
   
Asian   
 
Caucasian  
 
Afrocarribean  
 
Other 
 
 
8. Height (cm):                                  cm 
 
9. Weight (kg):                      .           kg 
 
 
Medical History Questions 
 
10. How often does your child get a cold or chest infection? 
 
Every two weeks  
 
Every month 
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Every 3-4 Months 
 
Every 6 months    
 
Once a year 
 
Less than once a year 
 
Never 
 
 
11. Has your child ever had pneumonia?    Yes                No 
 
 
12.  Has your child ever been admitted to hospital?        Yes          No 
 
If yes, what for? 
 
 
13.  Does your child have any other medical conditions?   Yes            No 
 
If yes, what are they? 
 
 
14.  What was the weight of your child when they were born?    
 
                          .            Kg 
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15. Did the doctors tell you your child had had growth problems in utero?    
 
Yes              No 
  
 
16.  Did the mother smoke during pregnancy?     Yes            No 
 
 
17.  Was the mother exposed to smoke during the pregnancy – e.g. father smoking at 
home? 
 
Yes            No 
 
 
18.  From being born to now, is the child exposed to cigarette smoke?     
 
Yes             No 
 
 
 
 
 
Now complete Wheezing Questionnaire. 
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10.4  Pilot study – wheezing questionnaire 
Questionnaire Before Testing – Wheezing Questionnaire – Modified from ISAAC study for 6-
7 year olds. 
 
Patient Code:  
 
 
Date:                      /                   / 
 
 
Interviewers Initials:   
 
Has your child ever had wheezing or whistling in the chest at any time in the past? 
 
Yes                  No  
 
If ‘NO’ go to question 6. 
 
At what age did your child first wheeze?   
 
Before 1st Birthday 
 
When they were one 
 
When they were two 
 
At age three years old or more 
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Has your child had wheezing or whistling in the chest in the last 12 months? 
 
      Yes               No 
 
    
  If ‘NO’ go to question 6 
 
 
 
How many attacks of wheezing has your child had in the last 12 months? 
 
None     
 
 
1- 3 
 
 
4-12 
 
 
More than 12 
 
 
In the last 12 months, how often, on average, has your child’s sleep been affected due to 
wheezing? 
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Never woken due to wheezing 
   
Less than one night per week   
   
One or more night per week  
     
 
In the last 12 months has the wheezing ever been severe enough to limit your child’s speech 
to only one or two words at a time between breaths? 
 
Yes                  No 
 
 
Has your child ever had asthma? 
 
      Yes                 No 
 
 
In the last 12 months has your child’s chest sounded wheezy during or after exercise? 
 
Yes                  No 
 
 
Has your child ever had a runny nose, blocked nose, sneezing when he/she does not have a 
cold? 
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Yes                  No 
 
If ‘NO’  go to question 11 
 
 In the last 12 months has your child had a runny nose, blocked nose, sneezing when he/she 
does not have a cold? 
 
Yes                   No 
 
If  ‘NO’ go to question 11 
 
When does this occur?  
 
January  
   
February 
 
March 
 
April 
 
May 
  
June 
 
July 
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August  
 
September 
 
October 
 
November 
 
December 
 
Has your child ever had hayfever? 
 
Yes              No 
 
 
Does your child ever have an itchy rash that comes and goes? 
 
      Yes             No 
 
 
      If ‘NO’ go to question 15 
 
 
In the last 12 months has your child had this itchy rash that comes and goes? 
 
       Yes            No 
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       If ‘NO’ go to question 15 
 
 
Has this itchy rash, at any time, affected any of the following places:  the folds of the elbows, 
behind the knees, in front of the ankles, under the buttocks, or around the neck, ears or 
eyes? 
 
Yes             No 
 
 
Has your child ever has eczema? 
 
Yes              No 
 
 
Does your child have any food allergies? 
 
      Yes             No 
If yes, what? 
 
Has it been medically diagnosed? 
 
Yes               No 
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Skin Prick Test Results [positive = ≥3mm wheal at 15 minutes] 
 
Skin Prick Test Completed?  Yes     No                  
    
 
 
Skin Prick Test Problem?    0 Nil            
      1 No clear skin     
     2 Antihistamine taken            
     3 Dermatographism 
       4 Other  
Details…………………………………………………………………………………………………
………………………………………. 
  
 
Skin Prick Test Site:  Back          Forearm   
 
Results 
 
Dust Mite  ____.____mm  Neg              Pos 
 
Cat                ____.____mm  Neg               Pos  
 
Dog             ____.____mm  Neg           Pos  
 
Grass Pollen  ____.____mm  Neg           Pos  
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Tree Pollen   ____.____mm  Neg           Pos  
 
Mould - alternaria ____.____mm  Neg          Pos 
 
Neg Control  ____.____mm 
 
Histamine ____.____mm  
 
Others (e.g. if child is reported to have food allergy): 
 
____________             ____.____m     Neg               Pos 
 
____________             ____.____mm  Neg               Pos 
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Patient Code: 
 
Date:                              /                     / 
 
 
Results of the Nasal Secretion test 
 
Nasal Secretion test competed? 
 
Yes                                   No 
 
 
Details:…………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
………………… 
 
Weight Before:                             .                     mg 
 
Weight After:                                 .                    mg 
 
Difference:                                    .                    mg 
 
 
Lab Results: 
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10.5 Main study - participant information leaflet 
Participant Information Sheet 
We would like to invite you and your child to take part in a research study. Before deciding you need 
to understand why the research is being done and what it involves.  Please take time to read the 
following information carefully. Talk to others about the study if you wish.  Ask us if there is anything 
that is not clear or if you would like more information.  Take time to decide whether or not you wish 
to take part. 
 
Part I tells you about the purpose of the study and what will happen if you take part. 
Part II gives you more detailed information about the conduct of the study. 
 
Part I 
What is the study about? 
In the UK, one in three children have a ‘wheezing illness’ before they are three, and one in five 
children develop asthma by age six.  We don’t know why so many children have wheezing illnesses, 
but new research has found a link between vitamin D intake during pregnancy and a child’s lungs 
development and risk of having wheezing illnesses. Vitamin D intake during pregnancy may also 
change how well a child’s bones and immune system develop. 
 
Why have we been invited to take part in this study? 
You have been contacted because you took part in a trial of different vitamin D supplements when 
you were pregnant a few years ago.  We would like to see whether the treatment that you took 
during pregnancy has had any effect on your child’s health – particularly the development of their 
lungs, their bones and their immune system. 
  
Do we have to take part? 
It is up to you to decide.  We will answer any questions that you have, and give you time to decide.  
We will then ask you to sign a consent form to show that you have agreed to take part.  You are free 
to withdraw from the study at any time, without giving a reason.  If you withdraw from the study it 
will not affect your usual medical care in any way. 
 
What will happen if we agree to take part? 
We would like you to bring your child, when they are aged three years, for a one-off health assessment  at the 
Paediatric Research Unit, St Mary’s Hospital.  We expect each study visit to take less than two hours, but it 
would be sensible to allow a morning, or an afternoon to complete the assessment.  This will involve the 
following: 
1. A short questionnaire about you and your child’s health. 
2. An examination of your child by a children’s doctor or nurse.   
3. Two simple breathing tests were we ask your child to breathe in and out of a machine that measures 
how he/she breathes, and what is in their breath. During one of the breathing tests we will ask your 
child to breathe in a medicine called salbutamol (or Ventolin), and then repeat the breathing test.  
Salbutamol is a medicine which helps children with asthma to breathe more effectively, and is very 
safe.  To give the medicine, your child simply breathes in and out of a plastic box filled with 
salbutamol spray for 6-10 breaths. 
The Effects of Prenatal Vitamin D Supplementation on Child Health 
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4. Allergy skin test. This is a test for allergy where small drops of liquid are placed on the child’s forearm 
or back, and a painless scratch is made through each drop into the surface of the skin.  15 minutes 
later the appearance of the skin is observed for signs of an allergic reaction.  We will discuss the 
results with you, and of course let your GP know and ask them to arrange appropriate follow up 
where necessary. 
5. Nose test. This is a test for allergy in the nose – we will place a small piece of paper in your child’s 
nose and leave it there for 2 minutes. After removing the paper we will look at the fluid which the 
paper has absorbed for signs of allergy. 
6. A blood test (about 10mls or 2 teaspoons) from both you and your child.  From this sample we would 
like to measure you and your child’s vitamin D levels.  If either of you have low levels of     vitamin D, 
we would recommend a vitamin supplement that your GP can prescribe.   
7. A test of you and your child’s skin darkness using a gentle probe placed on the skin. 
8. A test using a cotton bud to gently rub the inside of you and/or your child’s mouth for a minute.  
This allows us to collect cells which can be used for laboratory tests, and does not cause any 
discomfort. 
9. We will also write to your GP to ask for a copy of your child’s GP health records, so that we can 
see what breathing illnesses they have had. 
 
That seems like a lot of tests – do I need to do them all? 
We prefer that you and your child do all of the tests, but if you wish to only do some of them then you are still 
able to join the study. If it is very difficult for you to visit the hospital then we may be able to arrange an 
interview over the telephone.     
 
Will the tests hurt? 
The blood test can cause some discomfort. For both you and your child we will use a local anaesthetic cream 
to numb the skin, and distraction techniques as appropriate. All blood tests will be taken by fully trained staff.   
 
Expenses and payments 
We will reimburse your travel or parking expenses if you travel to the hospital for your health check by public 
transport or in your own vehicle. 
 
What else will we have to do? 
Once you and your child have completed the tests there is no other commitment.  However depending on the 
results of this study we may contact you again in the future to ask your permission to undertake a further 
health check for your child when they are older. 
 
Are there any disadvantages to taking part in this study? 
The main disadvantages are the time taken, and any discomfort from collecting the blood sample. Both allergy 
skin tests and the nose test may cause some slight itching during the test, which settles within a few minutes.  
 
Are there any benefits to taking part in this study? 
Your child will have a health check supervised by Dr Goldring who is a fully trained children’s 
specialist. This will include testing the health of their lungs, immune system and bones. We will 
provide you (and your GP if you agree) with a report of any test results that are important for your 
child’s healthcare. The information we get from the study may also help us to prevent other children 
from developing asthma, and to advise women on what vitamins to take during pregnancy.   
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm you or 
your child might have suffered will be addressed.  The detailed information on this is given in part 2. 
 
Will taking part in the study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information we have about you and your child 
will be handled in confidence.  The details are included in part 2. 
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Part 2 
 
What if relevant new information becomes available? 
Sometimes we get new information about the subject being studied.  If this happens the research 
doctor will contact you with the new information and the implications for the study, and for you and 
your child. 
 
What will happen if I don’t want to carry on with the study? 
If you withdraw from the study, or change your mind, any stored blood or tissue samples that can be 
identified as yours will be destroyed if you wish.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak to the researchers who 
will do their best to answer your questions.  If you remain unhappy and wish to complain formally, 
you can do this through the NHS complaints procedure which is called PALS (Patient Advice and 
Liaison Service.)   
 
What if something goes wrong? 
Imperial College London holds insurance policies which apply to this study.  If you experience serious 
and enduring harm or injury as a result of taking part in this study, you may be eligible to claim 
compensation without having to prove that Imperial College is at fault.  This does not affect your 
legal rights to seek compensation. 
 If you are harmed due to someone’s negligence, then you may have grounds for a legal 
action.  Regardless of this, if you wish to complain, or have any concerns about any aspect of the 
way you have been treated during the course of this study then you should immediately inform the 
Investigator (Dr Stephen Goldring, contact details at end of this leaflet).  The normal National Health 
Service complaint complaints mechanisms are also available to you.  If you are still not satisfied with 
the response, you may contact the Imperial AHSC Joint Research Office.   
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept strictly 
confidential, and any information about you which leaves the hospital will have your name and 
address removed so that you cannot be recognised.   
 
Involvement of your General Practitioner 
If you decide to take part in the study, we will ask for your consent to send a letter to you and your 
child’s general practitioner to let them know of your participation.  We would also like to include in 
that letter any relevant health information that we discover during the assessment that your GP 
should know about.   
 
What will happen to the blood and nose samples? 
These samples will be used to find out how our immune system responds to vitamin D during 
pregnancy. The blood samples will also be used to check you and your child’s vitamin D level. All 
samples will be labelled with a code with no identifying information about you. 
Some tests will be done straight away.  We know that samples from children are a precious 
resource.  We try and collect as little as possible, and also use as little as possible, so that when this 
study is finished we can store what’s left and use the samples for future ethically approved research. 
At any time you want, you can ask for these samples to be destroyed. 
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Will any DNA analysis or genetic tests be done? 
We would like to collect either a blood sample or  cells from the surface of the mouth from you and 
your child for genetic tests which may be done at the time of the study, or at a later date in other 
ethically approved studies.  The aim of these tests is to understand how vitamin D during pregnancy 
affects wheezing in children.   
Although unlikely, if we discover a genetic result that may be important for you or your child’s 
health, we will write to your GP who can make contact with you and arrange for a full explanation of 
the result, what it means for you and your child, and whether any further action is necessary.   
 
What will happen to the results of the research study? 
Results of this study will be published in scientific peer-reviewed literature, and presented at 
national and international congresses relevant to asthma and allergic disease. Results will also be 
disseminated to asthma patients via the funder Asthma UK.  Patients will not be identifiable in any 
report, publication or presentation. 
 
Who is organising and funding the research? 
The research is co-ordinated by Imperial College London and has been funded by Asthma UK, a 
national organisation that supports research into the causes of asthma.  It has also been reviewed 
and given a favourable opinion by the St Mary’s Hospital ethics committee. None of the investigators 
performing the research will benefit financially from the study. 
 
Who has reviewed the study? 
Patient representatives were consulted during the design of this research. Experts in vitamin D and 
asthma have reviewed the study, together with the charity Asthma UK. It has also been reviewed by 
the St Mary’s hospital research and ethics committee.   
 
Who to contact for further information  
If you would like more information or to discuss anything in this leaflet, please contact the study 
coordinator Dr Stephen Goldring, who will be happy to discuss any aspect of this study.   
 
Dr Stephen Goldring 
Clinical Research Fellow and Paediatrician 
Department of Paediatrics, Imperial College London, London, W2 1PG 
Dedicated contact number:  07590 250650 
Email:  sgoldring@nhs.net 
This information can be made available in other languages and formats if requested.  
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10.6 Main study - consent form  
 
 
 Consent Form for Parents/ Guardians 
  Please 
initial 
1. I confirm that I have read and understand the participant information sheet 
dated 03/03/10 for the above study.  I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily.   
  
□ 
2.  I understand that my child’s participation is voluntary, and that I am free to 
withdraw consent for my child at any time, without giving any reason and 
without my child’s medical care or legal rights being affected. 
 
□ 
3.  I understand that relevant sections of any of my child’s medical notes and data 
collected during the study may be looked at by responsible individuals from 
Imperial College London, from  Imperial College Healthcare NHS Trust and from  
regulatory authorities, where it is relevant to my child taking part in this 
research.  I give permission for these individuals to access my child’s records.  
 
□ 
4. I agree to my child’s general practitioner being informed of my child’s 
participation in the study 
 
□ 
5. I agree to the use of my child’s blood as described in the participant information 
sheet 
 
□ 
6. I agree to the use of my child’s blood or mouth swab  for genetic studies as 
described in the participant information sheet 
 
□ 
7.  I agree to the use of my child’s samples in any future ethically-approved studies. 
 
□ 
8.   I agree to my child taking part in the above study. 
 
□ 
________________________     ____________________     ________________ 
Name of Parent/ Guardian     Date      Signature 
 
_________________________   
Name of Child     
 
_________________________     ____________________     ________________ 
Name of Person taking consent     Date      Signature 
 
When completed:  1 for parent, 1 for researcher site file, 1 to be posted to GP (if consent given)  
Child’s name:  
DOB:  
Study number:  
The Effects of Prenatal Vitamin D Supplementation on Child Health 
Protocol Version 2.0   21/06/10.  Consent form version 3.0  21/06/10 
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10.7 Main study questionnaire 
  302 
 
Interviewer ID:    (Steve-1 Bob-2 Heather-3 Other:……………………-4)  
 
Date of questionnaire __ __/__ __/__ __ __ __ 
 
Date of assessment __ __/__ __/__ __ __ __ 
            
Mother’s Name……………………………………………D.O.B__ __/__ __/__ __ 
     Surname   First Name  
Child’s Name…...…………………………………… 
……D.O.B__ __/__ __/__ __ 
     Surname   First Name 
Sex:   □ 1 Male       □ 2 Female 
Current Address……………………………………………………………………………………… 
…………………………………………………………………………………………………………. 
…………………………………………………………………………………………………………. 
Current phone…………………………………………………………………………………………
   Home      Work    Mobile 
Current email……………………………………….@…………………………………………....... 
Place of interview  □ 1 Phone       □ 2 PRU □ 3 Home visit  
Interviewee:     □ 1 Mother   □ 2 Father   □ 3 Other…………………………………. 
Translator required: □ 1Yes  □ 2 No   Language………………………………… 
Checklist (please tick when completed)   
Pre-assessment  □  Check no exclusion criteria (severe congenital respiratory 
abnormality) 
□  Appointment letter sent (+Map+PIL) 
□  Reminded to bring red book 
□  Translater booked if required 
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□  Booked on PRU google diary 
□  Phone before appointment and offer to do questionnaire over phone 
 
On the day (Child) □  Consent   □copy to mother   □copy for GP   □Original copy 
for research file   □  Ametop applied  
□  Questionnaire       
□  Height       
□  Weight        
□  Colorimeter reading     
□  SCORAD score     
□  ENO       
□  IOS (pre)      
□  Salbutamol      
□  Check no antihistamines 
□  Skin prick test □  Read at 10/15 mins    
□  IOS (post)      
□  Blood test  □Sheree sample  □DNA sample in -80 Freezer on PRU 
□FBC + form labeled for eosinophils taken to haem reception 
□  Nasal sample □ Weight recorded  □Stored in -80 freezer on PRU   
□  Buccal swab   □Stored in -4 fridge on PRU 
 
On the day (Mother) □  Consent form 
□  Colorimeter 
□  Buccal swab  □Stored in -4 fridge on PRU 
Post assessment  □  eHR from GP  □  Phone/ fax GP with request (Letter/ 
consent form/ PIL) 
□  Received eHR back from GP   
□  Data entry  □  Questionnaire  □  eHR data  
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   □  Chase eosinophil result 
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CHILD HEALTH  
Q1.  Birth weight?                                             g   
 
Q2.  Gestational age?       weeks 
 
Q3.   SCBU?     1Yes□        0No□        99N/A□ 
Details........................................................................................................................................
................................................................................................................................................... 
 
Q4.  The child’s immunisation data is taken from: 
 
□ 1 Red book     □ 2 Verbal     □ 3 GP electronic records     □ 99 NA    
 
Q5.  Has the child completed the immunization schedule? 
 
8 week   DTaP/IPV/Hib  □ 1Yes   □ 0No   □ 99NA 
   PCV   □ 1Yes   □ 0No   □ 99NA 
12 week   DTaP/IPV/Hib  □ 1Yes   □ 0No   □ 99NA 
   Men C   □ 1Yes   □ 0No   □ 99NA 
16 week   DTaP/IPV/Hib     □ 1Yes   □ 0No   □ 99NA 
   Men C   □ 1Yes   □ 0No   □ 99NA 
PCV         □ 1Yes   □ 0No   □ 99NA 
12 month   Hib/MenC  □ 1Yes   □ 0No   □ 99NA 
13 month   MMR   □ 1Yes   □ 0No   □ 99NA 
PCV      □ 1Yes   □ 0No   □ 99NA 
3 years 4 months:    MMR    □ 1Yes   □ 0No   □ 99NA 
DTaP/ IPV       □ 1Yes   □ 0No   □ 99NA 
dTaP/IPV    □ 1Yes   □ 0No   □ 99NA 
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Q6.  Any congenital abnormalities?     □ 1Yes   □ 0No   □ 99NA 
Details........................................................................................................................................
................................................................................................................................................... 
 
Q7.  Is your child on any regular medications?   □ 1Yes   □ 0No   □ 99NA 
Details........................................................................................................................................
.................................................................................................................................................. 
 
Q8. Does your child have any health problems?   □ 1Yes   □ 0No   □ 99NA 
Details........................................................................................................................................
................................................................................................................................................... 
 
RESPIRATORY TRACT INFECTIONS 
 
Q9.  Since your child was born have you ever been told by a health professional that your 
child has bronchiolitis, bronchitis, croup, pneumonia or a chest infection?     
□ 1Yes   □ 0No   □ 99NA 
 
Q10. Since your child was born have they ever had to be admitted overnight in hospital 
because of bronchiolitis, bronchitis, croup, pneumonia or a chest infection? 
      □ 1Yes   □ 0No   □ 99NA 
 
 
 
 
 
Q11. Details of all episodes:  
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Age 
 
Months 
99 = N/A 
Parents report of 
diagnosis  
1=bronchitis 
2=bronchiolitis 
3=croup 
4=Pneumonia 
5=Chest infection 
6=Other (describe) 
99=N/A 
Antibiotics 
 
1=Yes 
0=No 
99=N/A 
Management 
 
1=Managed at home 
2=Attended A+E but discharged 
3=Admitted to hospital overnight 
99 = N/A 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
    
    
 
 
 
 
 
Q12. How often does your child have an upper respiratory tract infection, with at least 2 of 
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the following symptoms: cough, runny nose, fever? 
        □ 1 Never 
        □ 2 1-4 per year 
        □ 3 5-8 per year 
        □ 4 9-12 per year 
        □ 5 >12 per year 
        □ 99 NA 
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WHEEZING 
Q13. Has your child ever had wheezing or 
whistling in the chest at any time in the 
past? 
 
□ 1Yes   □ 0No   □ 99NA 
 
Q14. Has your child’s breathing ever been 
like this (show video)? 
 
□ 1Yes   □ 0No   □ 99NA 
 
If you have answered ‘No’ to both these questions please skip to q21 
 
Q15. At what age did your child first 
wheeze? 
 
 
 
□ 1 Before 1st Birthday     
□ 2 When they were one  
□ 3 When they were two  
□ 4 At age three or more 
Q16. Has your child had wheezing or 
whistling in the chest in the past 12 
months? 
 
□ 1Yes   □ 0No   □ 99NA
 
If you have answered ‘No’ please skip to question 21 
 
Q17. How many attacks of wheezing has 
your child had since birth? 
 
Q18. How many attacks of wheezing has 
your child had in the past 12 months? 
 
    
   Episodes  □ 99NA 
 
    
 
   Episodes  □ 99NA 
Q19. In the last 12 months, how often, on average, has your child’s sleep been 
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disturbed due to wheezing? 
 
 □ 1 Never woken with wheezing 
 □ 2 Less than one night per week  
 □ 3 One or more nights per week  
 □ 99 N/A 
  
Q20. In the last 12 months, has wheezing 
ever been severe enough to limit your 
child’s speech to only one or two words at 
a time between breaths? 
 
 
 □ 1Yes   □ 0No   □ 99NA
_________________________________________________________________________ 
 
Q21. Has your child ever had asthma? □ 1Yes   □ 0No   □ 99NA 
 
Q22. In the past 12 months, has your 
child’s chest sounded wheezy during or 
after exertion?  
 
  □ 1Yes   □ 0No   □ 99NA 
Q23. In the past 12 months, has your child 
had a dry cough at night, apart from a 
cough associated with a cold or chest 
infection?  
  
 
  □ 1Yes   □ 0No   □ 99NA 
 
Q24. Since your child was born have they 
had wheezing without a cold? (API)  
 
□ 1Yes   □ 0No   □ 99NA 
 
 
WHEEZING MEDICATION 
Q25. Has any health professional ever prescribed a blue (salbutamol or reliever) 
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inhaler for your child? (show inhaler)   □ 1Yes   □ 0No   □ 99NA 
 
Q26. If yes to Q25, on average, how often have you used this inhaler for your child 
during the following time periods? 
 
 
Q 
0-12 months 
Q 
12-24 months 
Q 
24-36 months 
Q 
Age 36m+ 
1 Daily     
2 Most weeks     
3 Most months     
4 Occasionally     
5 Never     
99 NA     
 
Q27. Has any health professional ever prescribed a brown or purple or white/red 
(steroid or preventer) inhaler for your child? (Show inhaler) □ 1Yes   □ 0No   □ 99NA 
 
Q28. If yes to Q27, on average, how often have you used a steroid/preventer) inhaler 
for your child during the following time periods? 
 Q 
0-12 months 
Q 
12-24 months 
Q 
24-36 months 
Q 
Age 36+ 
1 Daily     
2 Most weeks     
3 Most months     
4 Occasionally     
5 Never     
99 NA     
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Q29. Has any health professional ever prescribed a course of oral steroids (pink 
tablets/ liquid) for your child? (Show)    □ 1Yes   □ 0No   □ 99NA 
 
Q30. If yes to Q29, How many courses of oral steroids as your child ever had? 
 Q 
0-12 months 
Q 
12-24 months 
Q 
24-36 months 
Q 
36+months 
Number of 
courses 
99 NA 
    
 
Q31. Has any health professional ever prescribed monteleukast (Singulair) for your 
child? (Show packet)      □ 1Yes   □ 0No   □ 99NA 
 
Q32. If yes to Q31, On average, how often have you used monteleukast (Singulair/ 
granules) for your child? 
 
 Q 
0-12 months 
Q 
12-24 months 
Q 
24-36 months 
Q 
36+months 
1 Daily     
2 Most weeks     
3 Most months     
4 Occasionally     
5 Never     
99 NA     
 
RHINITIS  
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Q33. Has your child ever had a problem with sneezing, or a runny, or blocked nose when 
he/she DID NOT have a cold or the flu?           □ 1Yes   □ 0No   □ 99NA 
 
If you have answered ‘No’ please skip to question 38 
 
Q34. In the last 12 months has your child 
had a problem with sneezing, or a runny, 
or blocked nose when he/she DID NOT 
have a cold or the flu? 
 
 
□ 1Yes   □ 0No   □ 99NA
 
If you have answered ‘No’ please skip to question 38 
 
Q35. In the past 12 months, has this nose 
problem been accompanied by itchy-
watery eyes? 
 
□ 1Yes   □ 0No   □ 99NA   
 
Q36. In which of the past 12 months did this nose problem occur?  (Please tick any which 
apply) 
 
 □ 1 January  
 □ 2 February  
 □ 3 March  
 □ 4 April  
 □ 5 May  
 □ 6 June 
 □ 7 July  
 □ 8 August  
□ 9 September    
□ 10 October        
□ 11 November     
□ 12 December 
 
Q37. In the past 12 months, how much did 
this nose problem interfere with your 
child’s daily activities? 
 
 
 
□ 1 Not at all 
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□ 2 A little 
□ 3 Moderate amount  
□ 4 A lot 
□ 99 NA 
 
 
Q38. Has your child ever had hayfever? 
 
 
 
   □ 1Yes   □ 0No   □ 99NA  
Q39. Since your child was born have they 
had doctor diagnosed allergic rhinitis? 
(API) 
 
□ 1Yes   □ 0No   □ 99NA 
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ECZEMA  
 
Q40. Has your child ever had an itchy skin 
rash that was coming and going for at 
least six months? 
 
□ 1Yes   □ 0No   □ 99NA
 
If you have answered ‘No’ please skip to question 46 
 
Q41. Has your child had this itchy rash at 
any time in the past 12 months? 
 
□ 1Yes   □ 0No   □ 99NA
 
If you have answered ‘No’ please skip to question 46 
 
Q42. Has this itchy rash, at any time, 
affected any of the following places:   
 
The folds of the elbows, behind the knees, 
In front of the ankles, under the buttocks, 
or around the neck, ears or eyes? 
 
 
 
 
 
 
□ 1Yes   □ 0No   □ 99NA
 
Q43. At what age did this itchy rash first 
occur? 
 
 
 
 
□ 1 First 6 months     
□ 2 Before 1st birthday 
□ 3 Age one 
□ 4 Age two  
□ 5 Age three or more 
□ 99 NA 
Q44. Has this rash cleared completely at any time during the past 12 months? 
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□ 1Yes   □ 0No   □ 99NA  
 
Q45. In the past 12 months, how often, on 
average, has your child been kept awake 
at night by this itchy rash? 
 
 
□ 1 Never in the past 12 months 
□ 2 Less than one night per week 
□ 3 One or more nights per week 
□ 99 NA 
 
 
Q46. Has your child ever had  
eczema?  
 □ 1Yes   □ 0No   □ 99NA 
 
Q47. Since your child was born have 
they had doctor diagnosed eczema? 
(API) 
 
 
 
 
 
 
 
 
 
 
 
□ 1Yes   □ 0No   □ 99NA 
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FOOD ALLERGY 
History of possible food allergies?   
      
Q48a. Has your child ever had a possible food allergy?   □ 1Yes   □ 0No   □ 99NA 
Q48. History of possible egg allergy                    □ 1Yes   □ 0No   □ 99NA 
Q49. History of possible cow milk allergy                   □ 1Yes   □ 0No   □ 99NA 
Q50. History of possible peanut allergy              □ 1Yes   □ 0No   □ 99NA 
Q51. History of possible tree nut allergy              □ 1Yes   □ 0No   □ 99NA 
Q52. History of possible fish allergy                 □ 1Yes   □ 0No   □ 99NA 
Q53. History of possible seafood allergy               □ 1Yes   □ 0No   □ 99NA 
Q54. History of possible soy allergy                    □ 1Yes   □ 0No   □ 99NA 
Q55. History of possible wheat allergy              □ 1Yes   □ 0No   □ 99NA 
Q56. History of possible sesame allergy              □ 1Yes   □ 0No   □ 99NA 
Q57. History of other possible food allergy    □ 1Yes   □ 0No   □ 99NA 
 
History of doctor diagnosed food allergies?   
  
Q58. History of doctor diagnosed egg allergy       □ 1Yes   □ 0No   □ 99NA  
Q59. History of doctor diagnosed cow milk allergy         □ 1Yes   □ 0No   □ 99NA  
Q60. History of doctor diagnosed peanut allergy    □ 1Yes   □ 0No   □ 99NA 
Q61. History of doctor diagnosed tree nut allergy    □ 1Yes   □ 0No   □ 99NA  
Q62. History of doctor diagnosed fish allergy    □ 1Yes   □ 0No   □ 99NA  
Q63. History of doctor diagnosed seafood allergy     □ 1Yes   □ 0No   □ 99NA  
Q64. History of doctor diagnosed soy allergy       □ 1Yes   □ 0No   □ 99NA  
Q65. History of doctor diagnosed wheat allergy   □ 1Yes   □ 0No   □ 99NA 
Q66. History of doctor diagnosed sesame     □ 1Yes   □ 0No   □ 99NA  
Q67. History of other doctor diagnosed food allergy   □ 1Yes   □ 0No   □ 99NA 
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HOME ENVIRONMENT AND FAMILY BACKGROUND 
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Q68. What is the ethnic group of the child’s father?  
□ 1 White (British/ Irish/ Other white) 
□ 2 Mixed (White + Black Caribbean/White +Black African/ White +Asian/ Other______) 
□ 3 Asian (Indian/ Pakistani/ Bangladeshi/ Other_______) 
□ 4 Black (Caribbean/ African/ Other_______) 
□ 5 East Asian 
□ 6 Other ethnic group _______ 
□ 99 NA 
 
Q69. What is the ethnic group of the child’s mother? 
□ 1 White (British/ Irish/ Other white) 
□ 2 Mixed (White +Black Caribbean/White +Black African/ White +Asian/ Other______) 
□ 3 Asian (Indian/ Pakistani/ Bangladeshi/ Other_______) 
□ 4 Black (Caribbean/ African/ Other_______) 
□ 5 East Asian 
□ 6 Other ethnic group _______ 
□ 99 NA 
 
 
Q70. Age mother left full time education?                            years □ 99NA 
 
Q71. Age father left full time education?             years □ 99NA              
 
Q72. How many adults live in your household?             adults □ 99NA 
   
Q73. How many children live in your household?             children □ 99NA 
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Q74. Does your child attend nursery?          □ 1Yes   □ 0No   □ 99NA 
 
Q75. If attending nursery from what age did they start?           months  □ 99NA 
       
Q76. How many older brothers and sisters does your child have?       
          older      □ 99NA 
 
Q77. How many younger brothers and sisters does your child have?                      
                                                                                                        younger  □ 99NA  
 
Q78. Have you ever had a household pet?  Cat □ 1Yes   □ 0No   □ 99NA 
       Dog □ 1Yes   □ 0No   □ 99NA 
       Other □ 1Yes   □ 0No   □ 99NA 
       Details......................................... 
 
Q79. Do any household member smoke cigarettes? □ 1Yes   □ 0No   □ 99NA 
 
Q80. Did the child’s mother (female guardian) smoke cigarettes during this pregnancy? 
        □ 1Yes   □ 0No   □ 99NA 
Q81. Have you or a family member ever had doctor diagnosed asthma? (API) 
Mother  □ 1Yes   □ 0No   □ 99NA 
Father  □ 1Yes   □ 0No   □ 99NA 
Sibling  □ 1Yes   □ 0No   □ 99NA  
 
Q82. Have you or a family member ever had doctor diagnosed Rhinitis? 
Mother □ 1Yes   □ 0No   □ 99NA  
Father  □ 1Yes   □ 0No   □ 99NA 
Sibling  □ 1Yes   □ 0No   □ 99NA 
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Q83. Have you or a family member ever had doctor diagnosed Eczema? 
Mother □ 1Yes   □ 0No   □ 99NA  
Father □ 1Yes   □ 0No   □ 99NA  
Sibling □ 1Yes   □ 0No   □ 99NA 
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CHILD VITAMIN D SUPPLEMENTATION 
Q84. Have you ever given your child vitamin supplements?   □ 1Yes   □ 0No   □ 99NA 
 Q84 
0-12 months 
Q84 
12-24 months 
Q84 
24-36 months 
Q84 
36+months 
Multivitamins 
Eg abidec/ dalivit/ 
Healthy Start vitamins 
□ 1Yes    
□ 0No    
□ 99NA 
Brand name 
 
□ 1Yes    
□ 0No    
□ 99NA 
Brand name 
□ 1Yes    
□ 0No    
□ 99NA 
Brand name  
□ 1Yes    
□ 0No    
□ 99NA 
Brand name  
Specific Vitamin D 
supplements 
Eg vitamin D, cod liver 
oil 
□ 1Yes    
□ 0No    
□ 99NA 
Brand name  
□ 1Yes    
□ 0No    
□ 99NA 
Brand name  
□ 1Yes    
□ 0No    
□ 99NA 
Brand name  
□ 1Yes    
□ 0No    
□ 99NA 
Brand name  
 
Other Vitamin 
supplements 
 
□ 1Yes    
□ 0No    
□ 99NA 
Brand name  
□ 1Yes    
□ 0No    
□ 99NA 
Brand name  
□ 1Yes    
□ 0No    
□ 99NA 
Brand name  
□ 1Yes    
□ 0No    
□ 99NA 
Brand name  
 
 
Q85. Why did you give them? □ 1 HV recommended 
     □ 2 GP recommended 
□ 3 Other health professional recommended 
□ 4 Personal choice 
□ 5 Other (Describe) _____________________ 
□ 6 Recommended during antenatal care 
□ 99 NA   
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CHILD DIET QUESTIONNAIRE 
 
Q86. Was your child breastfed?      □ 1Yes   □ 0No   □ 99NA 
 
Q87. For how long did you breast feed for?                  Months □ 99NA 
 
Q88. At what age did your child start a formula?               Months □0never given □99NA 
 
Q89. At what age did your child start solids?        Months □ 99NA  
Q90. Do you observe any of the following diets for your child?  
□ 1 Vegan (No animal products)  
□ 2 Vegetarian (No meat)  
□ 3 Vegetarian (No meat or fish)  
□ 4 Other_____ 
□ 5 No  
□ 99 NA 
 
Q91. How often does your child eat oily fish (Salmon/ trout/ mackerel/ sardines)? 
□ 1 Weekly 
□ 2 Less than weekly 
□ 3 Never 
□ 99 NA 
 
Q92. How often does your child eat margarine?  □ 1 Daily 
       □ 2 Weekly 
       □ 3 Less than weekly 
       □ 4 Never 
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       □ 99 NA 
 
Q93. How often does your child eat eggs?   □ 1 Daily 
       □ 2 Weekly 
       □ 3 Less than weekly   
       □ 4 Never 
□ 99 NA 
 
CHILD SUNLIGHT EXPOSURE  
 
Q94.  How much time, on average, did your child spend outdoors in daylight hours each day 
in the last month?     □ 1 <15mins  
□ 2 15-30mins  
□ 3 30-60mins  
□ 4 1-2 hours 
       □ 5 3-4 hours  
□ 6 >4hours  
□ 99 NA 
 
Q95. During sunny weather in the United Kingdom or abroad, how often would you apply 
sunscreen or clothing to your child?  
□ 1 Often 
□ 2 Sometimes 
□ 3 Rarely 
□ 4 Never 
□ 99 NA 
 
Q96. How much time does your child spend watching TV or using a personal computer each 
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day?       □ 1 None 
□ 2 <1hr 
□ 3 1-2hr 
□ 4 2-3hr 
□ 5 3-4hr 
□ 6 >4hr 
       □ 99 NA 
 
Q97. Does your home have access to a garden?    □ 1Yes   □ 0No   □ 99NA 
 
Q98.Does your home have access to a terrace or balcony?   □ 1Yes   □ 0No   □ 99NA 
 
Q99.  Which one of the 6 categories below best describe your child’s skin type and your 
child’s skins response to the midday sun in summer months? 
 
□ 1  My child has extremely fair skin.  He/she always burns and never tans. 
□ 2  My child has fair skin.  He/she always burn and sometimes tans. 
□ 3  My child has pale coloured skin.  He/she sometime burns and always tans. 
□ 4  My child has an olive skin.   He/she rarely burns and always tans. 
□ 5  My child has moderately pigmented brown skin which never burns and always tans 
□ 6 My child has markedly pigmented black skin which never burns and always tans. 
□ 99 NA 
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MOTHER VITAMIN D SUPPLEMENTATION  
 
Q100. Are you currently taking regular vitamin D supplements? 
□ 1Yes   □ 0No   □ 99NA Brand............................. 
 
Q101. Are you currently taking regular multivitamin supplements?  
□ 1Yes   □ 0No   □ 99NA Brand............................. 
 
MOTHER DIET QUESTIONNAIRE  
 
Q102. Do you observe any of the following diets? □ 1 Vegan (No animal products) 
       □ 2 Vegetarian (No meat)  
□ 3 Vegetarian (No meat or fish)  
□ 4 Other_____  
□ 5 No 
□ 99 NA 
 
Q103. How often do you eat oily fish (Salmon/ trout/ mackerel/ sardines)? 
□ 1 Weekly 
□ 2 Less than weekly 
□ 3 Never 
□ 99 NA 
 
Q104. How often do you eat margarine?   □ 1 Daily 
       □ 2 Weekly 
       □ 3 Less than weekly 
       □ 4 Never 
□ 99 NA 
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Q105. How often do you eat eggs?    □ 1 Daily 
       □ 2 Weekly 
       □ 3 Less than weekly 
       □ 4 Never 
□ 99 NA 
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MOTHER SUNLIGHT QUESTIONNAIRE  
 
Q106. Do you usually wear clothing to cover all skin except face and hands when outdoors?
       
□ 1Yes   □ 0No   □ 99NA 
 
Q107. Do you usually wear clothing to cover all skin including the face and hands when 
outdoors?       
□ 1Yes   □ 0No   □ 99NA 
 
Q108.  How much time, on average, did you spend outdoors in daylight hours each day in 
the last month?      
□ 1 <15mins  
□ 2 15-30mins  
□ 3 30-60mins  
□ 4 1-2 hours 
       □ 5 3-4 hours  
□ 6 >4hours  
□ 99 NA 
 
Q109. During sunny weather in the United Kingdom or abroad, how often would you apply 
sunscreen or clothing?  
□ 1 Often 
□ 2 Sometimes 
□ 3 Rarely 
□ 4 Never 
□ 99 NA 
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Q110. How much time do you spend watching TV or using a personal computer each day? 
(Hyponnen)      □ 1 None 
□ 2 <1hr 
□ 3 1-2hr 
□ 4 2-3hr 
□ 5 3-4hr 
□ 6 >4hr 
       □ 99 NA 
 
Q111. Have you used a sun bed in the last year? □ 1Yes   □ 0No   □ 99NA 
 
Q112. Which one of the 6 categories below best describes your skin type and your skins 
response to the midday sun in summer months? 
 
□ 1 I have extremely fair skin.  I always burn and never tan 
□ 2 I have fair skin.  I always burn and sometimes tan 
□ 3 I have pale coloured skin.  I sometime burn and always tan 
□ 4 I have an olive skin.   I rarely burn and always tan. 
□ 5 I have moderately pigmented brown skin which never burns and always tans 
□ 6 I have markedly pigmented black skin which never burns and always tans 
□ 99 NA 
 
 
 
 
 
 
PHYSICAL EXAMINATION 
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Q113. Height                               ·         cm  □ 99 NA 
 
Q114.  Weight                         ·       kg □ 99 NA 
 
 
 
 
COLORIMETER READINGS:  
 
Q115. Infant colorimeter readings taken?    □ 1Yes   □ 0No    
 
Q116. Mother colorimeter readings taken?   □  1 Yes □  0 No  
        
 
INFANT 
Q117. FOREHEAD  Q118. FOREARM   Q119   TUMMY 
 
E=               .      E=              .     E=              . 
 
M=               .    M=             .     M=             . 
                                                             
L=                .    L=              .     L=              . 
 
A=          .   A=              .     A=              . 
 
B=               .   B=              .     B=              . 
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MOTHER 
Q120. FOREHEAD     Q121. FOREARM   
 
E=               .         E=              . 
 
M=               .       M=             . 
                                                                   
L=                .       L=              . 
 
A=          .      A=              . 
 
B=               .      B=              . 
 
 
 
 
 
SCORAD SCORE 
 
Q122. SCORAD score (part A/5)     □ 99 NA 
 
Q123. SCORAD score (part B*3.5)        □ 99 NA 
 
Q124. SCORAD score (part C)           □ 99 NA 
 
Q125. SCORAD score [TOTAL] (0-103)     
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ENO SAMPLE COLLECTION: 
Q126.  ENO sample collected?       □ 1Yes   □ 0No    
 
Q127.  If no, why? □ 1 Equipment problem         
□ 2 Subject refused           
□ 3 Other________        
□ 99 NA 
 
Q128. Number of samples collected:           Samples 
 
Q129   ENO value sample 1                      ppb  □ 99NA 
 
Q130   ENO value sample 2                      ppb  □ 99NA 
 
Q131   ENO value sample 3                      ppb  □ 99NA 
 
 
 
IOS MEASURMENT 
Q132.  Pre IOS measurements taken?   □ 1Yes   □ 0No    
 
Q133.  If no, why? □ 1 Equipment problem        
 □ 2 Subject refused           
□ 3 Other________        
□ 99 NA 
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Q134   Was salbutamol given?    □ 1Yes   □ 0No   
 
Q135.  If no, why? □ 1 Equipment problem       
  □ 2 Subject refused           
□ 3 Other________        
□ 99 NA 
 
Q136.  Post IOS measurements taken?   □ 1Yes   □ 0No   
 
Q137.  If no, why? □ 1 Equipment problem         
□ 2 Subject refused           
□ 3 Other________        
□ 99 NA 
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SKIN PRICK TESTS   Results [positive = ≥3mm wheal at 15 minutes] 
 
Q138. Skin Prick Test carried out?         □ 1Yes   □ 0No    
 
Q139. Skin Prick Test Problem?       □ 0 Nil 
   □ 1 No clear skin 
   □ 2 Antihistamine taken  
   □ 3 Dermatographism 
           □ 4 Other  
Details………………………………………………………………………………………… 
 
Q140. Skin Prick Test Site:  □ 1 Back □ 2 Forearm       □ 99NA 
 
 
Q141.   Dust mite                  mm    □ 0Neg   □ 1Pos   □ 99NA 
    
Q142.   Cat                   mm   □ 0Neg   □ 1Pos   □ 99NA 
      
Q143.   Silver birch                 mm    □ 0Neg   □ 1Pos   □ 99NA 
    
Q144.   Grass                 mm    □ 0Neg   □ 1Pos   □ 99NA 
       
Q145.  Alternaria                        mm    □ 0Neg   □ 1Pos   □ 99NA 
     
Q146   Cladosporum                  mm   □ 0Neg   □ 1Pos   □ 99NA 
 
Q147.  Peanut                            mm   □ 0Neg   □ 1Pos   □ 99NA 
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Q148.  Egg                                 mm   □ 0Neg   □ 1Pos   □ 99NA 
 
Q149. Cow’s Milk                        mm   □ 0Neg   □ 1Pos   □ 99NA 
 
Q150. Dog                                mm   □ 0Neg   □ 1Pos   □ 99NA 
 
Q151. Neg Control                  mm   □ 0Neg   □ 1Pos   □ 99NA 
 
Q152.  Histamine               mm        mg/ml  □ 0Neg   □ 1Pos   □ 99NA 
 
 
Q153.  Atopy? (≥1 +ve SPT)     □ 0No     □ 1Yes   □ 99NA 
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NASAL SAMPLE COLLECTION: 
Q154. Nasal sample collected?    □ 1 Yes      □ 0 No 
          
 
Q155. No. mcl collected                                   mcl □ 99 NA 
 
Any collecting issue? 
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………………………………………………………………………… 
BLOOD TEST COLLECTION 
Q156. Blood test collected from child?   □ 1 Yes      □ 0 No 
 
Q157. Number of mls blood taken                                       . 
 
□ 99 NA 
 
Q158 and 159 HAVE BEEN REMOVED NOW ONLY TAKING BUCCAL SWAB 
 
DNA SAMPLE COLLECTION 
 
Q160. INFANT DNA sample collected?   □ 1 Yes (Blood) 
 □ 2 Yes (Buccal swab) 
□ 0 No 
 
Q161. Mother’s Buccal DNA sample collected?  □  1 Yes     □  0 No  
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e-HR Data 
Q162. e-HR received from GP    □ 1 Yes      □ 0 No 
 
IMMUNISATIONS 
Q163.  Has the child completed the immunization schedule? 
 
8 week   DTaP/IPV/Hib  □ 1Yes   □ 0No   □ 99NA 
   PCV   □ 1Yes   □ 0No   □ 99NA 
12 week   DTaP/IPV/Hib  □ 1Yes   □ 0No   □ 99NA 
   Men C   □ 1Yes   □ 0No   □ 99NA 
16 week   DTaP/IPV/Hib     □ 1Yes   □ 0No   □ 99NA 
   Men C   □ 1Yes   □ 0No   □ 99NA 
PCV         □ 1Yes   □ 0No   □ 99NA 
12 month   Hib/MenC  □ 1Yes   □ 0No   □ 99NA 
13 month   MMR   □ 1Yes   □ 0No   □ 99NA 
PCV      □ 1Yes   □ 0No   □ 99NA 
3 years 4 months:    MMR    □ 1Yes   □ 0No   □ 99NA 
DTaP/ IPV       □ 1Yes   □ 0No   □ 99NA 
dTaP/IPV    □ 1Yes   □ 0No   □ 99NA 
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e-HR Data:  LOWER RESPIRATORY TRACT INFECTIONS 
Q164.  Do the records describe any episodes of bronchiolitis, bronchitis, croup, pneumonia 
or a chest infection?    
□ 1Yes   □ 0No   □ 99NA 
 
Q165. Details of all episodes:  
Age 
 
Months 
99 = N/A 
GP diagnosis  
1=bronchitis 
2=bronchiolitis 
3=croup 
4=Pneumonia 
5=Chest infection 
6=Other (describe) 
99=N/A 
Antibiotics 
 
1=Yes 
0=No 
99=N/A 
Management 
 
1=Managed at home 
2=Attended A+E but discharged 
3=Admitted to hospital overnight 
99 = N/A 
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e-HR Data:  UPPER RESPIRATORY TRACT INFECTIONS 
Q166.  Do the records describe any episodes of upper respiratory tract infection?     
□ 1Yes   □ 0No   □ 99NA 
Q167. Details of all episodes:  
Age 
 
Months 
99 = N/A 
GP diagnosis  
1=URTI 
2=Cold 
3=Flu 
5=Other (describe) 
99=N/A 
Antibiotics 
 
1=Yes 
0=No 
99=N/A 
Management 
 
1=Managed at home 
2=Attended A+E but discharged 
3=Admitted to hospital overnight 
99 = N/A 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
    
    
 
 
